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Abstract
While the feasibility of whole human genome sequencing was proven by the success of the Human
Genome Project several years ago, the prevalence of personal genome sequencing in the medical
industry is still elusive due to its unrealistic cost and time requirements. Micro$eq is a startup company
with the goal of overcoming these limitations by sequencing a minimum of 12 complete human genomes
per day at an error rate less than ten parts in million at a profitable market price of less than US$1000 per
genome. To overcome the technology bottlenecks hindering current biotech companies from achieving
these target throughput, error rate, and market price goals, Micro$eq has developed an innovative
sequencing technique that uses shortread fragments with high coverage on a microfluidics platform.
Short, amplified DNA fragments are generated from an input of customer saliva. 6 base pair(bp)
sequence hybridization is used for sequencing each of the DNA fragments individually. The results are
these hydridization reads are then assembled via de Bruijn graph theory and the graphical reconstructions
of each fragment’s sequence are then assembled to a complete genome via shotgun sequencing with an
expected error rate less than 1 in 100,000bp. Upon the completion of financial analysis, both a small-scale
business model producing 72 genomes per day at US$999 per genome, and a largescale business model
producing 52.2 genomes per year at a market price of US$299 per genome were found to be profitable,
yielding Micro$eq investors return margins of ~90% and 300% for the small and large scale models,
respectively. With a market price Micro$eq offers personal genome sequencing at one-tenth of its nearest
potential competitor’s cost. Additionally, its ability for bulk-sequencing allows it to profitably venture into
the previously untapped Pharmaceutical Industry market sector, enabling the creation of large-scale
genome databases which are the next step forward in the quest for truly personalized.
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Abstract
While the feasibility of whole human genome sequencing was proven by the success of
the Human Genome Project several years ago, the prevalence of personal genome sequencing in
the medical industry is still elusive due to its unrealistic cost and time requirements. Micro$eq is
a startup company with the goal of overcoming these limitations by sequencing a minimum of
12 complete human genomes per day at an error rate less than ten parts in million at a profitable
market price of less than US$1000 per genome. To overcome the technology bottlenecks
hindering current biotech companies from achieving these target throughput, error rate, and
market price goals, Micro$eq has developed an innovative sequencing technique that uses shortread fragments with high coverage on a microfluidics platform. Short, amplified DNA fragments
are generated from an input of customer saliva. 6 base pair(bp) sequence hybridization is used
for sequencing each of the DNA fragments individually. The results are these hydridization reads
are then assembled via de Bruijn graph theory and the graphical reconstructions of each
fragment’s sequence are then assembled to a complete genome via shotgun sequencing with an
expected error rate less than 1 in 100,000bp. Upon the completion of financial analysis, both a
small-scale business model producing 72 genomes per day at US$999 per genome, and a largescale business model producing 52.2 genomes per year at a market price of US$299 per genome
were found to be profitable, yielding Micro$eq investors return margins of ~90% and 300% for
the small and large scale models, respectively. With a market price<US$1000, Micro$eq offers
personal genome sequencing at one-tenth of its nearest potential competitor’s cost. Additionally,
its ability for bulk-sequencing allows it to profitably venture into the previously untapped
Pharmaceutical Industry market sector, enabling the creation of large-scale genome databases
which are the next step forward in the quest for truly personalized.
Micro$eq – Chomvong, King, Mahmoud
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CHAPTER 1

Introduction to Personal Genome
Sequencing
Personal genome sequencing has become a research challenge and promising investment
option for the past decade. The goal of the personal genome project is to allow individuals to get
their own genome sequenced at a reasonable price. Personalized genomic information allows
personal healthcare treatment, personalized medicine and individual disease risk projection. The
benefits of personal genome sequencing to human health improvement and healthcare industry
growth are tremendous. Upon its completion, personal genomics can possibly alter the nature of
healthcare service industry and individuals’ approach to their health treatment.

Micro$eq – Chomvong, King, Mahmoud
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Human genome analysis was initiated in 1990. The two main goals of the Human
Genome Project (HGP) were to identify all genes in human DNA and to determine the sequences
of the 3 million different pairs of coding molecules that are unique in every individual. The
project was completed in 13 years with many additional years required to analyze acquired data
(HGP, 2011). The total cost of the project was reported to be $3 billion (HGP, 2004). With such
a high sequencing cost and infeasible processing time, the Human Genome Project cannot be
directly implemented for personal genomics purpose. Nevertheless, information provided by the
project allowed improvements in advance medicine, human biology and knowledge of human
origins. In addition, the technology platform developed for the project is applicable to personal
genome project initiative.
Upon the unprecedented achievement of the HGP, the Personal Genome Project was
established. The goal of the Personal Genome Project extended from that of HGP. However, its
emphasis was on allowing human genome sequencing to be available broadly for general public
(PGP). In order to do so, the cost and time required to sequence each genome must be reduced
significantly from that of the Human Genome Project. Many researchers have dedicated their
work to improving feasibility of personal genome sequencing. With face-paced sequencing
technology development, sequencing cost and time have decreased dramatically
.

1.1 MARKET ANALYSIS
Micro$eq’s advanced technology has proven that personal genome sequencing is feasible
at less than $1000/genome bulk retail price. Our design allows 12 genomes to be sequenced per
day; however the plant can be scaled up to respond to high market demand. With breakthroughs
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in reduced cost and time required to sequence human genome, the personal genome project
becomes achievable and provides a promising alternative healthcare approach.
Micro$eq’s specialization is to deliver personal genome sequences at a relatively low
price, within reasonable time frame and with an acceptable error rate. Micro$eq’s products are
sequences of coding molecules that are unique in every individual. However, it is important to
note that Micro$eq does not provide sequence interpretation service. Besides the current market
sector for personal genoming, which consists primary of private wealth individuals, two
additional market sectors lend themselves to Micro$eq’s low-cost, high-throughput genome
product.
First, The Pharmaceutical Industry is as a main target market sector due to the potential
application of personal genome sequencing to their existing clinical trial protocols. One of many
expensive steps that pharmaceutical companies must complete before the launch of new drug is
the testing of potential drugs on prospective patients. The cost of this process is reported to often
exceed $25,000 per patient (PR Newsire, 2006). Depending on the drug type and condition,
hundreds or thousands of patients are required for each trial. Personal genome sequencing can be
incorporated as part of a clinical trial to identify relationships between variable genetic
sequences and effectiveness of drug response. Drug response information against variation of
genetic factors is incredibly valuable in healthcare service because it allows pharmaceutical
companies to target appropriate patients. In the final consumers’ perspective, this database
allows personalized medicine in which patients are at lower risk of being given ineffective drugs.
The low cost and quick turnaround time of Micro$eq’s technology makes incorporating personal
genome sequencing into clinical trials feasible. With the estimated market price of less than
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$1000 per genome, the increase in cost per patient during a trial is minimal compared to its
potential benefits to the Pharmaceutical companies.
Second, Health Insurance firms are Micro$eq’s potential target market sector. In this
case, personal genome sequencing can be integrated as part of health insurance plan. Individuals
who choose to have their genome analyzed can receive supplemented personalized drug and
treatment from their primary care physicians. Again, Micro$eq will provide only the sequence
information while the Health Insurance firms will be responsible for its interpretation. In 2010,
the average annual cost of health insurance coverage as part of a group plan is reported to be
$4,824 for individual and $13,375 for family (Banning, 2010). With the addition of personal
genome analysis option, the price of insurance coverage will increase by approximately 25%
(including interpretation cost). Healthcare insurance is considered Micro$eq’s secondary target
market because of two challenges associated with this business. First, the current average health
insurance coverage cost is not high enough to make additional cost of personal genome
sequencing negligible. Initially, individuals who choose personalized medicine options may have
to pay the extra coverage cost on their own. However, if the cost of overall healthcare is reduced
due to increased efficacy of personalized treatment, it may be beneficial for Healthcare firms to
supplement the sequencing cost. Second, the system is designed so that health insurance firms
have access to individual genome information. Ethical, legal and social issues could arise
because of the firm’s ability to predict their customer’s risks of having diseases. With such
powerful information on hand, Health Insurance firms might refuse to insure or increase
coverage cost for customers who are like to have symptoms which are expensive to treat.

Micro$eq – Chomvong, King, Mahmoud
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OVERVIEW OF GENOME SEQUENCING
Before any process for genome sequencing can be designed, it is important to understand
the nature of the human genome and the available technology that allows it to be sequenced.

1.1.1 The Human Genome Structure
The

human

comprised

of

genome

is

double-stranded

DeoxyriboNucleic Acid (ds-DNA).
ds-DNA is an assembly of two singlestranded polymers, called nucleotides,
that are made up of alternating 5carbon sugar and phosphate residues
which

are

connected

by

phosphodiester bonds. Each sugar is

Figure 1.1 DNA Structure showing the chemical structure of the
phosphate-sugar backbone (right) and the dimensions of the double-helical
structure (left) (Cummings).

bound to the functional group of that particular monomer (called a nulecotide base, or base).
Four different functional bases exist in human DNA. Adenine (A), Thymine (T), Guanine (G),
and Cytosine (C). The functional groups of the bases are able to create hydrogen bond with one
another in a base pair, thus binding the two single-stranded polymers to form ds-DNA as shown
on the right of Figure 1.1. The tertiary structure of the ds-DNA is a double-helix, as seen on the
left of Figure 1.1.

The particular combination of the four different base pairs of the DNA sequence in a
particular individual determines that person’s genetic makeup. Analysis of this sequence is
Micro$eq – Chomvong, King, Mahmoud
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essential to discover the genetic abnormalities of any individual and how they might affect
disease susceptibility, drug response, and a myriad of other biological phenomena. It is important
to note that not just the base pair sequence of the DNA, but also particular aspects of its 3-D
structure (termed epigenetic factors) act in both determining the genetic make-up and in
regulating the genetic expression in any given human cell. The base pair sequence is identical in
every single cell present in the individual. However, the 3-D structure of the DNA may vary
between different cell types (i.e. a skin cell versus a brain cell). The scope of this project is only
to investigate only the base pair DNA sequence and does not extend to any epigenetic
considerations.

1.1.2 The Human Genome Size and Sequencing
A complete human genome contains approximately 3 billion base pairs in length – for a
total of 6 billion bases in the genome. While many of these bases are conserved between
different samples (one sample being defined as one individual) of human DNA, for an effective
whole genome sequencing process, every single one of the 6 billion bases needs to be read from
the sample DNA and used to construct the sample’s particular sequence. The length of the
combined 3 billion base pairs of one genome is approximately 3m (Mitchell, 1997). For
microbiology purposes, working with a molecule this long is completely impractical. DNA does
not exist naturally in the cell as one continuous molecule, but is instead segregated into various
subsections. Still, even when divided, the DNA exists in fragments of length on the order of 10
million base pairs. Therefore, any sequencing process must begin by breaking the DNA into
workable length fragments (<10,000bp).

Micro$eq – Chomvong, King, Mahmoud
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1.1.3 Genome Sequencing
From the broken down DNA fragments, their base pair sequence can be read using a
variety of methods. While different approaches to sequencing require the use of different sized
fragments, almost all approaches involve the addition of a fluorescently-tagged molecules to the
target DNA. Generally, the presence or absence of fluorescence is used to determine the presence
or absence of a particular base pair or sequence of base pairs in the target DNA. The most
commonly used method is the addition of fluorescently-tagged single base pairs where each type
of base is tagged with a different color. The sequence is then analyzed one base pair at a time and
the color at each base pair position indicates which base pair is present there.
As sequencing of DNA is done in fragments, short sequence reads from each fragment
will be generated and

then reassembled

into the longer complete sequence using a

computational approach.

1.1.4 Genome Assembly
Currently, sequencing technology is not applicable to read the entire human genome at
once. The length of human genome is too long to be read directly; thus, shorter reads are
generated from sequencing step. Genome assembly is then required to reconstruct the original
sequence. Generally, total length of all reads combined must be many times longer than that of
original sequence. This is because genome assembly relies on over-generation of information.
The short reads are aligned and merged using assembling algorithm or assembler software to
regenerate meaningful original sequence.

Micro$eq – Chomvong, King, Mahmoud
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1.2 COMPETITIVE ANALYSIS
In order to move forward with the business model for Micro$eq, it is critical to perform
an analysis of the competitive environment and the major companies that offer similar services,
but with different techniques. The major companies offering these technologies are Illumina,
454 sequencing, and Pac Bio. Since genome sequencing is a relatively new market and most of
the products being offered are still in their infancy, not all of the information regarding the
products, such as potential costs, is available to the public. This section includes some technical
details which are not explained until later in the report. In the event that any of the molecular
biology of the technology descriptions is unclear, please refer to Chapter 4 to a more detailed
discussion.

1.2.1 Illumina
Illumina relies on Solexa technology in order to sequence their genomes. Template
preparation begins with solid phase amplification. High density forward and reverse primers are
covalently attached to a solid surface. The ratio of the primers to the template on the support
defines the surface density of the amplified clusters (Metzker, 2010). Amplification takes place
in two steps: intial priming and extension of the single-stranded template followed by bridge
amplification of the immobilized template with adjacent primers to form clusters.

Illumina’s

amplification approach can be seen in Figure 1.2.

Micro$eq – Chomvong, King, Mahmoud
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Figure 1.2 Illumina’s Template Immobilization Strategy: Amplification takes place in two steps: intial priming and extension
of the single-stranded template followed by bridge amplification of the immobilized template with adjacent primers to form
clusters.

Following amplification, fluorescently tagged reversible terminators are added along with
the polymerase to the single-stranded solid-phase amplified DNA. Reversible terminators halt
DNA synthesis so that fluorescence imaging can take place. llumina’s imaging technology then
reads out the different wavelengths emitted for each nucleotide. The dye and terminator groups
are cleaved and the support is washed. This process is repeated again until the entire strands are
read. A summary of Illumina’s sequencing process is illustrated in Figure 1.3 on the next page.
The fragments are then assembled into a genome sequence using an unreleased algorithm. The
complete overview of Illumia’s process may be seen

Micro$eq – Chomvong, King, Mahmoud
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Figure 1.3 Illumina’s Sequencing Strategy, Fluorescently tagged reversible terminators are added along with the polymerase to the
single-stranded solid-phase amplified DNA. Reversible terminators halt DNA synthesis so that fluorescence imaging can take
place. (Figure adapted from (Metzker, 2010))

One of the advantages of the Illumina technology is the simplicity of the flow cell design.
There are no specific wells or beads that need to be attached to, and the amplification of the
clusters allows for a large viewing concentration. The very nature of the clusters themselves
Micro$eq – Chomvong, King, Mahmoud

11 | P a g e

guarantee a strong signal, as they are very concentrated as opposed to the single fluorescent
molecule that has to be detected for other designs.
A major disadvantage of this technology is the required washing step and large cost.
Washing steps increase the variable costs associated with the process and decrease throughput.
Furthermore, careful attention must be made to make sure that base additions are synchronous.
If careful track of how many bases were added to each template, then a greater sequencing error
rate is incurred.

Illumina advertises comprehensive genetic sequence information at a cost of

$19,500 per genome. If a group of five individuals ordered through the same physician: $14,500
per genome. Medical indicated cases approved through a
subsidy program cost $9,500 per genome.

1.2.2 Helicos Biosciences
Helicos Biosciences uses a similar sequencing
strategy as Illumina.

Native genomic DNA is sheared,

treated with terminal transferase to generate a poly-A tail and
loaded onto an instrument. The tailed fragments hybridize to
complementary strands anchored on the flow cell surface.
Helicos Virtual Terminators are labeled with the same dye
and dispensed individually in a predetermined order,
analogous to a single-nucleotide addition method. Following
total internal reflection fluorescence imaging, a cleavage step
removes the fluorescent dye and inhibitory groups using
TCEP to permit the addition of the next dNTP analogue

Micro$eq – Chomvong, King, Mahmoud

Figure 1.4 Helicos Biosciences’ Sequencing Strategy:
Helicos Virtual Terminators are labeled with the same
dye and dispensed individually in a predetermined order,
analogous to a single-nucleotide addition method.
Following total internal reflection fluorescence imaging,
a cleavage step removes the fluorescent dye and
inhibitory groups using TCEP to permit the addition of
the next dNTP analogue ( (Metzker, 2010)
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Figure 1.4. This is followed by the next nucleotide addition.
Helicos Bioscience’s sequencing approach requires a large number of flushing, scanning, and
washing cycles, which results in very small throughputs. In addition, the nature of the washing
cycles limits the average read length to 35 to 400
bases. Also a large number of samples are usually
required

to

justify

machine operation (Pacific

Biosciences).

1.2.3 Roche/454 Sequencing
Roche/454 pyrosequencing uses a titanium platform
loaded with DNA-amplified beads in PicoTiterPlate
(PTP) wells (Figure 1.5). dNTPs are flown across
PTP wells and a charged coupled device (CCD)
camera

detects

light

generated

from

pyrosequencing reaction (Metzker, 2010).

the
This

technology has proven to be very robust with very few
substitutions errors, allowing denovo sequencing.
However, the setup relies on PCR which may result in
an amplification bias and requires a great deal of time.
Furthermore, one nucleotide species is introduced
during each cycle, which is detrimental to both
throughput and reagent costs. 454 Sequencing quotes
a run time of one billion bases in a day using the GS

Micro$eq – Chomvong, King, Mahmoud

Figure 1.5 454 Sequencing: dNTPs are flown across PTP wells
and a charged coupled device (CCD) camera detects light
generated from the pyrosequencing reaction. (Figure is
adapted from (Metzker, 2010)
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FLX Titanium series sequencing kit. No complex optics or lasers have to be used (Roche
Biotech).

1.2.4 Pacific Biosciences
Pacific Biosciences uses “Single Molecule Real Time” (SMRTTM) DNA sequencing
technology. This novel technology platform enables single molecule, real-time detection of
biological processes. Zero-mode waveguides (ZMWs) are employed which are tiny aluminum
wells that house the growing DNA strands (Figure 1.6). Phospholinked nucleotides enter the
limits of detection zone as they are incorporated and a fluorescence pulse is detected (Metzker,
2010).
Long reads promote simpler more accurate assembly because they can span varied
genomic regions that can present problems for shorter read-length platforms. However, the

Figure 1.6 Pacific Biosciences Sequencing Strategy: This novel technology platform enables single molecule, real-time
detection of biological processes. Zero-mode waveguides (ZMWs) are employed which are tiny aluminum wells that house
the growing DNA strands (Figure 5). Phospholinked nucleotides enter the limits of detection zone as they are incorporated
and a fluorescence pulse is detected

Micro$eq – Chomvong, King, Mahmoud
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drawback of this sequencing approach is that expensive detection schemes and platforms must be
made in order to real time sequence on the molecular scale.

1.2.5 Competitive Analysis Conclusion
The current bottleneck of technology is imbedded in the fact that the majority of
sequencing approaches rely on single base pair additions which requires a large number of
flushing, scanning, and washing cycles, and thus result in very small throughputs. Furthermore,
the nature of washing cycles limits the average read length from 35 to 400 bases, which are hard
to generate without an immobilization step, which again decreases throughput. Finally, a large
number of samples are usually required to justify machine operation (Pacific Biosciences).
Single molecule approaches to sequences require expensive machinery to maintain a reasonable
signal to noise.

1.3 CONCLUSIONS
The field of personal genome sequencing research is one of the foremost challenges in
the Biotechnology Industry this decade. The potential of having personalized medicine and
treatment as well as individual disease risk projections hast the potential to transform the nature
of the Healthcare Industry and people’s everyday lives. Because of the enormity of its potential
benefits, many organizations have entered the whole genome sequencing market. Illumina,
Helicos Biosciences, Roche/454 Sequencing and Pacific Biosciences are some of the current and
most promising players in the personal genomics industry. With its proposed unique set of
technologies, Micro$eq is confident that its approach is capable of delivering high quality
personalized genome sequences at a large demand volume. In addition, Micro$eq’s technologies
reap the benefit of first mover competitive advantage in the low cost personal genome
Micro$eq – Chomvong, King, Mahmoud
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sequencing market. With an expected market price of less than $1000 per genome, Micro$eq’s
product has potential marketability in the clinical trial sector of the Pharmaceutical Industry as
well as in the Health Insurance Industry.

Micro$eq – Chomvong, King, Mahmoud
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CHAPTER 2

Micro$eq’s Proposed Challenge
With existing competitors in personal genome industry, Micro$eq’s mission is to deliver
superior value of sequenced genome product. Customers’ demand specifications on delivered
sequenced genomes are relatively simple—low cost and high accuracy. However, the challenge
of the industry is how to respond to such demand with the current technology limitation.
Nevertheless, innovative technologies have been developed constantly; thus, allowing an
entrance to lower cost and higher accuracy regime which was previously inaccessible. In this
chapter, Micro$eq’s initial scheme is presented along with an expected price range, minimum
error rate and required throughput. In addition, relevant technologies required for proposed
Micro$eq – Chomvong, King, Mahmoud
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process are introduced. Detailed discussions on how each technology is applied to Micro$eq’s
process are further illustrated in this report.

2.1 INITIAL SCHEME
Micro$eq’s goal is to design ‘$100 genome’ under a condition of a startup biotechnology
company. Raindance Technologies’ microfluidic microreactor technology is proposed as a
unique approach to genome sequencing. The scope of Micro$eq’s service as previously
introduced in section 1.1 is to sequence client’s patient samples and deliver whole genome data
to the client within 30 days. The delivered products are a sequenced genome with no associated
interpretation. The delivered products are allowed to have no more than ten parts per million
error rate for non-repeating intronic sequences. Initially, the expected throughput is 2500
genomes per year with assumed series A funding. The market price is expected to be within the
range of $100-300. Micro$eq’s throughput is expected to quadruple after series B funding to
10,000 genome per year. Finally, after the market has adopted the application of personal
genome sequencing, the expansion is expected to reach over a million throughput genomes per
year.
The summary of Micro$eq’s initial proposal is presented in Table 2.1. Specific goals,
project scope, deliverables and timelines are clearly illustrated.
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Project Name

Removing the Personal Medicine Bottleneck: $100 Genomes using
Raindance Technology

Project
Champion

Dr. John Crocker

Project Leaders

Kulika Chomvong, Eyas Mahmoud, Amanda King

Specific Goals

Sequence 10,000 human genomes per year for less than $100 per sequenced
genome, with an error rate of less than ten parts per million for nonrepeating intronic sequences.

Project Scope

In Scope:
•
•
•
•

Identify and investigate high throughput screening techniques
Provide in-house whole genome sequencing through application of
the most promising technology
Select appropriate equipment and staff
Develop a working a profitable business model centered on the
aforementioned production level, investment, and genome price.

Out-of-Scope:
•
•
•
•
•
•

Fabrication of microfluidic chip
Synthesis of reversible terminator nucleotides
Focused screening of genome (such as SNP screening)
The provision of genetic or medical consultation
Synthesis of 6-base oligos library
Correlating sequence analysis to patient conditions

Deliverables

•
•
•
•

Market assessment and competition analysis
Technical feasibility assessment
Full scale manufacturing requirements and protocol
Financial analysis over a 4-year project life cycle

Timeline

•
•
•
•

Working sequencing prototype within 12 months
Scale-up operations within 2-years
Full-scale production in years 3-4 with simultaneous R&D
Liquidate or sell the company at the conclusion of the fifth year

Table 2.1 Project Charter Summary of project champion, project leaders, specific goals, project scope, deliverables and
timeline
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In order to achieve the project goals specified, Micro$eq must approach personal genome
sequencing challenges in a distinctive fashion to generate barrier to entry against potential
competitors. To take advantage of first mover in ‘$100 genome’ category, genome sequencing
technologies which Micro$eq implements must minimize the process cost such that Micro$eq
can set its retail price in the hundred dollar range and yet yield appreciable returns to its investor.
To do so, necessary steps of genome sequencing are studied to explore potential technology
improvement that results in lower processing cost.

Figure 2.1 Project Charter A process flow sheet of Micro$eq’s approach to human genome sequencing. The process flow
walks through the planned progress of Micro$eq from patient’s sample acquirement, presequencing, DNA sequencing, genome
assembly and finally delivered product.

Figure 2.1 clearly illustrates the necessary steps Micro$eq plans to take in order to
accomplish low cost human genome sequencing. Micro$eq receives input sample, patient’ saliva,
from its clients such as pharmaceutical firms. The sample is then prepared to properly suit
Micro$eq’s unique DNA sequencing approach during Pre-sequencing process. The typical
sample preparation steps—DNA purification, DNA fragmenting and DNA amplification—are
implemented. However, the application of Raindance Technologies’ droplet microreactor plays
significant role during this process, minimizing labor and reagent costs required in normal
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microbiology lab setting. Fragments of patient DNA are sheered then PCR amplified in large
droplets (>1 nanoliter) that then broken down into thousands of smaller (~1 picoliter) droplets,
each containing many copies of the original fragment. The prepared DNA fragments are then
sequenced using 6mer oligonucleotide hybridization scheme. All 4,096 combinations of bases
(A, T, C or G) with the length of 6 are generated, along with distinctive fluorescence barcode
identifier to distinguish each one of them. The bases have specific binding system such that A
always binds with T and C always binds with G. Thus, when droplets with inserted fragments
from presequencing process are merged in 1:1 fashion with the oligo library droplets, the
information of the fragment sequence can be determined. The merged droplets are then arrayed
on a flat slide, and incubated to allow hybridization to occur in those droplets where the oligo
finds a 6-base complementary section in the patient fragment. After the oligos hybridize with the
fragments, the droplets are scanned to detect whether certain oligo combination exists in the
fragments using a custom made high speed charged coupled device (CCD) camera. The
information on whether each of the 4,096 oligos bind with the inserted fragments are then passed
along to Genome Assembly where de Bruijn graph assembly and shotgun sequencing recombine
patient’s whole genome at acceptable error rate (10 parts in a million). Finally whole genome
product is delivered to the client within specified 30 day time frame.

2.1.1 Technology Readiness Assessment
Genome sequencing technology development is possibly one of the fastest growing
research fields. With tremendous potential benefits associated with personal genome sequencing,
private and public organizations have invested time, money and personnel to certify their
superior standing in the market. For example, in 2006, the X Prize Foundation, along with the J.
Craig Vetner Science Foundation launched the Archon X Prize for Genomics, which was to be
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awarded to the first team that can build a device which has the capability of sequencing 100
human genomes in 10 days or less, with an error rate of 1 in 100,000 bases at the cost of $10,000
per genome (Archon Genomics X Prize Overview). Since the launch of this challenge, a race to
the commercialization of whole genome sequencing has lead to many of innovations.

Figure 2.2 Innovation Map Customer value proposition, products, product technologies, technical differentiation,
process/manufacturing technology and material technology of personal genome industry are illustrated.
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The use of genetic information to predict disease has the power to revolutionize our
healthcare system. The possibilities of proactive care provide consumers with an impetus to seek
out whole genome sequencing. However, whole genome sequencing was initially very costly
and non-accessible. Subsequently, requirements were added for accuracy, high throughput, low
cost, and clinical use.

In Figure 2.2, current material technology, process/manufacturing

technology, technical differentiation, product technologies, existing alternative products and how
they respond to customer value proposition are shown. Companies such as Illumina and Helicos
Biosciences used reversible chain-terminating DNA sequencing technology. However, these
processes have large throughput times and large associated costs. Recently, Pacific Biosciences
announced a high-throughput design which used single-molecule real time DNA sequencing
(SMRT). Nevertheless, costs per sequenced human genome continue to be excessive. Microseq
seeks to design the next generation of whole human genome sequencing to meet customer
demands by using Raindance Technology’s microfluidic platform to drive down cost. Using
very small amounts of reactants to gain sequencing information, drives down the cost of human
genome sequencing per base. Currently, the use of microfluidic platform has not been
implemented by any of Micro$eq’s potential competitors; thus, allowing Micro$eq to take full
advantage of prospective low processing cost which satisfies customer value proposition at
acceptable error rate.

2.1.2 Customer Requirements
Customer value propositions are illustrated in Figure 2.2. The four main propositions are
high throughput, low cost, accuracy and clinical use. Due to the scope of the project, the aspect
of clinical use of the final genome is irrelevant because Micro$eq’s service does not include
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genome sequence interpretation. The rest of the four customer value propositions are studied to
design the process which responds best to what consumers are looking for.
In the scope of the project, target market of Micro$eq is pharmaceutical firms. The use of
personal genome sequencing can be incorporated in their essential clinical trials where large data
sets are required to test efficiency and safety of newly developed drugs. Complete patient
genome sequencing could be included as part of the clinical trials to acquire the complete
relationship between drug response and individual’s genome variation. With such a large volume
of data collected, pharmaceutical firms can potentially understand the origin of diseases and
invent drugs directly attack the cause of the diseases. As discussed in section 1.1, average cost of
a clinical trial per patient is estimated to be $25,000 (PR Newsire, 2006).
With the aforementioned needs of pharmaceutical firms, their requirements on personal
genome sequencing can be analyzed. First, pharmaceutical firms, with large number of patients
per clinical trial require high sequencing throughput. The database of relationship between drug
response and genome variation has little meaning if it is not statistically reliable. On average,
2,186 patients are tested per new drug application (CISCRP, 2007). In order to deliver sequenced
genome within 30 days, Micro$eq must have a minimum daily throughput of 73 sequenced
genomes. The given example illustrated that high throughput yields competitive advantage and
potentially increases Micro$eq’s market share if its competitor cannot meet such a high demand.
Second, pharmaceutical firms prefer low costs. In fact, any customers would prefer low cost if all
other factors are kept unvaried. However, pharmaceutical firms are not as price sensitive as
individuals or smaller entities because their overhead costs for clinical trials are relatively high.
The additional cost of less than $1000 per patient is most likely accepted considering valuable
database they can acquire. Finally, customers value accuracy of sequenced genome. However,
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there is a tradeoff between cost and accuracy. Higher accuracy results in higher cost. Hence,
pharmaceutical firms would choose the highest error rate they would be willing to tolerate to
minimize their expenses
Overall, the three main customer requirements—high throughput, low cost, and
accuracy—can be satisfied using Micro$eq’s technology platform. Potential high throughput due
to implementation of Raindance Technologies’ droplet microreactor awards Micro$eq’s
competitive advantage over its competitors because it can meet pharmaceutical firms’ demand.
With expected price less than $1000 per genome, Micro$eq offers the lowest price thus far in the
market at specified maximum error rate.

2.2 RELEVANT TECHNOLOGIES
Micro$eq’s initial approach to developing its own novel genome sequencing strategy
begins with an analysis of what technologies are available on the marketplace and can adapted to
fit Micro$eq’s project goals. This section aims to outline the necessary steps in DNA
preparation, sequencing, and genome reassembly that Micro$eq will be using, and their
feasibility given currently available technologies.

2.2.1 DNA Fragmenting
While it is absolutely necessary to break down the genomic DNA into at least workable
fragment sizes, as previously discussed, sequencing can be further optimized by specifying the
length of the DNA fragments. This optimal length is determined by the methods of sequencing to
be used as well as the reassembly. For now, it is assumed that the required fragment length is
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feasible to produce within the limitations of molecular biology, and will be chemically stable
during the rest of the process. This assumption will be discussed in detail in later chapters.

Various mechanical, chemical, and biological methods exist for the digestion of DNA.
The most common means of DNA digestion is sonication, which using hydrodynamic shearing
of the covalent bonds in the DNA structure by exposing the DNA to brief period of sonication.
This technique was originally used to break up kidney stones or larger tissues but has been
adapted to DNA fragmenting. Typical sonication procedures today allow the generation of
fragments between ~150-1500bp in length (Sambrook, 2001). This size of DNA fragments are
standard in most sequencing processes and encompasses the ~1000bp fragment originally cited
by this project as the optimum length for genome reassembly.

2.2.2 DNA Droplets as Microreactors
As previously stated, the platform for operation in this project is microfluidics. Many
current methods of sequencing involve handling the DNA in a batch-like manner which severely
increases processing time. The use of microfluidic technology increases process efficiency by
allowing a continuous process. Additionally, microdroplets can be thought of as microreactors.
DNA may be isolated inside the droplet and processed in volumes on the nano- or even pico-liter
scale. This drastically decreases required processes space and reagent volume. While the idea of
microdroplet technology is fairly novel, the vast amount of research in this field over the past 5
years has produced a variety of methods for generating and handling droplets in the context of
biomolecular processes.
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2.2.2.1 Droplet Generation
In general, droplets are small bubbles of an aqueous
solution and are suspended in a hydrophobic solution. The
repulsion between the two different solutions and the surface
tension of the aqueous droplets allows the droplets to retain their
shape and their contents to remain isolated from the hydrophilic
environment. Droplets are generated using a T-junction as
Figure 2.3 Droplets are generated by
infusing aqueous samples at a
perpendicular angle to opposing oil
streams. Repulsion between the oil and
aqueous solution supplement the
droplet’s inherent surface tension,
further stabilizing the droplets and
providing a biocompatible environment
for the contents (Theberge, 2010).

shown in Figure 2.3 where the aqueous solution is forced through
a small pore. The hydrophilic solution, which will be an oil in
this case, interrupts the hydrophilic flow solution at uniform
intervals, thus forcing separation of the flow stream into droplet

suspended in the oil. The rate generation and droplet size are determined by both the T-junction
pore size as well as the flow rate of the oil. Standard droplet size range is from 0.5pL -25µL and
varies by ~1% from the specified volume (Theberge, 2010).
2.2.2.2 Droplet Stability
The fluid dynamic concerns of microdroplet flow are far more complex than those of
macrofluidics. The major criteria to be considered are droplet flow rate, flow channel size, and
their effects on droplet stability. In order to maintain the integrity of the droplet as a
microreactor, it is strictly necessary that the droplet does not break up, hence exposing its
contents to the surrounding environment. Fluid dynamic limitations on the droplet flow rate will
affect the droplet throughput, and size requirements for the channels will affect the required
microfluidic plumbing for the process. These phenomena and how they relate to this specific
process will be discussed in more detail in a later on.
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It is possible to further supplement droplet stability by the addition of surfactants to the
hydrophobic solution or by the addition of polymers to the aqueous droplets. The addition of
surfactants to the suspension oil is standard in droplet generation as it stabilizes the droplet
without altering the droplet contents. It is
also conventional to use a surfactant with
a perluoropolyether (PFPE) tail. The
fluorination presence in the oil offers
many

advantages

over

typical

hydrocarbon oils, including improved
oxygen permeability and immiscibility
with

organic

compounds

(Theberge,

2010). A recent surge of research in this
field has found many possibilities for oil
and surfactant choice, dependent on the
scale and goal of the microfluidic
process.

Additionally,

the effect

Figure 2.4 Fluorinated surfactants that improve biocompatibility
and droplet stability (Theberge, 2010).

of

different hydrophilic head groups such as carboxylic acid of poly-L-lysine (Theberge, 2010). The
most commonly used modified surfactants can be seen in Figure 2.4.
The presence of polymers in the droplet not only increases droplet stability, but also
allows thermal control of this stability as the polymers will be in different conformations
dependent on the droplet temperature. However, the addition of excess reagents to the droplet
can complicate any reactions that take place inside, and thus are generally avoided unless
absolutely necessary.
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2.2.2.3 Droplet Handling
As seen above, droplets are analogous to reactors in their ability to isolate reaction
solutions. Additionally, droplets have the ability to merge or split, similar to the splitting or
merging

of

solutions

in

macrofluidics.
Two distinct streams of
droplets can be merged to
create a unified steam of new

Figure 2.5 Droplets are generated by infusing aqueous samples at a
perpendicular angle to opposing oil streams. Surfactants present in the oil
stabilize the droplets while providing a biocompatible environment for the
contents of the droplets.

droplets. In order for droplet
coalescence

to

occur,

the

surface tension of each of the individual droplets must be temporarily broken and then reformed
around the new aggregated droplet. Droplet merging may be performed in multiple ways,
depending on the droplet makeup. Droplets stabilized by polymers may be merged via a
chemically-induced temporary suspension of polymer stability. Hydrophilic droplets suspended
in a hydrophobic medium such as oil can be merged with the use of an electric pulse which
temporarily disrupts the electrostatic interactions between the surface water molecules ( Figure
2.5).

Droplets may be split using similar technology. The surface tension of the original
molecule is momentarily broken and a single molecule is forced through a membrane or sieve
whose pore size determines the new size of the droplets. Upon passage through these pores the
surface of the new droplet is regained.
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2.2.2.4 Micro$eq and Droplet Technology
The properties of microdroplet technology will be capitalized upon in Micro$eq’s
sequencing process. Standard techniques that traditionally use batch reactors will instead be
applied to a continuous process in which each droplet is its own reactor. The feasibility of
droplet merging, splitting, and manipulation allows complex reactions and handling processes to
be executed on the microscale level, thus significantly reducing the space and time that would be
required were this process to take place in a macrofluidic platform.

2.2.3 DNA Sequencing
DNA sequencing is used to determine the order of the nucleotide bases (A,T,C,G)—
adenine, guanine, cytosine, and thymine in a molecule of DNA.

Micro$eq’s sequencing

approach involves combining a synthetic single-stranded, 6-base pair probe (6mers) with a single
strand of the target DNA.

The probe fluoresces if all of the 6 base pairs on the 6mer are

complementary to a 6 base pair sequence on the sample DNA, indicating that these 6 base pairs
are present in the target DNA. If all possible 6 base pair combinations are tested against a
fragment of sample DNA, a read out of all existing 6bp sequences and all non-existing 6bp
sequences on each fragment of DNA can be obtained. This readout will then be reassembled via
computer algorithim to generate the total sequence of the DNA fragment.
2.2.3.1 6mer Library
In order to obtain a comprehensive analysis of each DNA fragment with each possible
6mer, a library of droplets is created which contains all of the possible 6-base pair long strands of
DNA. Each 6-base pair long DNA fragment can have an adenine, guanine, cytosine, or thymine
as its first base. This gives four possible bases for the first base. Similarly, four different bases
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exist for the second base, and four different bases for the third base and so on. In total there are
46 or 4096 possible 6 base pair fragments of DNA. However, 32 strands of 6-base pair DNA are
palindromes. This means that they read the same forward as backward. 4064 copies of an
identical target DNA fragment must be combined with 4064 different 6-base pair long fragment
in a 1:1 fashion. An important component of this droplet combination process is the idea that the
4064 different 6mer droplets must be marked (“barcoded”) in some as to be able to keep track of
which DNA fragment is in which drop in order to extract the binding versus non-binding reads
for each 6mer.
2.2.3.2 Droplet Scanning
The extraction of this binding information is performed during the final step of the
sequencing process. The merged droplets containing one type of sample DNA fragment and one
type of 6mer are optically scanned for fluorescence. The basic approach to this scanning method
involves excitation of the fluorophores via a laser and detection of the subsequent fluorescence
or lack of fluorescence in each merged droplet via high-speed camera, and is feasible to
accomplish with current marketplace technology.

2.2.4 Genome Reassembly
The reads generated from the sequencing step are the 6-mer oligos which are bound to
the fragments in the drop. The 6 bp fragments are building blocks of the original genome. The
reads are originally assembled using de Bruijn graph approach to generate secondary reads
which are the length of fragments inserted into microdroplets. Secondary reads are then
assembled using shotgun sequencing to regenerate original genome. The two step assembly is
necessary because the reads with length of 6 bases are too short and not suitable for shotgun
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sequencing algorithm. De Bruijn Approach, on the other hand, is capable of handling short reads.
However, it is memory intensive if applied to assemble the entire genome. Hence, the mentioned
strategy is selected. The two step assembling scheme is discussed separately.
2.2.4.1 De Bruijn Approach Overview
One of the suitable assembling algorithms for
6mer oligo library is de Bruijn Approach. Bruijn or
Eulerian Path approach utilizes the concept of de Bruijn
graph theory. It is a direct graph that represents
sequence of symbols and the edge of the graph indicate
where the sequence may overlap. 6mer oligo library
raw sequencing data is suitable for this approach
because de Bruijn is capable of handing small
fragments. De Bruijn graph is constructed where the
Figure 2.6 de Bruijn Graph Construction The
overlapping scheme of de Bruijn Graph is shown.
For the reads with 6 bp length, 6-1 = 5 bases of
two nodes need to overlap in order for the two
nodes to be connected. The blue fragments
represent reads derived from bound oligo library
and the green fragment represented assembled
secondary read which is an output of de Bruijn
Graph Approach

nodes for the graph represent the sequence of bound
6mer and the paths in the graph represent connectivity
condition among them. The two nodes are connected
when their 6-1=5 bases overlap (Figure 2.6) (Abegunde,

2010). The sequence of the fragment is interpreted from de Bruijn graph by walking through the
directed path and visiting every node. For example, in Figure 2.6, by walking on the path, the
assembled fragment is ‘A B C D E F G H’. This satisfies the de Bruijn requirement because the
paths which assemble the sequence visit all three existing nodes in the graph.
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The fragments inserted into the drops are assembled with the same algorithm to generate
fragments with its original length. These assembled fragments are referred to as secondary reads
which are used as inputs for subsequently shotgun sequencing assembly.
2.2.5.2 Shotgun Sequencing Overview
The secondary reads generated from de Bruijn graph assembly are used as shotgun
sequencing building blocks. Each secondary read is comprised of bases with expected length
equal to that of original fragments inserted into the microdroplet. Shotgun sequencing employs
the aligning and merging strategy of secondary reads to generate the entire genome (CBCB).
The total length of all secondary reads must be many times longer than that of the original
sequence. This is so that the each base in the final interpretation is covered by more than one
fragment which vote to determine the base with satisfactory accuracy.

Figure 2.7 Shotgun Sequencing Overview The overlapping scheme of shotgun sequencing assembly is shown. The secondary
reads (represented in green which are the output from de Bruijn graph assembly are used as shotgun sequencing building blocks.
The secondary reads are aligned and the original genome (represented in red) is generated using the overlapping information.

In Figure 2.7 shotgun sequencing aligning and overlapping scheme is presented. The
original sequence (represented in red) is reassembled using overlapping information of the
secondary reads (represented in green). Secondary reads must be random and cover all base
positions of the original sequence in order for the reassembled sequence to be continuous with no
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gabs in between. If number of secondary reads generated is not sufficient, gaps will occur upon
completion of genome assembly.
Generally, gaps are allowed in human genome project. Based on acceptable error rate, a
certain number of secondary reads is required. Since secondary reads are assembled from
fragments inserted into microdroplets, the number of drops required to achieve specified total
error rate is a function of number of secondary reads required to reconstruct original genome.

2.2.5 Relevant Technologies Summary
An analysis on relevant genome sequencing technologies shows potential applications of
aforementioned technologies in Micro$eq’s process. The necessary steps of typical genome
sequencing – DNA presequencing, DNA sequencing and genome assembly—are outlined in this
chapter. More specific technologies in which Micro$eq can potentially applied to its design are
also outlined. DNA droplet as microreactor, 6mer hybridization, droplet scanning, de Bruijn
graph assembly and shotgun sequencing are first introduced in this chapter. More detailed
discussion on each technology can be found throughout the report.

2.3 MICRO$EQ’S APPROACH CONCLUSIONS
In this chapter, Micro$eq’s proposal and introduction to relevant sequencing technologies
are presented. The goal of the project is to offer ‘$100 genome’ at the rate of 10,000 genomes per
year after the scale up. The acceptable error rate in this case is specified at 10 parts per million.
Micro$eq implements Raindance Technologies’ droplet microreactor to achieve high throughput,
low cost and high accuracy – satisfying customers requirements. Main target market for
Micro$eq are pharmaceutical firms who conduct clinical trials for their newly developed drugs.
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Micro$eq is expected to deliver whole genome sequences but not the interpreted information of
the sequences. In addition, relevant technologies are analyzed in this chapter to effectively
design Micro$eq’s process. Technologies related to genome sequencing steps—presequencing,
sequencing and genome assembly—are introduced. Further detailed discussion on implemented
technologies can be found throughout the report.
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CHAPTER 3

Micro$eq’s Base Case Approach
3.1 INTRODUCTION OF BASE CASE
Micro$eq’s base case of personal genome sequencing is given by Weitz’s new startup,
GnuBio. A library of 6 base oligonucleotides is selected. All combinations of the 6 base are
generated and are combined with fragments of the patient’s DNA. As previously discussed in
section 2.1, after the nanoliter droplets are broken into thousands of smaller (picoliter) droplet,
the drops are merged in 1:1 fashion with the oligo libray drops. Roughly 1,000 base fragments of
patient DNA are generated from 6 base oligonucleotide hybridization. These 1,000 base
fragments are then reassembled to generate the whole genome.
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In this chapter, the infeasibility of the base case proposed is explored when one fragment
of approximately 1000 base pairs long is inserted in the parent droplet. Presequencing,
sequencing and genome assembly’s overview and results are discussed. Furthermore, solutions
to existing difficulties are proposed at the end of this chapter and explored in detail throughout
the report.

3.2 BASE CASE PRESEQUENCING PROCESS OVERVIEW
As discussed earlier, pre-sequencing preparation of the input sample must be performed
so that the DNA is in optimal form for subsequent sequencing and reassembly. The input for this
process will be the customer’s saliva. From the saliva the DNA must be extracted, purified, and
then fragmented. Fragmentation to ~1000bp fragments will be performed via sonication as
previously discussed in section 2.2.1. For the 3 billion base pair human genome, a minimum of
3 million 1000bp fragments will be required to cover the entire genome twice. While the actual
number of fragments required to sequence an individual’s genome will be much greater than this,
the details of these requirements will be discussed later in this chapter. For now, it can be
assumed that our number of fragments to be processed is 3 million. These fragments will then be
amplified (copied) in order to achieve the necessary concentration for optimal hybridization with
the 6mer library during the sequencing process.

3.2.1 Droplet Screening
As the proposed reassembly step requires each fragment to be sequenced separately, it is
essential that each droplet of DNA that is merged with the 6mer sequencing library contain
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copies of only one type of DNA fragment. To achieve this droplet homogeneity, the fragmentcontaining droplets will need to be screening prior to amplification so that only droplets
containing single molecules are amplified, thus generating strictly homogenetic droplets to be
used for sequencing.

3.2.1.1 Single Molecule Droplet Generations
Single-molecule droplets are generated by diluting the input DNA solution such that the
average DNA per molecule is low enough to be able to yield single-molecule droplets. (λ) =
~0.3. The distribution of DNA molecules will be a Poisson distribution such that the
probability(P) of having k number of DNA molecules per droplet is expressed in terms of the
average number of DNA molecules per droplet (λ) as seen in Equation 3.1:
( )=

!

Equation 3.1

When the concentration is diluted such that the average number of molecule per droplets of a
given size is λ=0.3, the distribution of DNA molecules will be such as is seen in Table 3.1:
k
% droplets

0
90.0

1
9.00

2
0.45

3
0.015

>3
3.8e-6

Table 3.1 Pre-amplification DNA molecule distribution in droplets

Generating accurate uniform droplet generation with an average number of DNA
molecules less than 0.3% is virtually impossible, thus this droplet distribution in Table 3.1 is the
closest to single molecule droplets that can be achieved.
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3.2.1.2 Single Molecule Droplet Detection and Sorting
A fluorescent-activated droplet sorting
system (FADS) can be used to efficiently sort
the droplets using dielectrophoresis. In order to
detect the presence of DNA in the droplets, a dsDNA intercalating dye will be added during the
DNA sample preparation and purification
process described above. This die becomes
highly

fluorescent

when

intercalated

into

double-stranded DNA. The droplets are then
analyzed using an optical setup of a 488 nm
laser and photomultiplier tubes (PMT) which
measuring epifluorescene in the wavelength

Figure 3.1: Schematic Representation of optical setup (Nie,
1997)

range of emission by the ds-DNA dye. The full
optical setup for this procedure is shown in Figure 3.1. As seen in Figure 3.1, light is emitted
from the laser (LAS) shaped into a laser line (LL) and transmitted through a multi-edge dichroic
beam splitter (DBS) to the microscrope (OBJ). Inside the microscope, the laser light will pass
through the beam splitter (BS) and is reflected up into the objective by a conventional mirror
(M). The shaped laser beam is focused to a ~10x150 µm line across the sorting flow channel
which is imbedded in a microfluidic chip (CHIO). The beam excites the droplets one at a time as
they flow past. The fluorescent emission from each droplet is passed back along the path of the
laser beam, but is reflected by the DBS to the sensor of the photomultiplier tube (PMT) via
bandpass filter (F2). Filtered light from the microscope’s halogen lamp (LAMP) illuminates the
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channels and droplets, allowing the trajectories of droplets to be monitored by the high-speed
camera (CAM). The filter (F3) removes wavelengths of light that were detected by the PMT to
avoid a high background signal (Nie, 1997).
After the droplets pass through the laserexcitation point, they reach a Y-shaped sorting junction
(depicted in Figure 3.2). The junction consists of a largerdiameter branch, which is the default path of the droplet
due to lower hydraulic resistance, and a smaller-diameter

branch, into which chosen droplets will be sorted. The
sorting junction is adjacent to electrodes that are capable
of producing a pulse of high-voltage alternating current

Figure 3.2: Y-Shaped sorting junction.
Droplets flow to larger branch by default due
to lower hydraulic resistance. Droplets chosen
for sorting are deflected via electric field to
smaller branch when an AC is applied across
the electrodes.

(AC) in order to alter the path of the droplets.
The high-speed camera frames are processed by MATLAB (see Figure 3.3). The green
fluorescence of the ds-DNA intercalating dye is normalized against the background red dye
fluorescence and these results are then communicated to the electrodes (see Figure 3.3). Droplets
by default (without an AC pulse) will continue to the larger branch of the Y-junction. A DNApositive readout from the high-speed camera (CAM) sends a signal to the electrodes, which
causes them to generate an AC pulse. This pulse deflects the DNA-positive droplet trajectories
upward, causing them to be sorted into the smaller arm.

Micro$eq – Chomvong, King, Mahmoud

40 | P a g e

b)

a)

Figure 3.3 (a) Individual frames from the high-speed camera during sorting. In the first frame, the arrival of a green fluorescent
droplet was observed and fluorescence is depicted by the blue box. The trajectory of this droplet is monitored through the
junction by examining pixel changes in the two arms (second frame. The droplet is correctly sorted into the DNA+ arm (green
box). In the third frame, a red (lower) fluorescence droplet is detected (blue box). This level of fluorescence does not trigger any
sorting mechanism response and is correctly allowed to enter the DNA- arm (red box), as depicted in the fourth frame. (b) Time
sequences of the PMT signal (U; volts) and the AC pulses applied in response to sorting decisions (Usort; volts. The field was
applied on the falling edge of fluorescent peaks that exceeded the threshold voltage (in gray). U0 was a reference voltage (1 V)

Empty droplets sorted into the larger branch and sent to waste, whereas DNA-occupied droplets
sorted into the smaller branch will be sent to a droplet reservoir where they will enter into the
next stage of pre-sequencing processing.
3.2.1.3 Single Molecule Droplet Limitations

For the droplet DNA-content distribution described above in Table 3.1 , 90% of the
droplets will be DNA- and sorted to waste. The remaining 10% of droplets will be DNA+ and
sorted to the remainder of the pre-sequencing process at a rate of 50 DNA+ droplets per second).
Of these DNA+ droplets, 90% will have only a single DNA molecule, making them viable for
eventual sequencing. The remaining 10% will have two or more different fragments and thus
will yield heterogeneous droplet content upon amplification and will be ignored during the
sequencing readout as their data will be muddled.
This probability distribution in itself builds a 9% inefficiency rate into this approach to
sequencing. For the total of 3 million minimum required fragments as discussed above, 33
million droplets will need to be processed per genome. While the fluid dynamic limitations on
droplet flow will be discussed in later chapter, current accepted maximum droplet flow rates in
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the pL droplet size range are ~3000 droplets/second. This implies that the sorting process alone
would take ~20 minutes (1200 seconds). While this processing time is not significantly limiting
on overall process time, it is important to keep in mind the temporal implications of the required
droplet throughput.
Additionally, this process of droplet sorting is extraordinarily expensive. Each optical
setup will cost upwards of $100,000 (Phototron USA Incorporated). The most expensive portion
of this process is the high-speed camera. A high-speed camera is already required for the
sequencing portion of this to detect fluorescence associated with hybridization of DNA
fragments with the 6mers. Thus, the use of single molecule technology essentially doubles the
combined fixed costs of the pre-sequencing and sequencing processes

3.2.2 Single Molecule Amplification
The details of DNA amplification will be discussed in the next chapter of this report.
However, for the purpose of the present discussion, it is important to note that while the singlemolecule droplet sorting stage is a huge financial hindrance, single-molecule amplification is
also a process design obstacle.
Because the droplets are generated randomly, the amplification must target all possible
random sequences in order to guarantee amplification of each fragment. For complete targeting
of the sequences, a minimum of 786 trillion different amplification reactions are required, which
translates into 786 trillion different droplets. Only some of these droplets will contain amplified
copies of the DNA and thus will be able to be used in sequence. Thus, before the sequencing can
occur, the amplified droplets will need to be sorted again using the same method as described
above in the droplet sorting section. Not only will this again add the immense cost of an
additional optical detection setup, but processing the 786 trillion different required droplets will
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take ~8335 years. This time could be reduced if processing were done simultaneously in parallel
stations. However, the cost of adding, for example, eight thousand more optical setups is beyond
the capability of Micro$eq.
The details of these calculations will be discussed in the next chapter, but these
estimations indicate that not only is the single-molecule approach financially crippling on the
presequencing steps, but is temporally impossible.

3.3 BASE CASE SEQUENCING PROCESS OVERVIEW
3.3.1 Introduction
Micro$eq’s sequencing approach is to hybridized known 6 base pair long
oligonucleotides with a fragments of the patient’s DNA and detect hybridization fluorescence. A
microfluidic platform technology which uses microdroplets is well suited for this sequencing
scheme. Droplets containing fragments of the patient’s DNA and different oligonucleotides are
merged (Figure 3.4). The droplets are scanned to determine whether hybridization occurred.

Fluorescenct
Oligonucleotide
with
complementary
quencher

Rehybridization
which leads to
fluorescence
Fragments
of Patient
DNA

Figure 3.4 Depiction of Watson Crick Base Pair Hybridization sequencing using a microfluidic platform. In a microfluidic
platform, droplets containing fluorescent oligonucleotides are merged with fragments of patient DNA. Subsequently, the merged
drop is scanned for hybridization.

Micro$eq – Chomvong, King, Mahmoud

43 | P a g e

A design has to be created to combine 4064 copies of an identical target fragment with
4064 different oligonucleotides.

However, one has to keep track of or barcode which

oligonucleotide is in which drop in order to extract any useful information. The second process
sequencing task is scanning. An optical system has to be designed which can scan 106 droplets
per second for fluorescence.

3.3.2 Barcoding the Oligos Library
Barcoding the oligos library is a very unique but difficult task. 4064 unique signals have
to be created and detected in addition to fluorescence due to hybridization. Some proposed
approaches are described in the following sections and a concluding statement is made regarding
what makes an effective barcoding scheme.
3.3.2.1 ‘Barcoding’ the Oligos Library Using Microscopic Beads/Dyes
One proposed approach is to barcode the oligos library by using colored microscopic
beads.

Microsphere and nanosphere manufacturers, such as phosphorex, produce polymer,

fluorescent, phosphorescent microspheres ranging in size from 20 nm to 1000 microns
(Phosphorex, 2010). Their selection includes plain polymer microspheres and nanospheres,
colored dye microspheres and nanospheres made of polystyrene, polystyrene fluorescent
microspheres, and phosphorescent/luminescent nanospheres.
Droplets produced by microfluidic chips such as Raindance Technologies are on the
order of 30 nm in diameter. Considering this, one can add one micron sized beads to each drop.
4064 unique barcodes can be created by using a combinatorial approach to barcode the oligos
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library. The idea is that different colored microspheres and dyes are added to a microdroplet and
each colored microsphere adds to the value of a certain digit (Figure 3.5).

Figure 3.5 Combinatorial Approach using Colored Microspheres: Each colored microspheres represents a different digit.
The number of microspheres of that color is used to denote the number in that ordinate.

The number of blue microspheres signifies the number in the thousand digit while the
number of red microspheres is equal to the number in the hundreds digit and so on. Using this
approach the maximum number of beads is 30, which corresponds to the number 3999.
One can also add a dye to decrease the number of microspheres in each droplet. If a red
dye is added to an oligos library droplet, 3 units are added to the last 3 digits, if a blue dye is
added, 5 units are added to the last 3 digits, and if a green dye is added, 7 units are added to the
last 3 digits (Figure 3.6). In addition to a dye, one can decrease the number of beads required by
having two different sized beads, for example a 2µm sized beads and 1 µm sized beads. The
larger beads are used to represent the addition of 5 units to the corresponding digit (Figure 3.7).

Figure 3.6 Sample Microdroplets with dyes: A red dye adds 3 units to the last three digits, a blue dye adds 5 units to the
last 3 digits, and a green dye adds 7 units to the last three digits.
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Figure 3.7 Example of a microdroplet with different sized beads. Using the rules described in the text, the microdroplet
above represents the 3327th oligomer.

There are advantages associated with this barcoding scheme.

First of all the costs

associated with colored beads and food coloring for the dye are very low. However, the major
drawback associated with this system is the engineering required to ensure that certain colors of
microspheres are present in certain drops in certain amounts with certain dyes. It was envisioned
that Image J, which is an imaging program, contour function that can employed to locate and size
the microspheres, detect the colors, count the microspheres and automatically read the barcode.
However, many drops would be wasted in a prescreening process design to make sure that
certain numbers of microspheres are present in certain amounts with certain dyes. Furthermore,
a large number of drops would have to be scanned because each fragment is copied and merged
with 4,064 different droplets. This decreases the throughput time because a larger number of
drops have to be scanned. Having a system which has complicated and costly engineering to set
up is not efficient. It was decided that using fluorescent polymers or spatial barcoding would be
a lot simpler and involve less prescreening.
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3.3.3.2 Finding an optimal strategy of 'barcoding' the oligos library using fluorescent
polymers
We also sought to barcode the oligos library proposed in the Micro$eq’s design by using
fluorescent polymers that emit in three different colors. In total 4,064 6-base oligos need to be
labeled with distinctive fluorescent barcode identifiers. This approach uses the red, green, and
blue fluorophores at different wavelengths and intensities to ‘barcode’ the oligos library (Figure
3.8).

Figure 3.8 Combinatorial Approach: The Combinatorial Approach designed using fluorescent polymers seeks to multiplex the
system by using wavelength and intensity.

Bangs Laboratories Inc. manufactures fluorescent polymers with varying colors and

intensities. The fluorescent dye spectra of the polymers manufactured are given in the Appendix

A.

The Bangs Laboratories Inc. polymers were grouped based on the color of their emission
(Figure 3.9). In reality, modern microscopes would not be able to resolve the emission signals
associated with combinations of fluorophores because there is some overlap between the
channels. Modern microscopes typically image in four color channels by using rotating filters
and measuring intensity in a particular wavelength. This mechanism is not capable of capturing
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all of the information captured by the barcoding scheme. This can be resolved by having a
spectrometer capture the emission spectra and then to deconvolute which signals are present by a
curve fitting using MATLAB. Spectrometers measure the emission intensity across a set of
wavelengths.

Figure 3.9 Combinatorial Approach using Fluorescent Polymers: Bangs Laboratories Inc.’s fluorescent polymers are divided into
three pseudochannels based on their wavelength. Each fluorescent polymer is present in prepared in four concentrations except
the colors that are present in 5 intensities. For those, the most intense and least intense polymers are carefully diluted or
concentrated to give 10 combinations which do not overlap. The absorbance and emission peak wavelengths are provided.

However, the difficulty is still to get 4,064 unique signals. To reach this number of
combinations, each polymer is prepared in 4 different concentrations (1X, 10X, 100X, and
1000X). This is done for all polymers except the ones that are available in 5 intensities. For
these, the most intense and least intense polymers are carefully diluted into two concentration to
give 10 combinations which do not overlap.
According to this scheme, the total number of combinations is 4,752 (Figure 3.10). By
summing the signal and concentration, 12 different signals can be emitted in the pseudoblue
channel. Similar statements can be made about the red and green channel.
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Figure 3.10 Combinatorial Results for Fluorescent Polymer: By multiplexing concentration and signal 4,752 distinct
signals can be created.

The major drawback associated with this scheme is that there are a lot of noise issues.
Particularly, can different signals be considered distinct with a reasonable amount of confidence?
Will noise associated with the instrument make the multiplexed emission signals
indistinguishable? Furthermore, how will one be able to distinguish fluorescence hybridization
emission from the barcoding scheme? This second issue is particularly difficult to address and
invalidates this scheme. Although, the introduction of a spectrometer to map out an emission
spectra provides interesting possibilities, ultimately signal to noise issues and detection of
fluorescence hybridization invalidate this scheme.
What makes an effective barcode is multiplexing and reasonable signal to noise.
Multiplexing allows one to use combinatorics to create large numbers of distinct signals to
barcode. At the same time one has to maintain a reasonable signal to noise to be able to
distinguish the signals. Maintaining a reasonable signal to noise makes sure that fluctuations in
measurement and fluorophore concentrations do not give the wrong barcode.
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3.3.3 Scanning
One proposed method of optical scanning was to pass droplets by a flow cytometer and to
scan them for the barcode and hybridization using multiple detectors (Figure 3.11). In this setup,
laser light is aimed at a point where microdroplets pass through a capillary channel. Multiple
detectors are aimed at the point where the microdroplets pass through the laser light in order to
detect hybridization fluorescence. However, the current state of the art only allows us to scan
droplets at a rate of 10,000 droplets per second (bdbiosciences, 2011). This throughput is off by
several orders of magnitude from the target throughput of 106 droplets per second.

Figure 3.11 Flow Cytometer setup to scan microdroplets for fluorescence: light is aimed at a point where microdroplets
pass through a capillary channel. Multiple detectors are aimed at the point where the microdroplets pass through the
laser light.
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3.4 BASE CASE GENOME ASSEMBLY OVERVIEW
According

to

proposed

plan,

the

expected

assembled throughput per microdroplet is 1000 bases.
Statistically, the estimation is logical. Ambiguity in de
Bruijn graph assembly occurs when two or more 6mers
with identical first 5 bases are in presence (Figure 3.12).
Since there are four possible bases in human genome, A T
C or G, 6mer oligo library is used, the longest sequence
which 6mers can reconstruct using de Bruijn approach

Figure 3.12 de Bruijn Graph Ambiguity
When two or more than two 6-mer reads have
identical 6-1 = 5 bases, ambiguity of graph
interpretation arises. There are two probable
interpretation of this graph ‘A T C T A A G’
or ‘A T C T A A T’

before ambiguity arises is (Equation 3.2)
45 = 1024 bases

Equation 3.2

This calculation means that 6mer reads generate one to one relationship between each
reads until approximately 1024 bases are sequenced before branching or ambiguity arises.
However, experimentally, the ambiguity arises much earlier than expected, yielding less than
1000 bp secondary reads. In fact, MATLAB simulations show that the longest doubled strand
sequence which 6mers can reconstruct using de Bruijn approach before ambiguity arises is
approximately 35 bases. [See Appendix D]. The experimental throughput per droplet is 30 times
lower than the proposed plan. With the throughput of 35 assembled bases per drop and 10-5
acceptable error rate, sequencing specification and required time are presented in Table 3.2:
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Parameters
Fragment Length
Number of Doubled Strand
DNA Fragment per Drop
Number of independent
fragment per drop (nFrag)
Throughput
Adjusted Throughput
Error Rate
Required Coverage
Required Secondary Reads
Number of Parent Drops
Number of Daughter Drops
Pre-sequencing Time
Sequencing Time
Computing Time

Experimental Estimation
35 bp

GnuBIO Proposal
1000 bp

1

Frag/drop

1

Frag/drop

2

Frag/drop

2

Frag/drop

70
35
10-5
11.55
9.57x108
7.86 x 1014
2.0x1018
7.3x107
5.53x108
12

bp/drop
bp/drop

fragments
drops
drops
hours
hours
hours

2000
1000
10-5
11.52
3.34x107
786x1012
1.69x1010
8335
63369
0.42

bp/drop
bp/drop

fragments
drops
drops
years
years
hours

Table 3.2 Experimental Estimation vs. GnuBIO Proposal Experimentally, the longest sequence which can be reassembled
during de Bruijn assembly is 35 bases of doubled strand DNA per microdroplet. This throughput is 30 times lower than the
GneBIO claim.

As seen in Table 3.2, the volume of required droplets and thus the required throughput time for
this base case process is on the order of magnitude of 70,000 years. Clearly this timescale is
unrealistic and thus the process cannot be accomplished using the same proposed method as
GnuBio.

3.5 BASE CASE FEASIBILITY CONCLUSIONS
Sorting droplets for single molecules during presequencing requires costly control
systems. Furthermore, single-molecule amplification schemes are huge process obstacles. Thus
future work focused on engineering cost efficient system to circumvent these design challenges.
In addition, the implementation of nonrandom PCR reactions provides an interesting way to
reduce the number of PCR reactions. Micro$eq’s presequencing strategy is further discussed in
chapter 5.
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Base case feasibility designs on the sequencing system determined that an effective
barcoding strategy must take advantage of multiplexing to create many distinct signals and to
package multiple oligonucleotides per droplet. Also it was determined that state of the art
scanning by flow cytometry cannot achieve our scanning rate goal of 106 droplets per second at a
reasonable cost.

Thus, we decided to build our own optical system to scan the droplets.

Micro$eq’s sequencing strategy is further discussed in chapter 6.
With respect to genome assembly, it has been demonstrated that if one 35 base pair,
doubled stranded fragment is inserted per droplet, 1.83*1011 droplets need to be generate to
sequence a whole human genome. However, the requirement is not feasible because process time
and cost are not within the target range (12 genome/day and $100/genome).
To accomplish the target goal, Micro$eq proposes a solution to decrease number of
droplets required. Three steps are taken to accomplish this. First, non-random sequence
amplification is performed such that only two different amplification reactions, which may take
place in the same droplet, are used instead of the 768 trillion required for random amplification.
Second, the number of different fragments processed in each droplet is increased from one,
further decreasing the number of total droplets. Finally, the number of 6mers used for sequencing
per droplet is increased from one, even further decreasing the number of required droplet.
Because more than one randomized doubled strand fragments are inserted in each drop. The
break between fragments should decrease ambiguity in de Bruijn graph interpretation; thus
increasing de Bruijn assembly throughput. In other word, the accidental overlap between
incorrect reads is less likely to arise. Statistically, the probability of finding ambiguity in
assembling one 100 base fragment is higher than that of two random 50 bases fragments.
Optimization of number of doubled strand fragment per drop, average fragment length, and
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required number of secondary reads are studied to minimize number of drops needed to be
generated; decreasing time required for DNA scanning process and minimize cost of production.
A detailed outline of all technical aspects of Micro$eq’s modified strategy is in Chapters 5, 6,
and 7 of this report.
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CHAPTER 4

Molecular Biology Limitations on
Presequencing and Sequencing
Processes
While an outline of Micro$eq’s general approach to genome sequencing has been
discussed in the context of the financial and temporal challenges presented by this process, the
molecular biology limitations associated with all steps involving DNA processing have yet to be
mentioned.
The field of molecular biology is dynamic in that many of its basic principles are still
being determined or altered as new research is being done. This chapter aims to outline a few of
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the fundamental molecular phenomena associated with DNA and illustrate how these principles
limit Micro$eq’s approach to the presequencing and sequencing steps of its genome assembly
strategy. This chapter will also provide an outline of how Micro$eq has developed modified
approaches to these steps will work around the limitations presented here and thus render its
approach feasible on the molecular level.
4.1 MOLECULAR BIOLOGY CHALLENGES IN THE PRESEUENCING PROCESS
The required output from the pre-sequencing process is determined by the approach to
sequencing (merging with 6 base pair sequences) and the optimization of the reassembly
algorithm (to determine which combination of fragment size and fragment number allows for the
lowest error rate and quickest processing time). However, it is important to remember that the
requirements implicated by the later steps are determined by optimization of those steps and do
not take into account the limitations of molecular biology.
Two major challenges arise from the imposed requirements of the pre-sequencing output.
The first challenge is the generation and processing of an extremely small (<25bp) fragment of
DNA. Second, the generation and amplification of a precisely-sized DNA fragment. The
challenge of the pre-sequencing process will be to capitalize on available molecular biology
techniques and to design new molecular biology strategies based on known biochemistry in order
to adhere as closely as possible to the required output. This section outlines the biological
limitations that create these two major obstacles, and will discuss a proposed method of how to
overcome these limitations.
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4.1.1 DNA Thermodynamic Properties
The most important molecular biology concept which affects the feasibility of presequencing challenges is the stability of DNA molecule. While DNA exists naturally in the
human body (37°C) and is stable in this state, these fragments are on the order of 10 million base
pairs long. As previously discussed, the sequencing process requires the handling of much
smaller DNA fragments (<100bp). These smaller fragments are much less stable and must be
handled accordingly. Before a modified process can be designed to help deal with the potential
instability of small fragments, it is important to understand what causes this instability and its
impact on the pre-sequencing properties.
4.1.1.1 DNA Hybridization
The first consideration in terms of DNA stability is
the thermodynamics of DNA hybridization. For the most
part, DNA exists naturally in our body as a double-stranded
complex. Each half of the complex is a single-stranded
fragment referred to as an allele. The nucleotides in each
allele are covalently bound to the adjacent nucleotides in
that allele. The two alleles then form double-stranded DNA
Figure 4.1 Hydrogen Bond Base Pairing by
NucleotidesInvalid source specified.

via intermolecular interactions between their sets of base
pairs, referred to as Watson-Crick base pairing. These

interactions occur in the form of Hydrogen-bonds between the complementary bases. Specificity
of complementarity is determined by the chemical structure of the base pairs. As seen in Figure
4.1, Adenine (A) and Thymine (T) can only complement each other, as they bind via the
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formation of three hydrogen bonds whereas Guanine (G) and Cytosine (C) can only complement
each other as they bind via the formation of two hydrogen bonds.
As a result of the different number of hydrogen bonds between the two possible base pair
bindings, binding affinities will differ with the relative percentage of A/T pairings versus G/C
pairings. In longer strands of DNA, the percentages of the two different pairings are relatively
equal. However, in smaller strands of DNA, the representation of A/T versus G/C bases can be
very biased. Thus a small(<25bp) fragment of DNA that is A/T rich will have a much higher
binding affinity than one that is G/C rich. This variability in binding affinities makes it very
difficult to batch-handle small fragments of DNA.
4.1.1.2 DNA Melting Temperature Estimations
In addition to its dependence on the nucleotide makeup of the fragment, the binding
affinity of small fragments of DNA is already lower than that of larger fragments. These
affinities are more commonly analyzed in the context of fragment melting temperatures. The
melting temperature of a DNA fragment is defined as the temperature at which half of the DNA
fragments will be hybridized (thus double-stranded) and half will be denatured (single stranded).
The melting temperatures are crucial for any reaction involving DNA molecules, as (with the
rare exception of the presence of an enzyme that can disrupt a double-stranded DNA complex),
DNA must be single stranded such that its nucleotide’s reactive groups are exposed and may
participate in a chemical reaction.
For larger DNA fragments (>100bp), the melting temperature of the double-stranded
DNA may be estimated via Equation 4.1:
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∆Η o •1000
Tm = 
 − 273.15 + 16.6log[Na + ]
o
 A + ∆S + R ln(Ct / 4) 
Equation 4.1 Melting Temperature (°C) of Larger Oligonucleotides (Owczarzy R. ) where ΔH (Kcal/mol) is the sum of the
enthalpy changes associated with base pair binding, ΔS (eu) is the sum of the entropy changes associated with base pair
binding, A is a constant, R is the gas constant, Ct is the total concentration of DNA strands, and [Na+] is the solution salt
concentration.

Using Equation 4.1, along with empirically derived values for the entropy and enthalpy
of base pair bindings, it can be found that for large fragments of DNA (>10,000bp) the melting
temperature is around 95°C. It is also important to note that Equation 4.1 does not take into
account the A/T and G/C make-up of the strand, as these effects are minimized in larger strands
as discussed earlier. Additionally, it is important to note that the melting temperature depends on
both the DNA fragment and salt concentration in solution. This process will take advantage of
these dependencies in order to manipulate the melting temperatures, as will be discussed later in
this chapter.
4.1.1.3 The Nearest Neighbor Method
For smaller DNA fragments (<30bp), the melting temperature is estimated using the
Nearest Neighbor method (NN). This model assumes that the stability of a given base pair
depends on the identity and orientation of neighboring base pairs (SantaLucia J. , 1998). For
these smaller oligonucleotides, additional parameters for the estimation of duplex melting
temperatures must be applied (Derivation of nearest-neighbor properties from data on nucleic
acid oligomerse. II. Thermodynamics of DNA, RNA hybrids, and DNA duplexes, 1997). This
initiation parameter encompasses all other sequence-independent effects, including differences
between terminal and internal base pairs. In such small fragments, the terminal base pair, which
initiates the denaturation (or reannealing) of the fragments, plays a significant role in the doublestrand thermodynamics. To account for the differences with terminal A/T versus terminal G/C
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pairs,

two

different

differentiation

parameters have been developed (Allawi
&

SantaLucia,

1997).

For

self-

complementary duplexes (meaning the
two alleles of the DNA are identical), an
additional

entropic

penalty

for

the

maintenance of the C2 symmetry is also
included.
Table 4.1 : Nearest-Neighbor Thermodynamic Parameters for
Watson−Crick Base Pair Formation in 1 M NaCl (Allawi &
SantaLucia, 1997)

Recently, a study compiled

unified oligonucleotide NN parameters set
based on collection of 108 different

nucleotide duplexes studied in seven different laboratories (Allawi & SantaLucia, 1997). The
results of this compilation are displayed in Table 4.1 and are applied to the following
calculations.
The values in this table can be incorporated into Equation 4.4.2 below to calculate the total
free-energy of a small fragment hybridization.
o
o
o
o
∆Gtotal
= ∆Ginit
+ ∑ ∆GTo (i) = ∆H total
+ T∆Stotal
5

i=1

Equation 4.4.2 Gibbs Free energy of double-stranded binding where ΔH is the sum of the enthalpy changes associated with
base pair binding, ΔS is the sum of the entropy changes associated with base pair binding, and T is the absolute reaction
temperature

The application of Equation 4.4.2 to a hypothetical 6bp oligonucleotide duplex binding
event and comparison of the NN model’s result to empirically-derived value is displayed in
Figure 4.2.
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Note: In general, if a large
temperature
37°C

extrapolation

from

is

required,

then

the

difference

between

the

heat

capacities of the hybridized and
quenched states, ΔC°p, should be
accounted for. However studies
Figure 4.2 Application of the unified nearest neighbor parameters to
predict ΔG°37. The duplex used above is non-self-complementary and thus
ΔG°(sym) is zero (SantaLucia J. , 1998)

have shown that ΔC°p is relatively
small

for

nucleic

acids

(Rentzeperis, Ho, & LA, 1993), (Erie, Sinha, Olson, Jones, & Breslauer, 1987) between 25°C 37°C. Due to enthalpy–entropy compensation, ΔG°37 is relatively insensitive to ΔC°p. Thus, for
the purpose of the above thermodynamic estimation, the effects of temperature on the heat
capacity, and thus the overall free energy, have been ignored
From the comparison in Figure 4.2, it can be observed that the NN model adheres closely
to empirical data and is feasible to use for the thermodynamic data to be estimated for the
purpose of this project. This model will be discussed in more detail later in this chapter to
analyze the properties of interactions between the 6mers used for DNA sequencing. Additionally,
the above discussion illustrates the challenges involved in preparation of the small (<25bp) DNA
fragments.
4.1.1.4 Potential Stabilization Methods
Because of these thermodynamic challenges associated with small DNA fragments, most
approaches to sequencing that require working with small DNA molecules modify the DNA by a
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variety of methods. As discussed earlier, some companies choose to immobilize the DNA either
on slides, in well plates, or on the surface of beads. The immobilization process involves the
addition of a synthetic oligonucleotide to the end of the genomic DNA fragment, which then
binds complementary with another synthetic oligonucleotide on the surface, as previously
discussed in the Competitive Analysis section of this report. This approach both elongates the
DNA strand as well as inflates the free energy of reaction of the DNA as its orientation is fixed.
Another approach to handling small DNA fragments is isolating single molecules of DNA in a
microenvironment such as a droplet. If the DNA fragment is unable to interact with other
molecules, the consequences of its denaturation are virtually insignificant, as exposing the
reactive groups of each allele will not result in unwanted reaction.
However, as previously discussed, this project’s approach to sequencing allows neither
immobilization nor single molecule sequencing. Additionally, this project’s approach to genome
reassembly requires small DNA fragments. Thus, a new approach to small DNA fragment
handling must be designed in order to meet this project’s particular specifications, but the design
must still operate within the limits of molecular biology phenomena.

4.1.2 DNA Fragment Amplification
As previously discussed, single molecule DNA sequencing is not feasible in the context
of this project. Instead, a particular concentration of each DNA fragment must be present in
order to optimize the thermodynamics of the interactions between the DNA fragments and the
six base pair reads (6mers) that are to be used for sequencing. While the initial sample does have
multiple copies of the entire human genome, it is important that the multiple copies of the
fragments interacting with the 6mers are identical. If the copies are not identical, they will bind
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to different sets of 6mers and will not be able to be reassembled as a single fragment. The only
way to achieve multiple identical copies of any particular DNA fragment is to start with a single
molecule and amplify it to the required concentration using current molecular biology methods.
4.1.2.1 Polymerase Chain Reaction (PCR)
Amplification of DNA fragments via polymerase
chain reaction (PCR) is a standard protocol in the
biological research field. PCR is a thermally-controlled
cyclic reaction that generally takes place in solution. The
solution consists of the genomic DNA to be amplified,
short (10-25bp) oligonucleotides called primers, an excess
equal representation of A, T, C, and G of single
nucleotide bases (dNTP’s), a DNA polymerase enzyme, a
and a buffer solution, which contains cations such as
Magnesium to maintain a stable reaction environment. A
summary of this process can be seen in Figure 4.3.
As seen in this figure, the reaction cycle is
comprised of three main steps. First, the double-stranded
DNA is denatured to single-stranded DNA by heating the
sample to about 95C. Second, the temperature is
decreased to ~5°C below the melting temperature of the
primers

(which

were

also

denatured

during

the

denaturation step) so that the single stranded primers
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Figure 4.3 PCR Amplification Process. Blue
denotes the original genomic DNA, red
denotes the primers, and green denotes
newly synthesized DNA. Steps 1-3 are
repeated as required by target final copy
number (Artistik).
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anneal to each of the single-stranded DNA allele at the regions where they are complementary.
Third, the DNA polymerase binds to the site where the primers annealed and, using the dNTP’s,
extended the new DNA template to create two double-stranded copies of the genomic DNA. This
cycle is generally repeated between 20-45 times (depending on the starting number of copies and
desired ending DNA concentration), with each cycle doubling the number of DNA fragment
copies. The final of DNA copies can be calculated using Copies(n − cycles) = 2 n
Equation 4.3

Copies(n − cycles) = 2 n
Equation 4.3 Number of DNA copies present in solution after n PCR cycles

4.1.2.2 PCR Limitations
This technique to amplification is fairly straightforward and reliable. The error rate of the
DNA polymerase enzyme used is generally around 1 in 10,000bp . For a 40 cycle reaction that
generates ~1.1x1012 copies of a typically-sized DNA fragment (~50bp), the likelihood that a
particular base will be incorrectly amplified is negligible. However, as the (Innis M. G., 1988)
optimal length of the DNA fragments to be amplified in this project is 22bp. In addition to the
thermodynamic instability of small fragments as discussed earlier, this amplification of such an
extraordinarily short fragment is virtually impossible. The absolute minimum primer size usable
in PCR is 9bp, due to thermodynamic limitations as discussed in the previous section
(Dieffenback, General Concepts for PCR Primer Design, 1993). This means that 18 of the 22
bases in the 22bp fragment would be covered by primers. This 4bp gap makes it very difficult for
the DNA polymerase to bind and perform extension of the ds-DNA copy.
Additionally, in order for amplification to be unbiased across the whole genome, every
possible combination of the 9bp primers would need to be made and used in a PCR reaction. For
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the four different base pairs possible in each position on the primer, the number of different
primers will be 49 = 262,124. For the minimum of 1.4x108 different 22bp fragments required to
cover the entire 3x109bp human genome, this would mean an absolute minimum of amplification
of 3.6x1013 different PCR reactions required to unbiasedly amplify the genome once. Similar to
the previous chapter’s discussion of single-molecule amplification, this approach to 22bp
amplification yields an unrealistic fragment number requirement and a processing task that
would require a virtually impossible amount of time.
For these reasons, while Micro$eq’s sequencing approach does not involve single
molecules, its limitations on fragment size also do not allow it to employ the conventional PCR
method as described above. Instead, a modified method of genomic DNA fragment amplification
has been designed which allows unbiased amplification of 22bp fragments but at a fraction of the
cost and reaction time.

4.2 MICRO$EQ’S MODIFIED PRESEQUENCING APPROACH
The general principle behind Micro$eq’s modified approach to presequencing processing
relies on the addition of synthetic oligonucleotides to both ends of the genomic DNA. This
creates a longer DNA fragment, which then overcomes the molecular biology limitations
associated with the handling and amplification of small DNA fragments as described in the
previous section.
While the addition of synthetic sequences to genomic DNA is not a novel concept in
DNA processes, Micro$eq’s approach has two aspects that make it rather unique. First, is the use
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of small and exactly-sized genomic DNA fragments using restriction enzyme digestion? Second,
is the efficient amplification of small DNA sequences?

4.2.1 Restriction Enzyme Digestion
As previously discussed, most approaches to DNA fragmentation involve non-specific
mechanical shearing of the DNA using such methods as sonication. These methods generate a
distribution of fragment lengths. Instead, Micro$eq uses a biological method of shearing –
restriction enzyme digestion.
Restriction Enzymes are a class of enzymes that, upon the presence of a specific
nucleotide sequence in ds-DNA called a recognition site, cut the double stranded DNA. Each
type of restriction enzyme has its own specific recognition sequence. The mechanism of cutting
and the orientation of the cut from the recognition site are dependent on the type of restriction
enzyme used. For the purpose of this project, a type II restriction enzyme, which cuts a short
distance from its recognition site and only requires the presence of Magnesium in solution in
order to be activated.
4.2.1.1 Restriction Fragment Sizes
While restriction sites do exist in the human genome, they are generally spaced
~10,000bp apart. Additionally, they are not spaced equally apart, thus restriction enzyme
digestion of the unmodified human genome would yield large fragments of variable lengths. As
the Micro$eq approach requires uniformly-sized 22bp fragments, typical restriction enzyme
digest cannot be used. Instead, the recognition sites of the MmeI will be attached to the ends of
the genomic DNA via a synthetic sequence (adaptor). The MmeI enzyme then recognizes its
restriction site at the end of the adaptor, and subsequently cuts a short distance upstream of this
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site, at a digestion site that will fall in the genomic DNA sequence. MmeI is used as it cuts
exactly 22bp away from its recognition site (Dunn, McCorkle, & Praissman, 2002), thus 22bp
fragments of DNA can be generated as shown in Error! Reference source not found..

Figure 4.3 Adaptor Ligation and Restriction digest to generate 22bp fragments on genomic DNA. Genomic DNA denoted
in black, Adaptor sequences denoted in red, recognition sites denoted by blue triangles, digestion sites by orange stars

As seen in Figure 4.3 , the generated fragments consist of a 22bp genomic DNA fragment
ligated to a synthetic adaptor sequence. The practical implications of the presence of the nongenomic DNA sequence will be discussed later in this section. However, the important outcome
of this process is that 22bp of genomic DNA have been generated, but as a part of a longer
sequence, thus the thermodynamic instability of having a short DNA fragment is no longer an
issue. Additionally, because of the specificity of the restriction enzyme digest, all fragments are
exactly-sized to 22bp in length, an advantage to this process that will be discussed later in
chapter 7 of this report, the context of genome reassembly.
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4.2.2 Adaptor PCR
Now that the desired size of genomic DNA fragments have been precisely cut and
thermodynamically stabilized via the addition of an adaptor, these biological challenges have
been overcome. However, before amplification can take place, one final modification must occur
in order to eliminate the need for a large number of primers that would be the case if un-adapted,
non-specific DNA fragments were to be amplified.
As was seen in Figure 4.3, one end of the modified DNA fragment was bound to the
adaptor. As the adaptor was synthesized and the sequence is known, a specific PCR primer may
be designed to complement the end of the adaptor and allow initiation of amplification at that
end of the 22bp fragment. However, as previously discussed in section 4.1.2, amplification
requires primers to anneal to both ends of the fragment targeted for amplification. Thus, as one
end of the current fragment construct is non-specific genomic DNA, amplification of this
construct would still require all possible combinations of the 9bp primer sequence. To solve this
problem, an additional adaptor is added to the other end of the 22bp fragments. This adaptor’s
sequence is also known, and thus a specific PCR primer may
be designed to complement the other end of the 22bp
fragment, and thus amplification of the genomic DNA only
required two different primers, and thus one total PCR
reaction per fragment. This final construct with the strategy
for primer placement is illustrated in Figure 4.4.
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Figure 4.4 22bp with terminal adaptor
construct. Genomic DNA denoted by
black, adaptor 1 denoted by red,
adaptor 2 denoted by blue. 9bp
complementary primer 1 denoted by
pink arrow, 9bp complementary primer
2 denoted by purple arrow.
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It is important to note that not all of the two adaptor sequences will be amplified. The
primers are positioned at the terminal ends of the adaptors such that minimum non-genomic
sequence is present in the final fragments produced by the amplification reaction (amplicons).
This strategy is important for the efficiency of the sequencing step. As the sequencing involves
the hybridization of 6bp oligonucleotides (6mers) with fragments of the patient’s DNA, and extra
base pairs present in the sequenced fragments, such as the terminal ends of the adaptors, will also
hybridize with the 6mers, giving a potential false positive of binding of that particular 6mer with
the genomic DNA. While the presence of some synthetic sequence is impossible to avoid, by
using minimum primer size, its presence is minimized. Additionally, the two 9bp primer
sequences are known, so the 4 different 6mers with which they will bind can be known. How this
knowledge is used to correct the sequencing process for false positives will be discussed later in
chapter 6 under the context sequencing.

4.2.3 Summary of Micro$eq’s Modified Presequencing Approach
The total final output of the Micro$eq’s modified pre-sequencing approach as outlined
above will be a DNA fragment ~150bp in length, 22 base pairs of which are genomic DNA and
the remaining terminal ends are known synthetic base pair sequences. These adaptors allow the
handling of a small (<25) sample DNA fragment but in the context of a longer fragment which
reduces thermodynamic instability issues.
Using the designed primers as described above, the desired portion of this construct as
shown in Figure 4.4 can be amplified using conventional PCR methods with only two required
PCR reaction as outlined in section 4.1.1.
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4.3 MOLECULAR BIOLOGY CHALLENGES IN THE SEQUENCING
PROCESS
Similarly to the pre-sequencing process, the molecular and biological phenomena
associated with DNA described in section 4.1 of this chapter provide obstacles in the sequencing
portion of this project.

Many approaches, such as those used by companies cited in the

competitive analysis, have worked on strategies to overcome these limitations. This section will
outline some of those competitive strategies at the molecular level and address their molecular
limitations. Additionally, this section will outline in further detail portion of Micro$eq’s unique
approach to sequencing and both analyze how it overcomes biomolecular limitations as well as
how it improves upon the previously derived sequencing strategies.

4.3.1 DNA Sequencing Techniques
While an almost countless number of variations of DNA techniques have been explored,
this section will describe only the most commonly used general strategies.
4.3.1.1 Sanger Sequencing
Probably the most popular method of DNA
sequencing is dye-terminator sequencing or Sanger
Sequencing. In dye-terminator sequencing, four
dideoxynucleotide(ddNTPs) chain terminators are
labeled with fluorescent dyes, which emit light at
different wavelengths. ddNTPs lack an OH group on

Figure 4.5 Dideoxynucleotide(ddNTP). ddNTPs
lack an OH group on the 3’ Carbon as well as the 2’ C
of the deoxyribose sugar which prevents anew bases
from being added to a DNA strand after ddNTP
addition.

the 3’-Carbon as well as the 2’C of the deoxyribose

Micro$eq – Chomvong, King, Mahmoud

70 | P a g e

sugar which prevents new bases from being added to a DNA strand after a ddNTP has been
added (Figure 4.5).
By reacting ddNTP’s and deoxynucleotide(dNTPs) with copies of a
single stranded DNA repeatedly, all the
possible lengths of DNA would be
represented

with

synthesized

DNA

every

piece

of

containing

a

fluorescent label at its terminus (Kae,
2003). Amplified DNA is then separated
according

to

its

size

via

gel

electrophoresis. This process involves the
deposit of all DNA molecules along one
edge of a polymeric gel. An current is run

Figure 4.6 Dye-Terminator Sequencing: DNA is unwound and
combined with fluorescent ddNTPs and dNTPs and run through
an agarose gel.

through the gel which generates an electric
field that puls the DNA fragments toward the opposite side of the gel. Larger molecules of DNA
have a harder time winding through the polymeric labyrinth of the gel, thus the strands will be
segregated in order of increasing size along the distance of the gel. A laser is used to pick up the
different fluorescent signals along the gel. The combinations of fragment size and fluorescene
color are compiled using computational methods to generate a graph which represents the
sequence of the strand. The overall process of dye-terminator sequencing is illustrated in Figure
4.
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4.3.1.2 Variations of Sanger Sequencing
The basic process of dye-terminator sequencing as described above is relatively efficient
and low in error. This is the major sequencing techniques used in automated sequencing. The
most important approach used in this method is the addition of single base pairs to the sample
DNA fragment to create a base pair by base pair approach to sequencing.
While other companies have adapted different variations of this approach, virtually all
current successful genome sequencing techniques on the market use a single-base pair
sequencing approach by tagging each of the four different base pairs with a different color
fluorophore.

4.3.2 Micro$eq’s 6mer-Hybridization Sequencing
Instead of using the conventional single base pair method, Micro$eq has used the same
idea of binding fluorescently-tagged complementary base pairs, but has extended it to a 6 base
pair at a time sequencing approach.
4.3.2.1 6mer Hybridization
Another possible sequencing approach is to hybridize, or Watson-Crick base pair, 6 base
pair oligonucleotides segments to target DNA. In this approach a known single-stranded 6 base
pair segment is combined with a single strand of the target DNA and a fluorescent label is
designed to give off a signal only when hybridization between the 6mer and sample DNA occurs.
Hybridization only occurs if the probe possesses bases complementary to the target DNA. Thus
when a signal is emitted, one can deduce that a 6 base pair sequence, complementary to the 6
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bases of the 6mer with which it binds, occurs somewhere along the target DNA. Repeatedly
combining the same target DNA molecule with known 6-base pair 6mers allows the creation of
an output of which 6 base pair sequences exist within the target DNA fragment and which don’t.
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Figure 4.7 Watson Crick Base Pairing Based Sequencing: In Watson Crick based base pairing sequencing, an oligonucleotide of
a known sequence is combined with target DNA. The oligonucleotide fluoresces when it Watson-Crick Hybridizes to the sample
DNA.

The summary of this process is illustrated in Figure 4.7. From this output the entire target
DNA sequence to be reconstructed via a bioinformatic algorithim by using the overlap between
the segments.
4.3.2.2 Sensing Hybridization
Sensing hybridization is used to detect which oligonucleotides bind fragments of the
patient’s DNA by using a fluorescence signal. As the hybrdization of 6mers with the sample
DNA is very different than the hybridization of a single base pair with the sample DNA, the
Micro$eq – Chomvong, King, Mahmoud

73 | P a g e

conventional method of base-pair specific fluorescence labeling as described in section 4.3.1
above cannot be used. Instead Micro$eq has designed a different method of detecting 6mer
hybridization based on a fluorescence-quencher labeled nucleotide system.
4.3.2.2.1 Hairpin Quenchers
In this approach, a target nucleic acid reveals itself by
separating the donor fluorophore from the acceptor fluorophore,
precluding the transfer of energy. Energy that is not transferred
through fluorescence resonance energy transfer (FRET) is emitted as
fluorescence. Many formats exist for fluorescnence energy transfer
contact-mediated quenching in oligonnucleotide probes (Salvatore
A. E. Marras, Efficiencies of Fluorescence resonance energy,
2002). Hairpin structures which pair a quencher and a fluorophore
on a single strand such as the one seen in Figure 4.8, exist, however

Figure 4.8 Hairpin Structure: One
proposed
fluorescence-quencher
labeled nucleotide format places the
fluorophore and the quencher at the
ends of a hairpin structure. When
the complementary strand is present,
the hairpin structure opens up and
the fluorophore is free to fluoresce.

these molecules involve pseudo- double-stranded DNA which
complicates the thermodynamic effects of binding and leads to inefficient and error-ridden
hybridization between the oligonucleotide and the sample DNA.
4.3.2.2.2 Double-stranded quenchers
An alternative method, involving the use of quenched fluorphores but without the hairpin
structure described above, places donor and acceptor fluorophores on different complementary
strands. When the donor fluorophore is brought within 20-100 Ǻ of the acceptor fluorophore, the
intensity of the fluorescence of the donor fluorophore decreases while the intensity of the
fluorescence of the acceptor fluorophore increases (Salvatore A. E. Marras, Efficiencies of
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Fluorescence resonance energy, 2002).

However, if the donor and acceptor are brought any

closer, most of the absorbed energy is emitted as heat and only a small amount of energy is
emitted as light.

Thus, by coupling the two moieties, one can completely suppress the

fluorescence. As summary of this fluorescence-quenching method is shown in Figure 4.7.

4.3.3 Thermodynamics of 6mer Annealing
As discussed earlier in this chapter, the thermodynamics of DNA denaturation and
annealing depend significantly on DNA fragment size. Section 4.1 of this chapter outlined a
detailed method for estimating the melting temperature and other thermodynamic properties of
small double-stranded DNA fragments. The same principles discussed in that section hold true
for an analysis of the thermodynamics of the 6mer hybridization with the sample DNA.
In order for hybridization to occur, both the 6mers and the sample DNA fragments must
be denatured. Following denaturation, the strands are allowed to rehybridize. The four single
stranded fragments (two from the sample DNA and two from the 6mer) will recombine as they
reanneal to form double-stranded fragments. This recombination allows some of the 6mers to
bind to the sample DNA and thus emit a fluorescence signal which can be detected by scanning.
As previously discussed, nucleic acid thermodynamics dictate how temperature affects
nucleic acid structure. The denaturation and reannealing process described in the previous
paragraph will be facilitated via thermal control. In order to determine the necessary thermal
cycle, the melting temperatures of the 6mers must be determined.
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4.3.3.1 Range of 6mer Melting Temperatures
Using the application of Table 4.1 data as illustrated in Figure 4.2, predicted free energies
of hybridization can be calculated for all of the possible 4064 6mers. From this method, the
6mers with the maximum and minimum free energies are found. It was found that the GCGCGG
oligonucleotide has the largest free energy of hybridization and thus will have the highest
melting temperature. This is expected as Guanine and Cytosine base pairings form three
hydrogen bonds compared to the two formed by Adenosine and Thymine. Additionally, the nonsymmetry of the oligonucleotide increases the hybridization energy as the molecular orientation
required for binding is more restrictive. Finally, the terminal base pairs are important for
initiation of hybridization, Guanine and Cytosine’s having the highest initiation energies.
Conversely, the TATTAT oligonucleotide was found to have the lowest hybridization energy,
and thus the lowest melting temperature. As previously stated, the minimum temperature must be
at least five degrees higher than operating temperature (assumed to be room temperature –
298K). The melting temperature of TATTAT was found to be 275K.
In order to alter the melting temperature, the salt concentration of the droplet can be
increased. Magnesium salts will be used, as is conventional in biological annealing processes.
Magnesium is especially effective as it is a diionic salt, thus a smaller increase in concentration
will affect melting temperature than would be required of a monoionic salt. These calculations
can be estimated from an empirically-derived relationship as seen below (Owczarzy, Moreire,
You, Behlke, & Walder, 2008):
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Equation 4.4.4 – Empirically derived relationship for Melting Temperature with varying salt concentrations (Owczarzy,
Moreire, You, Behlke, & Walder, 2008)

Where a-g are constants whose values are depicted in Table 4.2

Table 4.2 Constants for use in Equation 4.4.4 (Owczarzy, Moreire, You, Behlke, & Walder, 2008)

However, for the purpose of this report, further calculations will be approached in a more
standardized manner.
4.3.3.2 Integrated DNA Technologies Hybridization Calculator
While it is possible to perform the entire thermodynamic analysis of 6mer hybrdization
using the methods outlined in section 4.1 of this chapter, for the purpose of efficiency and
accuracy of calculations, the IDT Oligonucleotide Hybridization Calculator (IDT BioPhysics)
will be used to optimize the Magnesium concentration in order to have a minimum melting
temperature of 303K. This tool has the additional benefit of accounting for both 6mer and DNA
concentrations in the droplet.
With the input settings of 1mM and 7mM 6mer and DNA concentrations (these required
concentrations will be discussed in more detail in chapter 6 of this report in the context of
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hybridization detection), for the 6mer and sample DNA, respectively, the calculator is run with
an baseline Magnesium concentration of 0mM. The results of this calculation can be seen in
Figure 4.9.
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5'- T A T T A T -3'
3'- A T A A T A -5'

Tm Gibbs Energy (ΔG37) Enthalpy (ΔH) Entropy (ΔS)
[°C] [kcal/mol]
[kcal/mol]
[cal/(K·mol)]
Exact match 8.65 0.13

-32.10

-103.91

Duplex Length: 6
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM
Target Conc: 7000.00 µM Mg2+ Conc: 0.00 mM

Figure 4.9 Hybridization of TATTAT Thermodyanmics at [Mg2+]=0 (IDT BioPhysics)

It can be seen that these results are close to those found earlier in section 4.3.3.1 of this
chapter using the NN method. From these results it can be seen that the melting temperature
needs to be raised by ~22 degrees, which can be done by increasing the Magnesium ion
concentration in solution.
Micro$eq – Chomvong, King, Mahmoud

79 | P a g e

4.3.3.3 Manipulation of Melting Temperatures via Magnesium Salts
The same calculator as in section 4.3.3.2 above is then run with the same inputs except
with varying magnesium concentrations in order to find the necessary concentration to achieve a
30°C melting temperature. The results of these trials can be seen in Figure 4.10 (Compiled using
(IDT BioPhysics) results).

Tm as a function of Mg2+ Concentration
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Figure 4.10 Melting Termperature Sensitivity to [Mg2+] analysis

From Figure 4.10 it can be seen that the at a Magnesium concentration of 40nM, the melting
temperature exceeds 30°C, The complete results from the calculation at this concentration are
displayed in Figure 4.11
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5'- T A T T A T -3'
3'- A T A A T A -5'

Tm
[°C]

Gibbs Energy (ΔG37) Enthalpy (ΔH) Entropy (ΔS)
[kcal/mol]
[kcal/mol]
[cal/(K·mol)]

Exact match 30.19 -2.38

-32.10

-95.82

Duplex Length: 6
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM
Target Conc: 7000.00 µM Mg2+ Conc: 40.00 mM

Figure 4.11 TATTAT Hybridiztion Thermodynamics at [Mg2+] = 40mM (IDT BioPhysics)

Hence, the 6mer droplets merged with the DNA fragment droplets will have a combined
Magnesium concentration of 40mM. The results of figure show that all the hybridization drops
will be heated to at least 30°C. While it is known that the reaction mixture needs to be heated to
~95°C in order to denature the DNA, the maximum temperature of the required in order to
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exceed all of the oligonuclelotides’ melting temperatures needs to be calculated to determine if it
is above 95°C. the calculation is run for the GCGCGG 6mer, the results of which are shown in
Figure 4.12
5'- G C G C G G -3'
3'- C G C G C C -5'

Tm
[°C]

Gibbs Energy (ΔG37) Enthalpy (ΔH) Entropy (ΔS)
[kcal/mol]
[kcal/mol]
[cal/(K·mol)]

Exact match 82.53 -9.32

-48.60

-126.64

Duplex Length: 6
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM
Target Conc: 7000.00 µM Mg2+ Conc: 40.00 mM

Figure 4.12 Hybrdiziation of GCGCGG at [Mg2+]=40mM (IDT BioPhysics)
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As seen in Figure 4.12, the maximum melting temperature is 82.5°C. Thus, the maximum
required temperature by the oligomers is ~5°C above this maximum – 88C – and is still below
the DNA required temperature of 95°C.
After denaturation, as the reaction mixture cools, the 6mers with the highest melting
temperatures will reanneal first. As reannealing occurs, approximately half of the 6mers will
anneal to other 6mers and the remaining half will anneal to the fragment DNA, yielding ~0.5mM
of 6mer-bound DNA per each 6mer in the droplet. As previously discussed, it is these binding
events that will be detected during the scanning step and used to sequence the sample DNA.

4.4 SUMMARY OF MICRO$EQ’S APPROACH TO OVERCOMING
BIOMOLECULAR LIMITATIONS
Several key biomolecular properties of DNA that present challenges in the presequencing
and sequencing steps were presented in this chapter. In respect to each limitation, Micro$eq’s
approach to overcoming this obstacle was described. A few key results of Micro$eq’s approach
are important to reiterate in the context of the overall process.
First, Micro$eq’s ability to use conventional PCR methods, as outline in section 4.2, is
juxtaposition with the random amplification that required millions of different PCR reactions as
outlined in chapter 3 of this report. The use of conventional PCR methods allows an enormously
significant increase in sample throughput, bringing sample processing time and cost to a
reasonable level from the originally proposed single-molecule approach as outlined in chapter 3.
Second, Micro$eq’s use of restriction enzymes to generate exactly sized sample DNA
fragments allows optimal reassembly of the fragment sequence via computational methods. This
Micro$eq – Chomvong, King, Mahmoud

83 | P a g e

reassembly process is often the temporal bottleneck of genome sequencing, and producing its
optimum input helps minimize the computational process time and thus overall process time.
Third, Micro$eq’s adaptation of conventional sequencing techniques to a multi-base pair
sequencing method via the hybridization of 6mers allows a continuous instead of batch
sequencing process. This drastically decreases sequencing time – another potential bottleneck in
the overall process – and thus decreases overall process time.
As a whole, Micro$eq’s approach innovatively overcomes traditional biomolecular
limitations to optimize the presequencing, sequencing, and reassembly steps in its overall
genome sequencing process. Micro$eq’s unique approach also allows it to significantly decrease
temporal requirements for the two potential process bottlenecks – DNA sequence scanning and
fragment reassembly.
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CHAPTER 5

Presequencing Processes
As previously discussed, the first part in the sequencing process is the breakdown of the
genome to the appropriate fragment sizes that will then be sequenced and reassembled. For the
scope of this project, the approach to these beginning steps was determined by the requirements
of the later (sequencing and reassembly steps). While the details of these requirements will be
discussed later, the overall goal of the pre-sequencing preparations is to generate the optimal
length (22bp) and number of fragments (10 per droplet) of the customer’s genome for the later
steps in the overall process. The input to the pre-sequencing steps will be the customer’s saliva,
which contains their cells and thus DNA can be extracted from this sample. The output of these
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steps will be micro droplets, each containing the required concentration and number of
specifically-sized DNA fragments.
The required output from the pre-sequencing process is determined by the approach to
sequencing (merging with 6 base pair oligonucleotides) and the optimization of the reassembly
algorithm (to determine which combination of fragment size and fragment number allows for the
lowest error rate and quickest processing time). However, it is important to remember that the
requirements implicated by the later steps are determined by optimization of those steps and do
not take into account the limitations of molecular biology. Hence, the challenge of the presequencing process will be to capitalize on available molecular biology techniques and to design
new molecular biology strategies base on known biochemistry in order to adhere as closely as
possible to the required output. This chapter will outline the biological limitations that make
achieving these requirements difficult, and will discuss a proposed method of how to overcome
these limitations.

5.1 DNA EXTRACTION AND PRELIMINARY PREPARATION
Now that the basic approach to achieving the required output of the pre-sequencing
process has been outlined, a detailed process design will be explained. The explanation of this
process design is aimed at highlighting how the previously outlined general approach will be
executed. This discussion will include explanation of existing technologies that may be adapted
for the process’s purposes, as well as new technologies that are required for our design and while
feasible, do not yet exist on the market place. While the major molecular and biological
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challenges have already been discussed, this detailed process design will highlight even more
molecular and biological nuances and obstacles that must be addressed.

5.1.1 Initial DNA Extraction and Purification
The DNA sample is received from the customer as a
saliva sample. The DNA Genoteck Oragene® kit (full
protocol found in Appendix C) is used for both collection and
initial DNA purification. A kit is mailed to the customer and
he or she spits into the prepared sample and mails the kit back
to Micro$eq. The sample is then loaded into the Magtration
12GC (PSS Bio Instruments) which uses paramagneticparticle technology to purify the DNA from the Oragene®
solution.

Figure 5.1 Scattergram of DNA yield from
200μl of Oragene/Saliva sample. The
horizontal line represents the median yield at
3.8μg. (Lem, 2009)

The elution volume is 200µl with a median yield of 3.8µg/200µL of DNA and a median
A260/280 ratio of 1.95 (Lem, 2009). The full range of DNA concentration yields is shown in Figure
5.1and this translates into a median DNA concentration of 3.0x10-9M with a range of 1.610-9M to
6.310-9M (calculation done using source (Ambion’s Appendix)). The details of the required
initial concentration will be discussed in this chapter, but it is important to note that this starting
concentration is much greater than the required initial concentration of this process (1.8 x10-15M
– calculations of this requirement will be discussed in section 5.4.1 of this chapter). This implies
that even with significant loss of DNA during the preliminary preparation steps, achieving the
initial droplet concentration is very feasible by simply diluting to this concentration.
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Additionally, the expected variability between customer samples as illustrated in figure 6.6 will
not render samples on the lower end of the concentration scale unusable.

5.1.2 Preliminary DNA Fragmentation
While the final fragments used for sequencing will be fragmented biological via
restriction enzyme digest as discussed earlier in this chapter, the preliminary DNA input must be
reduced to smaller fragments for optimum efficiency of generating the modified 22bp genomic
DNA fragments.
The purified DNA from above is then fragmented using the s2 Shearer (Covaris), where
Adaptive Focused Acoustics energy (used more commonly in the process of breaking up kidney
stones or larger tissues) shears the double stranded DNA. By using the specifications found
below in Table 5.1, a target peak length of 1000 base pairs is achieved (full protocol may be
found in Appendix C).
Parameter
Base Pair Size
Duty Cycle
Intensity
Cycles per burst
Power Mode
Z Height
Temperature
Time
Degassing mode
Volume
DNA mass
Starting material
Water level(FILL/RUN)
AFA Intensifier

Setting
1000(bp)
5%
3
200
Frequency Sweeping
6mm
6-8 ( °C)
40 (s)
Continuous
200µl
<5µg
>50kb
S2 – level 12
E210 – level 6
Yes

Table 5.1 Covaris s2 shearing specifications to achieve a median DNA fragment size of 1000bp (Covaris)
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DNA fragments will be sheared into a distribution of sizes, as displayed in Figure 5.2
It can be seen in Figure 5.2 that the fragment size varies between ~50-1600 bp, with the
distribution being centered at
1000bp. However, the size
distribution of these fragments
is relatively insignificant on
the overall process, as the
actual

fragments

to

be

sequenced will end up as 22 bp
in length (Dunn, McCorkle, &
Praissman, 2002), and their
length

is

determined

by

Figure 5.2 Covaris Fragment size Distribution for 1000bp target fragment size
(Covaris)

enzyme activity and not by the original size of the fragment. The only means by which this size
distribution will affect the rest of the process will be discussed in a later section of this chapter in
the context of DNA circularization. While the concept of circularizing the DNA has yet to be
introduced, it will be explained how this is in fact necessary at one point in the pre-sequencing
preparations. At the circularizing step, the size distribution of the DNA fragments will affect the
process, as the smaller DNA may have difficulty forming a circle compared to the larger
fragments, This error is taken into account and will be discussed in more detail later.
The fragmented DNA strands are then purified using the QIAquick Purification Kit
(Quiagen) (see Appendix C for protocol) and are ready for the next step in presequencing
processing. These 1000kbp fragments are the starting genomic DNA fragments in Micro$eq’s
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outlined approach in section 4.2 of the previous chapter, and will undergo adaptor ligation and
restriction enzyme digest, as previously discussed.

5.2 ADAPTOR LIGATION AND PRELIMINARY AMPLIFICATION
While the idea of adding adaptor sequences, which contain the recognition site of the
MmeI restriction enzyme, to the genomic DNA has been previously discussed, the actual details
of how these adaptors are ligated to the genomic DNA was glossed over. Here, the chemical
interactions between the nucleic acids that allow this ligation process to take place and the
practical execution of these steps will be discussed in more detail.
While Figure 4.4 in chapter 4 depicted the ligation of adaptors as two separate sequences
on the termini of linear DNA, the key step to the adaptor ligation process actually involves the
circularization of the 1kbp sheared DNA fragments prepared above around a synthetic insertlinker. The Restriction Digest will re-linearize the DNA, but the circular DNA structure is the
optimal template for restriction enzyme activity. While a point that does not affect this process, it
is interesting to note that while restriction enzymes are indeed short sequences of DNA base
pairs that exist in the human genome, the enzymes themselves are not coded for in the human
genome and thus do not exist naturally in human cells. Restriction enzymes actually occur
naturally in bacteria, and are harvested for use in human molecular biology work. Bacterial
DNA, unlink human, is actually circular in form, hence why restriction enzymes operate most
efficiently on a circular DNA structure. For the MmeI restriction enzyme, it has been found that
~1kbp long circular DNA are optimal for enzymatic activity (Porreca, Shendure, & Church,
2006), thus the genomic DNA was prepared accordingly as described in the previous section.
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5.2.1 Circularization of DNA
Step 1: Addition of Adenosine tail
Before the fragmented DNA generated above can be ligated to the adaptor sequence, their
ends must be modified. The sheared genomic DNA fragments will have different terminal base
pairs, depending on where the fragmentation occurred in on the original DNA sample. However,
as the same adaptor sequence must be ligated to the ends of all DNA molecules, a single base
pair will be added to the ends of the DNA fragments such that all DNA fragments will have the
same terminal base pair and thus ligated with equal affinity to the adaptor sequence. The adaptor
sequence ends in a single-stranded 5’-Thymine (T) base, thus an Adenosine (A) base (which
binds complementary to the T base) will be added to the 3’ end of the genomic DNA in a
template-independent fashion.

Figure 5.3 Genomic DNA-Adaptor Ligation via Sticky ends. Genomic DNA denoted by black, Adaptor sequence denote by red,
hydrogen bonds between complementary sequences denote by dotted lines.

This addition of a single-stranded base to the terminus of a double-stranded DNA
molecule creates what is termed a “sticky end” to the DNA. As seen in Figure 5.3, both the
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adaptor (which is synthesized with a stick T base end) and the genomic DNA (which has a sticky
A base added to it) now have complementary single-stranded DNA termini. As DNA is more
thermodynamically stable in the double-stranded conformation, the adaptor will spontaneously
anneal to the genomic DNA (under the proper reaction conditions), as shown in Figure 5.4

Figure 5.4 Genomic DNA Circularization with Adaptors using sticky end ligtation. Genomic DNA denoted by black,
adaptors denoted by red, dotted lines denote hydrogen bonds between complementary base pairs

The addition of an Adenosine to the genomic DNA is a relatively simple procedure. Free
adenosine nucleotide (dATP’s) are added to a solution of the DNA fragments with a solution
buffer, a Taq DNA polymerase enzyme, and Magnesium chloride which provides the
Magnesium ions necessary for the polymerase activity. The solution is then incubated for 30min
at 70°C and then cooled to 4°C. The DNA is extracted out of the reaction solution via a
phenol/chloroform mixture and then precipitated using ethanol. The extracted DNA is
resuspended in a standard elution buffer and is ready for the next step in the process. (full
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protocol for this as well as all of the following steps in Appendix C – Note: some modifications
have been made to adapt this protocol for use in this specific project).
Step 2: Circularization of Genomic DNA around Synthetic Oligonucleotide Insert.
As described above, the generated fragments are combined with the two halves of a
synthetic 250bp oligonucleotide which anneals to each end of the fragment. The choice of length
for this synthetic adaptor will be discussed later in this chapter. It is important to note the
terminal ends of the two halves of the 250bp oligonucleotide which do not contain the sticky T
base end, also contain a sticky end. The sticky ends of the two halves are in fact complementary
such that in adition to annealing with the genomic DNA at one terminus, the two halves will
anneal to each other at the other terminus, thus creating a circular genomic DNA fragment with
the 250bp synethic insert. This process is illustrated in Figure 5.4.
The ligation of the synthetic oligonucletoide is also a relatively simple process.
The DNA fragments and oligonucleotides are combined in a solution containing a T4
DNA ligase ezyme along with a ligation buffer. The T4 ligase facilitates the ligation of the sticky
ends to create a continuous double-stranded DNA. The solution is heated in a thermal cycler
(Biometra) to 95°C for 10 min, thus denaturing both the oligonucleotides and the genomic DNA.
The solution is then slowly cooled to 25°C over the course of an hour. During this cooling
process, the two halves of the synthetic oligonucleotide are ligated to both the other half and the
genomic DNA to create circularized DNA, as described above. The solution is then incubated at
room temperature for 10 min and then the enzyme is heat-inactivated for 10 min at 65°C.
Step 3: Exonucelolysis
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While this process is relatively efficient, their will be excess reagents as well as the
smaller DNA fragments that were unable to be circularized still remaining in solution. All
noncircularized material is therefore eliminated via exonucleolysis. Exonucleolysis in a
biological process by which exonucelase enzymes digest linear DNA into single dNTP’s by
cleaving the covalent bonds between adjacent bases. Exonucleases act by binding to the terminal
end of the DNA and moving along the linear stucture. As all DNA of interest in now
circularized, the exonucelase’s cannot digest this, and instead will only digest undesirable noncircularized material.
This process is also relatively straight-forward. Exonuclease I and III are added with their
associated buffers to the reaction solution from step 2 above. The solution is incubated at 37°C
for 45 min and the remaining material is ready to be used directly in the next step without further
purification.

5.2.2 Restriction Enzyme Digestion
As previously discussed, the desired 22bp genomic DNA fragments will be generated via
restriction enzyme digest using the MmeI enzyme that cuts 22bp from its recognition sites. The
MmeI recognition site is the 5bp nucleotide sequence 5’-AGGYT-3’ bound to its complementary
sequence 3’-TCCRA-5’ where the Y denotes either pyrimidine base (T or C) and the R denotes
either purine base (A or G) (AK7). For the purpose of this process, the purine has been chosen as
A, with its complementary pyrimidine being T. the 5’ end A on the recognition site corresponds
to the A base ligated onto the genomic DNA, with the remaining 4 base pairs of the site being the
5’ terminal end sequence of the adaptor such that when the modified genomic DNA and
sequence are ligated, the AGGTT sequence is the directly adjacent to the genomic DNA
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sequence. Similarly, the 3’ end T of the complementary recognition site corresponds to the 3’
terminal sticky end of the adaptor sequence, with the remaining 4 base pairs of the site being
directly upstream in the adaptor such that when the DNA and adaptor are modified, the
complementary site also exists directly adjacent to the genomic DNA, implying that restriction
site are present directly adjacent to both ligation sites between the adaptor and the genomic
DNA. This allows the MmeI to digest 22bp upstream in either direction of the restriction site,
thus generating a linear fragment consisting of two 22bp fragments of DNA linked by the 250bp
adaptors between. This scheme of digestion is
illustrated in Figure 5.5
The restriciton enzyme digestion process
is fairly simple. The circular DNA solution from
step 2 is combined with the MmeI digestion
enzyme, its co-substrate S-Adenosyl Methionine
(SAM) and the appropriate buffer solution. The
solution is heated to 37 °C for 30 min, then the
DNA is immediately extracted and then the DNA
Figure 5.5 Restriction enzyme digest of Circularized
construct. genomic DNA denoted in black, synthetic
adaptor denoted in red.

is immediately extracted out of the reaction
solution via a phenol/chloroform mixture and

then precipitated using ethanol. The extracted DNA is resuspended in a standard elution buffer
and purified using the QiAquick purification kit (Qiagen) as in section 6.3.2 of this chapter.
Before these DNA fragments can be used in the next step of the processes, the ends must
be repaired. During digestion, he restriction enzyme cleaves the final base pair (the 22nd genomic
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DNA base pair) such that it leaves a 1bp sticky end. In order to preserve the integrity of the
genomic DNA sequence, a full 22bp ds-DNA must be present to be sequenced. Thus the ends are
repaired via the End-It DNA end repair kit (EpiCenter Biotechnologies).
This repair process is trivial and involves the addition of ss-dNTP’s with a mix of ligase
enzymes and their appropriate buffer solution to the purified DNA fragments generated by the
digest above. The reaction mixture is incubated at room temperature for 45 min, during with the
ligase enzymes ligate the ss-dNTP’s from the mixture to the ss-sticky ends of the DNA
fragments in a complementary base pair fashion in order to create fully double-stranded 22bp
genomic DNA sequences on either sides of the adaptor. The repaired DNA is again extracted out
of the reaction solution via a phenol/chloroform mixture, precipitated using ethanol and then
resuspended in a standard elution buffer. These repaired linear adaptor-DNA fragments are now
ready for the next step in the process.

5.2.3 Addition of FDV/RDV PCR adapters
The two terminal adaptors (FDV on one end and RDV on the other) which will be added
to the ends of the genomic DNA fragments must be similarly ligated to the new terminimal ends
of the genomic DNA. For the sake of the adaptors’ stability, the full FDV and RDV sequences to
be added are 44bp long – much longer than the required 9bp primer sequences. The excess
sequence beyond the 9bp primer sequence is insignificant however, as they will not be amplified
as they are beyond the scope of the amplification process and therefore will not exist in the final
amplicons to be sequenced (this point was illustrated earlier in Figure 5.5). Identical to the first
set of adaptors added in section 5.4.1 above, the terminal adaptors also contain a single T base
pair sticky end. Thus, the genomic DNA fragments will require the addition of a single A base
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pair to their termini before they can be ligated to the FDV and RDV adaptors. This single base
pair additon will be performed identically to step 1 in section 5.4.1 above.
The terminal adaptors will be then be ligated to the sticky-end DNA fragments in the
exact same manner as the first adaptors were ligated in step 2 of section 5.4.1 above. However,
the FDV and RDV adaptors only have one sticky end, which will be used to ligate to the DNA
fragment, and therefore cannot ligate to each other. This allows the final DNA fragment with the
terminal adaptors added to remain linear. The
output DNA fragments from this process is
therefore a 344bp long fragment with two

Figure 5.6 22bg Genomic DNA fragments flanked by
adaptor sequences. Genomic DNA denoted by black,
internal adaptor by red, terminal adaptors by blue.

25bp terminal adaptors, one 250bp internal adaptor, and two 22bp genomic DNA fragments
between the adaptor sequences as seen in figure Figure 5.6. These fragments are ready for the
next stage in the process.

5.2.4 Internal Adaptor Shearing
From the modified fragment in FIGURE it can be seen that two different 22bp genomic
DNA fragments exist in each single adaptor-DNA construct. However, the goal of the process is
to be able to handle each genomic DNA fragment individually, thus this construct must be cut in
some fashion such that the two genomic DNA fragments are separated.
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Figure 5.7 Adaptor-DNA construct potential PCR products. Genomic DNA in black, internal adaptor in red, terminal
adaptors in blue

As previously discussed, there are four different PCR primer-annealing sites in this construct,
two sets of two, each flanking the two 22bp fragments. If this entire fragment were to be PCR
amplified using the two sets of primers, three different PCR products would result, as any
combination of a forward and reverse primer will produce an amplicon, as can be seen in Figure
5.7.
As the large middle PCR product in Figure 5.7 is undesirable, the internal adaptor must
be cut so that the middle product cannot be formed. While it would have been possible to do this
digestion by restriction enzyme digest in a fashion similar to the original digestion described
earlier in this chapter, the size specificity of the cutting is not a huge issue. The only requirement
for specificity is that the 9bp primer anneal sites on the two ends of the internal adaptor are
preserved. Thus, fragment sizes must range between 56bp (25bp terminal adaptor, 22bp genomic
DNA, and 9bp internal adaptor primer sequence) and 288bp (25bp terminal adaptor, 22bp
genomic DNA, and 241bp of internal adaptor – excluding its other 9bp primer site).
The Magtration shearing device used in preliminary DNA shearing in section 5.1.1 will
be used again in this step. This time, the target base pair length will be set to 150bp (see
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Appendix C for full adjusted protocol). The fragment size distribution from this target base pair
can be seen in Figure 5.8.

Figure 5.8 Fragment distribution for target size of 150bp (Covaris)

As seen from the distribution, the generated fragment size range is contained mostly
within the 56-288bp size range, with ~90% of fragments within this range. This inefficiency will
be built into the droplet generation step of the process.

5.2.5 Initial Amplification
As the presequencing process continues, it is important to note what is present in the
reaction solution. After the internal adaptor shearing described in the previous section, there will
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exist in solution fragments of DNA, particularly portions of the internal adaptors, that are not
desirable. The droplet generation stage, as it requires only 5 double-stranded fragments per drop,
is very sensitive to DNA concentration. Thus, it is important that when the concentration of the
solution to be made into droplets is measured, it measures only the DNA fragments that will
count towards the total of 5 fragments per droplet. As there is NO way to distinguish between the
desired and undesired fragments at this point, and initial amplification step, which will select for
the desired products, will take place.
The two sets of 9 bp primers complementary to the 9bp primer sequences on the adaptor
sequences, as portrayed in Figure 5.7 will be used to amplify the targeted 22bp genomic
sequences. As the DNA has been sheared in the middle of the internal adaptor sequence, only
the left-most and right-most PCR products will be produced. If 15 cycles of PCR are run, this
will amplify the targeted DNA 210 = 1024 times. Thus, on average, only 1 out of every ~1000
fragments in the amplified solution will be an undesired product. This efficiency will also be
taken into account during the droplet formation step.
This preliminary PCR protocol will follow a standard PCR format as previously outlined
in chapter 4. The reaction will be thermocycled using the same Themal Cycler (Biometra) as
was used in the preliminary steps of DNA processing described in section 5.1 of this chapter.
Post amplification, the DNA will be extracted out of the reaction solution via a
phenol/chloroform mixture and then precipitated using ethanol. The extracted DNA is
resuspended in a standard elution buffer and is ready for the next step in the process.
A summary of the DNA fragment preparation process up to this point is illustrated on the
next page in Figure 5.9. It can be seen that at this stage in the process, the DNA has been
transformed from raw genomic DNA to selected 22bp genomic DNA fragments with 9bp primer
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annealing sequences on either end. These preliminary preparation steps have already achieved
one of the necessary outputs of the pre-sequencing process: 22bp genomic DNA Fragments. The
steps necessary second presequencing requirement (particular concentration of 5 different DNA
fragments per droplet) will be described in the follow sections of this chapter. However, the two
9bp primer annealing tags on each fragment make the necessary DNA amplification to achieve
desired concentration feasible.
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Figure 5.9 Summary of Pre-amplification DNA processing. Genomic DNA denoted by black, Internal adaptor sequence denoted
by red, terminal adaptor sequence denoted by blue.
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5.3 DNA FRAGMENT DROPLET GENERATION
The remainder of the pre-sequencing process will be done in droplet form on a
microfluidics platform. The fragments generated above in section 5.2.5 are the final fragments to
be sequenced. However, as previously discussed, these fragments need to be amplified to
required final concentration for the sequencing step. In order to ensure that the sequencing reads
for a fragment are from only one (or a defined number of) particular fragments at a time,
amplification must target only one (or a defined number of) certain fragments such that the
copies of each fragment are isolated for subsequent sequencing. To achieve this isolation,
amplification will take place in droplets to be used as microreactors which allows the generated
fragment copies to be contained in droplet form and thus will not mix with different fra

gments

which would be detrimental to the sequencing process accuracy.

5.3.1 Droplet Concentration
The optimal number of different droplets per droplet for sequence reassembly is found to
be 10 single-stranded fragments, or 5 double-stranded fragments (discussion of this number is
found in Chapter 7 of this report). However, the inefficiencies in the pre-sequencing preparation
steps require that the target concentration of the droplet will generate more than 5 doublestranded fragments per droplet such that the average total usable number of fragments per droplet
is actually 5. As discussed above in section 5.4.5, a 0.1% inefficiency in built into this process.
as discussed in section 5.4.4, a 10% inefficiency in built into this process, making the total presequencing process efficiency to be ~10.1%. Thus the average number of fragments per droplet
will be targeted to be 5.5 ds-fragments, so that the overall number of usable (able to be
sequenced) ds-fragments will be ~5.
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The DNA concentration in the reaction solution from step 5.4.5 is analyzed using a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). The DNA fragment droplets to be
generated will be 0.5nL in size, thus the required concentration for the solution is 5.5
droplets/5nL (1.8x10-15 M). The original reaction solution will then be manually diluted using
deionized water such that its final concentration is 1.8x10-15 M.

5.3.2 Droplet Generation
As previously stated, the average
DNA per molecule (λ) = 5.5. The distribution
of DNA molecules will be a poison
distribution, as discussed in section 2.2.2 of
this report.
Using λ=5.5, the distribution of DNA
molecules is displayed in Figure 5.10

Figure 5.10 Fragments per Droplet Distribution for target average
of 5.5 fragments/droplet

While the droplet distribution is not as tight as necessarily desirable, this error will have
negligible effect on the remainder of the pre-scanning process and will only significantly affect
the process in the reassembly stage (see chapter 7). Additionally it should be noted that it is
impossible to generate a non-integer number of fragments (such as 5.5 fragments), but the goal is
to average as close to the required output as possible.
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5.4 PCR AMPLIFICATION IN DROPLETS
As previously discussed, PCR amplification will involve two different sets of primers.
The exact same amplification process will take place as in section 5.2.5 of this chapter with two
major modifications. First, the primers to be used will be quenched, to avoid binding with the
6mer and thus sequenced in the sequencing step. Second, the amplification process will be run to
completion. Completion of the amplification reaction will be defined as the complete exhaustion
of the limiting reagent, which in this case, are the primers.

5.4.1 Primer Quenching and Exhaustion
As previously discussed, the presence of the 9bp primer annealing sites on each side of
the genomic DNA fragment will present a challenge in the sequencing step. If amplification were
performed as in section 5.2.5 without any further modification, these primer annealing sequences
would bind with equal affinity to the 6mers that are used for sequencing as would the genomic
DNA and thus will be incorrectly taken to be part of the genomic sequence. Two modifications
in the pre-sequencing process are made to minimize the effect of this issue. Additionally, a
modification in the sequencing process, which will be discussed later in Chapter 6 of this report,
will adjust the sequencing readout as to account for this complication.
5.4.1.1 Primer Quenching
First, the primers will be tagged with quenchers, using the same oligonucleotide
quenchers as described in section 4.3.2 of this report. As the final DNA fragments will contain
the original primers used (as described in the context of PCR amplification in Chapter 4 of this
report), the presence of these quenchers will increase their affinity for binding to the DNA
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fragment. In the sequencing step, the quenched primer tags on each end of the genomic DNA
fragment will denature, as explained in section 4.3 of this report. However, the when the 6mers
anneal to the 9bp quenched sequence, they will not fluoresce as the quencher prevents this (as
described in section 4.3.2). thus, the presence of these 6mers in the will not be detected unless
the . the concentrations of the particular 6mers that will bind to the primer sequence will need to
be increased in order to maintain the thermodynamics of the sequencing hybridization. These
adjustments will be discussed in the context of the 6mer library preparation in Chapter 6 of this
report.
5.4.1.2 Primer Exhaustion
A second modification is made to the amplification process in order to minimize required
adjustment 6mer concentration. In general, such as with the amplification in section 5.3.1.1, after
PCR processes are completed, the generated DNA amplicons are extracted from the remaining
reactants. Thus, it is conventional in PCR processes to use the cycle number to determine the
number of DNA copies generated and have all reagents exist in excess. However, as the PCR
reactions are performed in droplets and must remain in droplets to continue into the sequencing
step, it is impossible to extract the isolated DNA without rupturing the droplet structure. Thus, all
remaining reagents will exist in the droplets that are sequenced. This presents two potential
issues. First, the primers will bind with the 6mers. While these will not fluoresce, as discussed in
section 5.5.1.1 above, they will increase the required concentration of their complementary
6mers to maintain the 6mer-DNA binding thermodynamics. Second, if all available reagents are
present, a pseudo-amplification step may take place during the heating step required for the 6mer
hybridization.
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Hence, to avoid these two problems, the primers will be used as the limiting reagents in
this process. The required output concentration of the DNA in each 1nL droplet (0.5nL from the
generated DNA fragment Droplet and 0.5nL from the PCR reagent droplets) is 14mM (as
discussed in Chapter 4 of this report) which subsequently requires 43 of PCR cycles as seen from
the calculations below.

[

]=

×

=

= . ×

×
=

=

×

.

×

.

×

=

×

As the concentration of each primer must be at least that of the final target DNA
concentration, the input concentration of each primer in the reaction mixture will be just slightly
greater than this, ~14.1mM. The PCR will then be run for an additional 3 cycles to ensure that all
primers are used, and thus the two potential complications described in the previous paragraph
are avoided.

5.4.2 PCR Reagent and DNA Fragment Droplet Merge
The master PCR mix (with the necessary reagents and primers, as discussed in Chapter 4
of this report) will be prepared independently of the DNA fragments in solution form. This
solution will then be generated as droplets in the same fashion as used for all droplet generation
in this process.
The number of total required DNA fragment droplets is 3.6x108 (the calculation of this
number will be discussed in section 7.4 of this report). Each DNA fragment droplet will be
merged with a single PCR reagent droplet (each 0.5nL in size). The two libraries of droplets will
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be merged in a 1:1 fashion using an electric field as depicted in Figure 2.5 in Chapter 2 of this
report). These droplets are now ready for the thermally controlled amplification step.

5.4.3 Reservoir-based PCR Amplification in Droplets.
As previously stated, each combined droplet containing the PCR reaction mixture and the
DNA fragments will be 1.0nL in size. The merged droplets will then be shuttled off the
microfluidic chip which performed the droplet merge and into a standard 0.5mL cap tubes to be
used in the same thermal cycler (BioMetra) as used in the previous presequencing processes. The
thermal cycler will cycle the tubes through the 46 PCR cycles allowing each droplet to contain
the required 14mM concentration of DNA by the end of the ampliciation It is important to note
that during the amplification process, as the droplets are emulsified in oil, they will remain intact
even if they exist in the same tube, allowing isolated amplification to occur inside each droplet.
PCR will be performed in a batch processes. For 3.6x108 1.0nL droplets, suspended in oil,
the volume occupied by all droplets can be calculated. Assuming the oil suspension occupies the
same volume as the droplet, the total volume is 7.2mL, which required 8x0.5mL tubes for each
sample. As the Biometra Thermal Cycler can accommodate 60x0.5mL tubes at a time, ~7
complete genomes can fit into the Thermal Cycler at a time. At the completion of the cycle,
droplet suspension will be reintroduced into a new microfluidic chip where the droplets will be
split in preparation for the sequencing process.
Another important consideration in whole genome amplification that has yet to be
discussed is heterogeneous single nucleotide polymorphism (SNP) representation. SNP’s occur
when a single base pair is mutated on either one of both alleles. Some SNP’s are enough to cause
an entire disease, such as the Sickle Cell Trait. Heterogeneous SNP’s are when the base on one
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allele is mutated and the other is not. When the two alleles have different base pairs as the same
location of a SNP, primer and dNTP adhesion rates vary between the two alleles. Most
approaches have been shown to have ~ 97% equal representation of each of the two alleles
containing a heterogeneous SNP, implying an input error rate to the sequencing of a
heterogeneous SNP of 3%. (Brayer, 2009) However, as the sequencing approach described
above to amplification does not involve primers annealing directly to the genomic DNA, but
rather instead to the synthetic end adaptors, this amplification bias is eliminated.

5.5 PARENT DROPLET SPLIT AND COMPLETION OF
PRESEQUENCING PROCESS
Once the DNA fragments are amplified, these droplets (from hereon referred to as parent
droplets) must be split into daughter droplets. The splitting on each droplet is required so that the
exact same fragments are presence in each drop that is merged with all 505 drops in the 6mer
library.
Each parent droplet will be split into 508 daughter droplets so that they may be paired in
a 1:1 fashion with each droplet in the 505 droplet 6mer library set. When the parents droplets are
reintroduced to the microfluidic chip an air bubble will be inserted in the flow stream between
each droplet such that each set of 505 droplets may be maintained separately, for the purpose of
sequencing later on. The necessity of this separation as it applies to the sequencing process will
be further discussed in Chapter 6. All parent droplets will reside in a larger diameter reservoir,
which will then be funneled toward a droplet splitter (as described in Chapter 2 of this report).
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The target droplet size will be 2.0pL so that each 1nL parent droplet splits into NUMBER
daughter droplets.
The generation of these daughter droplets concludes the presequencing steps of this
process. The fate of these daughter droplets which will be merged with the 6mer library set, will
be continued in Chapter 6 of this report with the sequencing process. A summary of the entire
presequencing process is illustrated in Figure 5.11

Customer
saliva

Purified
DNA
Fragments

22bp DNAAdaptor
Constructs

Parent
Droplet
Generation

Amplification
Droplet Splitting

Daughter
Droplets

Sequencing

Figure 5.11 Presequencing Process Flow Diagram

5.6 PRESEQUENCING THROUGHPUT
While the laboratory steps of presequencing have been outlined in detail in this chapter,
the sample throughput in the context of a commercialized setting have not been discussed. For
the scope of this project, it is important to examine the time and labor requirements of the
presequencing processing to see if the proposed design above can actually be executed. This
section aims to outline the overall timeframe of the presequencing steps and show that, with a
few adjustments, the presequencing process in this step is feasible for use in the context of
Micro$eq’s product output.
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5.6.1. Parallel Sample Processing
While it has not been discussed, it is important to note that the entire presequencing
process as described above will be performed simultaneously on multiple different samples. The
initial Magtration purification machine can process 12 samples in parallel, thus this will be the
base throughput number per process completion (integer multiplications of this base throughput
number will be completed based on the financial analysis of throughput numbers, as discussed in
Chapters 8 and 9 of this report). The steps that take place in solution will be performed
simultaneously for all 12 samples. The steps that take place on the microfluidic platform will
take place in 12 parallel channels on the microfluidic chips. The initial streams of droplets will
be generated from 12 different droplet generators (1 per sample), which will feed into the 12
identical parallel microfluidic processes described. The number of parent droplets being
processed per each sample is 3.6 x108. At a flow rate of 1x106 droplets per second (the fluid
dynamics of which will be discussed in Chapter 6 of this report), it will take 360 seconds to
generate all droplets from one customer sample. The 6 hours required to generate droplets is
impractical for the overall efficiency of the process, thus each sample will be split into 10
sections, and will be processed on the microfluidic chip in 10 parellel process, for a total of 120
parallel processes on each chip for each base set of 12 samples.

5.6.2 Presequencing Timeline
For each step in the above outlined process, an estimated execution time was given. A
summary of this basic timeline for the presequencing preparation of 12 samples simultaneously
is summarized below in Table 5.2.
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Step
Magtration Purification
DNA Shearing 1
Qiagen Purification 1
A-tail Addition 1
Adaptor Ligation 1
Exonucelosis
Restriction Enzyme Digestion
Qiagen Purification 2
A-tail Addition 2
Adaptor Ligation 2
DNA Shearing 2
Amplification 1
Droplet Generation 1
Amplification 2
Droplet Generation 2/Splitting
Total

Time (min)
30
12
5
30
80
45
45
5
30
80
10
45
10
200
25
652 ( 10.9hrs)

Table 5.2Summary of basic timeline for the presequencing preparation

As each batch of 12 samples takes a total of 10.9 hours (assumed to be one full day, as
the ligation step is incubated overnight), this base process can be performed over the course of
one full work day (with two shifts of workers). This timeline is as ideal as, while not necessarily
required, the optimal treatment of the input sample in the Oragene-Saliva (Genotek) kit is an
overnight incubation at 50ºC before sample processing (Chemagen, 2011). This allows the
sample to be received at any point on day 1, incubated overnight, and the complete
presequencing process will be completed at the end of day two.
While ideally this process would lead directly into the sequencing step, which could be
performed overnight, it is important to note that the presequencing process has the flexibility to
be able to pause overnight. The products of the Amplification 2 step may be stored, in their
suspension in the original 10ml tubes used for amplification overnight at 4ºC.
It is important to note that, while manual-labor intensive, this base presequencing process
for 12 samples may be feasibly completed by a two lab technicians (1 for each shift). In fact, it is
feasible for a lab technician to complete two complete base processes (24 total samples) in one
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day, if the two processes are staggered by 3.5 hours as to avoid any machine overlap. Therefore,
the true base presequencing process is 24 replicates for each set of workers. Any integer increase
in this base throughput number will require an equal integer increase of all required machines
and personnel.

5.7 PRESEQUENCING PROCESSING SUMMARY
This presequencing process achieves the requirements imposed upon it by the later stages
of the project. From the input of patient DNA, this process generates the required 3.6x108 1nL
parent droplets, which are split into the 505 daughter droplets at a DNA concentration of 14nM
to be merged with the 6mer library droplets and continue on with the sequencing process.
A huge benefit of the above described process is that a very minimal amount of input
DNA is required. As discussed earlier in this section, the amount of DNA provided by the
customer sample is significantly greater than the amount required for the process. This allows a
wide range of customer samples (i.e. amount of saliva, density of cells in saliva) that will all be
able to process in the same manner.
Additionally, this approach to sequencing allows the generation and amplification of
22bp fragments in droplet form– a nearly impossible task to accomplish without this type of
protocol. The unique scanning and reassembly methods that will be described in the following
chapters require these small fragments. All other companies that use small fragment (<40bp) for
sequencing assembly do so by immobilization of the fragments. This immobilization not only
drastically increase the cost of processing, as microfluidic chips are required to anneal the
fragments and must be disposed of after each use, but also significantly increase the throughput
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time of the process, as scanning must be done in batch rather than continuous process. The
ability to amplify small fragments in droplet form allows a continuous process both pre and
during sequencing which severely decreases the cost and throughput time of both steps.
An final benefit of this process is that it allows the simultaneous preparation of several
samples, which minimizes throughput time as well as required lab personnel. Additionally, the
entire presequencing process can be accomplished in under a day, which is competitive with any
other presequencing processes described by competing companies.
Overall, the above described process meets the requirements of this particular project
design, as well as avoids some of the hindrances found in alternative processes

Micro$eq – Chomvong, King, Mahmoud

114 | P a g e

CHAPTER 6

Sequencing
6.1 INTRODUCTION
Micro$eq’s sequencing approach involves merging an oligos library of 6-mers with
fragments of patient DNA, denaturing and annealing the fragments, and scanning fluorescence
hybridization.

An offchip, macroscale process has been designed to both denature and

continuously anneal the probing fragments (the oligomers) with target DNA by using a gradient
block. Using fluorescent dyes, a barcoding scheme has been developed to both keep track of
which oligomers are in each drop, but also sense hybridization. Finally, Micro$eq’s scanning
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approach is discussed, which uses a back-thinned CCD image sensor and fancy microfluidics to
achieve the desired scanning throughput of 106 droplets per second.

6.2 DENATURIZATION AND ANNEALING
The downstream process begins following droplet merging.

Daughter droplets with

double stranded fragments of the patient’s DNA are merged with droplets containing the oligos
library. In order to sequence the fragments in each drop, the combination of 6-mers that bind the
fragments of patient DNA must be determined. In order for hybridization to occur, fragments of
the patient’s DNA must be denatured or unwound to allow the oligos library fragments to
hydrogen bond with the single stranded DNA. Following denaturation, the strands are allowed
to continuously. Fragments from the oligos library that bind emit a fluorescence signal when
hybridized which can be detected by scanning. A figure depicting the downstream process is
shown in Figure 6.1.

Droplet Merging
with Oligos Library

Denaturization

Rehybridization

Droplet Scanning

Figure 6.1 The Downstream Process. The downstream process follows droplet merging. Following merging, droplets are
heated to denature fragments of the patient’s DNA. The temperature is then decreased to allow for rehybridization. Oligos
library are tagged with fluorophores which can be scanned to sequence the fragments in each daughter drop.
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Nucleic acid thermodynamics dictate how temperature affects nucleic acid structure. As
defined previously, the melting temperature of double stranded DNA is defined as the
temperature at which half of the DNA strands are in double-helical state and half are in the
random coil state (SantaLucia J. , 1998). Thermodynamic calculations were completed (section
4.3.1.1) in order to determine the melting temperature of the 6-mers taking into account the
concentration of DNA and number of base pairs in each fragment.

These calculations

demonstrate that in order to denature the oligos library as well as fragments of the patient’s
DNA, a temperature of 95⁰C must be reached.
An offchip, macrosized process was designed to gradually denature and anneal the DNA
in each drop (Figure 6.2). Sets of droplets enter the system in plugs separated by air pockets.
These sets of droplets are the combination of an amplified fragment of patient DNA from many
daughter drops and all 4,064 oligos.

The droplets enter the system in plugs and their

temperatures are increased to the desired temperature to denature the DNA and cooled at a rate
of 1 ⁰C/sec for continuous anneal. Based on this heating rate and expected scanning throughput
of 1 million drops per second, the cold side of the gradient block responsible for decreasing the
temperature was sized:

=

ℎ

ℎ
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Figure 6.2 Gradual Denaturization and Annealing Process. An offchip, macroscale process was designed to ‘house’ 120
million droplets and to give a droplet residence time of 120 seconds. As droplets move down the length of the gradient block
their temperature is increased at a rate of 1 ⁰C/min. The droplets move down a capillary tube made of Teflon that is 1 mm wide.

The residence time in each plug can be determined by the cooling rate and the
temperature difference between the initial temperature and the final temperature. Thus the
number of droplets housed on the host side of the gradient block equals:

=

1 ∗ 10

∗

95

− 25
1

= 70

The merged droplets are 5 pL each. Thus, the total volume occupied by 70 million drops
is:

= 70 ∗ 10 ∗ 5

∗

10

= 0.00035 ∗

1
1000

∗

1000

= 350

Assuming a standard sized Teflon tube with a diameter of 1 mm and that the air bubles
take up an equal volume as the droplets in the pipe, a 22.3 cm Teflon pipe is required. The red
portion of the block in Figure 6.2 is used to ramp the temperature up to denature the fragments
while the other half is used to cool the drops back down to room temperature and continuously
anneal the fragments. The latter process allows oligomers to bind to the target fragment if the
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complementary sequence is present. If this is the case, the oligomer fluoresces. The cooling
temperature region ‘houses’ 70 million drops and the total residence time for the system is
roughly 70 seconds. The gradient block is heated on one end electrically. The heat exchange
across the tube is assumed to not be limiting. The gradient block used to heat the samples is
separated from the gradient block used to cool the samples. This system would be manually
built using Teflon tape and an electrically powered heating block or heated oil reservoir

6.3 SENSING HYBRIDIZATION
The sensing hybridization technique used in Micro$eq’s sequencing approach is based on
fluorescence-quencher labeled nucleotide system (Section 4.3.2.1). Oligos libraries can be made
to fit these specifications and quencher fluorophore systems can be purchases from biotech
companies such as Integrated DNA Technologies (IDT) and Jena Biosciences.
Fluorescent 6-mers are packaged with their complementary quencher sequences in the
oligos library droplets to suppress the signal in the absence of hybridization to the fragments of
the patient’s DNA. Once the 6-mers are denatured and continuously annealed with a patient
fragment DNA, either the complementary fragment won’t exist and the strands will rehybridize
and the hybridization fluorescence signal will be absent, or it will exist and if equal
concentrations are present, half of the fluorophore will bind the patient fragment and the other
half will bind the quencher (Figure 6.3). The fluorophore will then emit a signal which will be
detected. It is important to note that all of the fluorophores in the oligos library are excited by
same wavelength and emit in different channels.
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Fluorescenct
Oligonucleotide with
complementary
quencher

Fluorescenct
Oligonucleotide
with
complementary
quencher

Fragments of Patient DNA

Fragments of
Patient DNA

Rehybridization which
leads to fluorescence

Rehybridization
which does not
lead to
fluorescence

Figure 6.3 Possible results of Denaturization Annealing Cycle:Fragments of patient DNA are combined with
oligonucleotides from the oligos library. The oligomer droplets do not give off a hybridization fluorescence because of the
quencher emitter complementary pairing of the library. When combined with the library and denatured and annealed,
rehybridization may only yield a a signal if there exists a complementary strand to the fluorophore containing oligomer.

Additionally, a random sampling of 6-mers was used to assess the stability and
thermodynamics of the 6-base pair oligomers (Section 4.1.1)

6.4 SCANNING APPROACH: AN OVERVIEW
We are at the point in the process in which the daughter droplets have been merged with
the oligos library, denatured, and annealed. It is now necessary to scan the droplets to detect
which of the 4,064 possible six base pair oligomers hybridized with a parent sequence at a target
rate of 106 droplets/sec. However, there are some difficulties associated with this
implementation. For one thing, the oligos library needs to be barcoded. That is to say, a system
needs to be designed in order to keep track of which oligomer or oligomers are in each drop and
whether or not they have hybridized with a particular fragment of patient DNA. Secondly, the
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droplets have to be scanned at a target rate of 106 droplets per second. This encompasses the
design challenge. These constraints have lead to the design of an optical system that is beyond
the state of the art. That is to say, one cannot simply purchase the optical system. Thus, the
purpose of the following sections is to outline how we would build an optical system with
available optoelectronics.
A roadmap of the scanning strategy is described below. We decided to ‘barcode’ the
oligos library using fluorophores. The optical band width limits us to 7 distinct emissions signals
from fluorescent dyes. These emissions have to be read using a spectrometer. In order to
barcode the oligos library, combinatorial calculations show that it is necessary to have at least 10
distinct fluorophores. This can be achieved by multiplexing the emission signal. Therefore, two
intensities for each fluorophore were prescribed, thus giving us 12 distinct signals. 6-mers are
tagged with fluorophores and combined them into a droplet. The resulting distinct fluorescent
signal barcodes the drop, while hybridization is measured by the intensity of the fluorescence for
each fluorophore . Fluorophore bifunctionality adds an additional constraint to the system: each
signal must remain distinct given the fluctuation or noise associated with the process. Signal to
noise calculations were performed to make sure that the signals would remain distinct. These
calculations set the requirements on minimum concentration of fluorescent fluorophores needed
to maintain a reasonable signal to noise.

Furthermore, the laser power required is

correspondingly set. That completes the first portion of the scanning system.
In addition to engineering the fluorescent system, it was also necessary to delve into the
theoretical fluid mechanics of droplet coalescence and break up. This was necessary in order to
determine how quickly droplets can flow by a scanner. Given the desired throughput of 106
droplets per second, it was necessary to array the droplets in order to scan the droplets using a
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line scan CCD camera. By having a line scan camera which can scan at a rate of about 2000
frames per second, and aligning about 500 droplets onto the semipermeable electrode gated
platform one can reach the desired throughput of 106 droplets/sec. Finally, an overview of the
optical system is given. It is important to note that this optical system is beyond the state of the
art and the purpose of the following sections is to outline how we would build an optical system
with available photoelectronics.

6.5 BARCODING SCHEME
The oligos library is barcoded using bifunctional fluorophores which are used to barcode
the droplet and detect oligomer hybridization.

Multiple fluorescent, non-interacting

oligonucleotides are placed in a drop. The drop will emit a distinct signal and through curve
fitting the individual fluorophore signals may be deconvoluted. The intensity of the fluorophore
signals can be used to determine whether the particular oligomer has hybridized or not.
But how many distinct fluorophores are necessary to barcode 4,064 oligonucleotides?
Consider a simpler problem of barcoding 32 oligomers using four fluorescent signals.
Color
R
B
G
Y

1
X

2

3

4

X

5
X

6

7
X

8

9
X

10

X
X

11

X
X

12

X

13

14

16

17
X

18

19

X

X
X

15

X
X
X

20
X

21

22

24

25

26

27

28

X

X
X

23
X

X
X
X

X
X

X

29
X
X
X
X

Table 6.1 Barcoding Scheme using fluorescent labeling of oligos library. Combinatorics are used to package more oligomers
per droplet and to create a larger number of distinct droplets. The vertical lines in the table are used to border the contents of a
drop. 32 oligomers can be packaged into 15 drops.

Consider binding oligomer R1 to a red fluorescent tag. When the droplet is scanned, an
overall emission signal is read that corresponds exactly to the emission spectrum for the red
fluorophore. The intensity of the emission signal determines if oligomer R1 has hybridized with
the target DNA. Similarly, if only the blue channel shows up, then only oligomer B2 is present
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in the droplet and its hybridization state can be determined by the intensity of its emission.
However, this approach will only allow one to barcode as many oligomers as fluorophores. It is
not possible to have 4,064 distinct fluorophores due to the size of the detected band width.
Instead, combinatorics is used to layer the system.

Multiple signals and fluorophores are

combined into one droplet. For example, if an overall emissions signal comprised of the sum of
the red and blue emission signal is detected, then it means that oligomers R5 and B6 are present
in the droplet. The overall emissions signal can be deconvoluted to give its constituent spectra
through curve fitting. The intensity of the red fluorophore is associated with oligomer R5’s
hybridization state, and the intensity of the blue fluorophore is associated with B6’s
hybridization state. Different combinations of two channels can be used to increase the number
of barcodes (Table 6.1). Similarly, three fluorophores and three oligonucleotides can be added to
a drop as well as four. One of the advantages of this barcoding scheme is that it decreases the
number of drops required for the oligos library.
Mathematically, the number of oligos that can be barcoded using four different
fluorophores is a combinatorial problem.

The number of different signals that result by

packaging one oligos tagged with one of four possible fluorophores is:

( , )=

!

( − )! !

= (4,1) =

4!
=4
3! ∗ 1!

Equation 6.2

Similarly, the number of different signals that result by packaging two oligos tagged with two
different fluorophores out of a possible four fluorophores is:

(4,2) =
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Each signal is made of two different fluorescent oligomers, which allows one to package:

(4,2) ∗ 2 =
different oligomers.

4!
∗ 2 = 12
2! ∗ 2!

The total number of distinct signals (or number of droplets) created by packaging one to four
fluorophores into one droplet is:

Correspondingly, the total number of oligos that can be packaged in 15 drops is:

The total number of drops is really the sum of a binomial distribution:

Number of drops =
Number of oligos =

.

k

.

For an oligos library of 6-mers we need:
4 = 4,096

However, 32 of the oligomers are palindromes.
Thus the total number of unique oligos that need to be packaged is 4,064. It turns out,
that a minimum of 10 fluorophores are required in order to barcode the oligos library.
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As mentioned previously, the optical band width limits us to seven distinct emissions
signals from fluorescent dyes. We decided to barcode our oligos library by multiplexing six
different fluorophores. Therefore, six different fluorophores were prepared in two different
intensities. However, since we used 12 fluorophores instead of the minimally required 10, it is
possible to remove certain combinations that decrease the degree of multiplexing. Consider
using 8 of the 12 possible fluorophores to multiplex and 11 of the 12 possible fluorophores to
multiplex. The number of oligomers and droplets associated with this combination is:

However, only 4064 oligomers need to be packaged. Therefore, it is possible to remove certain
combinations. Consider removing two droplets from the oligos library that have 11 oligomers in
each:

Only 9 combinations of 11 fluorophrores are required. This results in a decrease in the number
of droplets by two.
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6.6 COLOR CHANNELS
The current approach is to use 6 color fluorophores at two different intensities to barcode
the oligos library. Each emitted signal is resolved by a spectrometer and the combination of dyes
present in each microdroplet is resolved by curve fitting (Figure 6.4).
These two intensities are generated by varying the concentration of fluorescently tagged
oligomers. As previously mentioned, the hybridization scheme implemented for the Micro$eq
design is a quencher-fluorophore type system. Thus for the lower intensity, there exists a case in
which the oligomer does not bind the patient fragment DNA, and this is unhybridized case. For
the case in which the oligomer binds the patient fragment, this is called the hybridized.

Figure 6.4 Resolving the Overall Emissions Signal: The overall emissions signal is resolved into its constituent emission
signals using curve fitting.
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The unhybridized state gives off a certain muffled signal which can be spectroscopically
resolved. The bound state gives off a different signal because fluorophore emissions are no
longer as quenched by the complementary quencher because they can now bind the patient
fragment DNA. Similarly, at the higher intensity the bound and unbound state have their own
distinct signals. (Figure 6.5).

Figure 6.5 Relative Intensity of a single fluorophore presented in all its intensities: The unhybridized state gives off a
certain muffled signal which can be spectroscopically resolved. The bound state gives off a different signal because fluorophore
emissions are no longer as muffled by the complementary quencher because they can now bind the patient fragment DNA.
Similarly, at the higher intensity the bound and unbound state have their own distinct signals. Relative intensities are drawn to
scale

The concentrations of fluorophore are adjusted such that the lower intensity in the
unhybridized case has a relative intensity of 1, the lower intensity hybridized case has an
intensity of 2, the higher intensity unhybridized case has a relative intensity of 4, and the higher
intensity hybridized case has an intensity of 8. This intensity scale can be created by adjusting
the concentration of fluorophore and quencher in the oligonucleotides. Combinations of a single
fluorophore at both intensities in a single droplet lead to eight different intensities. From a
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design perspective, it is important to make sure that each signal is distinguishable, and that one
signal may not be exchanged for another.

6.7 SIGNAL TO NOISE
Noise associated with the back end of the process can be attributed to deviations
associated with photoelectron emissions and noise associated with the instrument. At the front
end of the process, noise fluctuations can be attributed to deviation in the number of
fluorophores, i.e. deviation associated with the number of fluorophores per microdroplet.
Noise is added in quadrature. Thus for this process, the total noise associated with hybridization
detection is:

=
where

+

+

.

is the standard deviation assoiciated with electron emission,

noise associated with the detection device, and

is the

is fluctuation associated with the

concentration of fluorophores.
Statistically speaking, the standard error associated with electron emission is simply the
square root of the number of electrons. For example, if on average 4000 electrons are emitted
for the lower intensity unbound state, the standard deviation or noise associated with this signal
is 40001/2 or 63 electrons. As shown in Table 6.2, the number of electrons detected for each level
is chosen so that emission spectra of the first and second level are separated by 4000 electrons.
Typically, deviations from the mean emission value are evaluated half way in between the two
adjacent spectra. Thus, to spectroscopically resolve levels one and two, the amount of noise
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emitted is compared to 2000 electrons, which is half of the number of electrons that separate the
two levels. Thus, the 63 electrons associated with noise are compared to the 2000 electrons that
separate the spectra. In this case, the design was configured so that these spectra are about 31
standard deviations apart.

Higher intensity signals give off more noise.

Thus the noise

associated 40,000 photoelectron detection was compared to the separating line between levels
(2000 photoelectrons), and was found to be 10 standard deviations away. Thus, based on the
number electrons detected for the higher intensity, bound state this system is spectroscopically
distinct and resolvable. Table 6.7.1 also gives the fractional error associated with each level.
The fractional error is a ratio of the deviation in the number of electrons to the total number of
electrons:

=

(

)

.

Level

1

2

3

4

5

6

7

8

9

10

Electrons

4000

8000

12000

16000

20000

24000

28000

32000

36000

40000

Fractional

.016

.011

.0091

.0079

.0071

.0065

.0060

.0056

.0052

.005

error
Table 6.2 Error associated with barcoding scheme. The fractional error associated with photoelectron detection of
multiplexed fluorophores used to barcode the oligos library.

A Hamamatsu, high-speed operation, back-thinned FFT-CCD was selected as the image
sensor. It has a quantum efficiency of of 90% or more at the peak and its pixel size is roughly
the same dimensions as a 5 picoliter sized drop. Its complete specs are given in the appendix. A
custom camera can be bought from Hammamatsu which is compatible with this chip.
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To determine the fluctuation in signal associated with fluctuations in the concentration of
fluorophores per droplet one first has to calculate the number of fluorophores at 1µM in a 5 pL
droplet is:

= 1 ∗ 10

∗ 5 ∗ 10

∗

6.02 ∗ 10

= 3.01 ∗ 10

Error due to molecule fluctuation is simply the square root of the number of molecules. In this
case
3.01 ∗ 10 = 1734.94
In order to get an error rate in terms of the total number of photoelectrons detected, first divide
by total number of molecules to get error fraction:
1734.94
= 0.000576
3.01 ∗ 10^6

Then, multiply by total number of photons emitted on average to get error associated with
fluctuations in molecules.
0.000576 ∗ 40000 = 23.04

As far as instrument error, for this chip the error rate is 23 e- rms.
The greatest signal noise is associated with the largest intensity. The total error rate for a droplet
which leads to the detection of 40000 photoelectrons is:
=

40000 + 23 + 23.04^2 =202.6
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As mentioned in the subchapter titled channels, the total noise associated with a signal must be
small enough relative to the distance between two distinct signals.

This “distance” was

calculated to be 2000 photoelectrons. In this case, the signals are about 10 standard deviations
from their midline. Thus, there is a very small error associated with this configuration.

6.8 CALCULATING LASER POWER
As previous calculations have shown, the required laser has to have enough power to
emit 32,000 photons per microdroplet at the highest fluorescence concentration to maintain a
reasonable signal to noise. A spreadsheet has been prepared to calculate laser power based on a
given concentration of fluorophores.

BODIPY dyes will be used as the fluorophores and

monochromatic laser at 405 nm will be used for excitation. The calculations are described
below:
Beer-Lambert’s law is defined as:
=

.

where is ε is the molar absorbtivity or molar extinction coefficient with units of Lmol1

cm-1, b is the path length of the sample and c is the concentration of the compound in the

solution expressed in M. A fluorophore absorbs the energy of a photon and emits a electron at a
certain quantum efficiency ηquantum . The quantum efficiency is the ratio of photoelectrons
emitted to photons absorbed.

In addition to the quantum efficiency, there is a collector

efficiency ηcollector associated with the instrument’s capacity to capture the emitted photons. It is
simply the ratio of the total photoelectrons emitted to the number of photoelectrons absorbed.
The necessary power a laser must possess is also a function of the exposure time. As one can
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imagine, increasing the exposure time at a certain power increases the number of photoelectrons
emitted. For these calculations, an exposure time of 100 µsec was selected. In addition, it is
important to note that the absorbance of a given fluorophore varies as a function of wavelength.
Particularly, the molar absorbtivity is given at the maximum absorption wavelength, therefore it
is necessary to correct the molar absorbtivity to the wavelength of interest. This is done by taking
the absorbance spectra and taking the ratio of the peak height at the wavelength of interest to the
maximum peak height in the absorbance spectra (Figure 6.6). This ratio of max absorbance, to
the absorbance of interest is defined as ηmax/min .

Figure 6.6: A sample absorbance spectra of BODIPY Dye D100001. As can be seen, absorbance varies as a function of
wavelength. The excitation wavelength is 405 nm.The maximum absorbance is given by the absorbance of the largest peak. The
absorbance of interest is given by the intersection of the lower horizontal line and the intensity axis. A ratio of these two
quantities allows one to calculate absorbance at the wavelength of interest

The energy of a photon can be determined using the Planck relation:

=

ℎ

.

The question that has to be asked is what is the required laser power at a given
concentration of fluorophores that would result in the emission of 32,000 photoelectrons. Taking
the required laser power and multiplying it by the exposure time gives the total amount of energy
Micro$eq – Chomvong, King, Mahmoud

132 | P a g e

the laser gives off. However, not all of that energy is absorbed by the fluorophores. To account
for the various inefficiencies the quantum efficiency, the collector efficiency, and the ratio of the
absorbance at the wavelength of interest to the wavelength of the molar absorption coefficient is
given at are multiplied. This is multiplied by the molar absorbtivity, the path length, and the
concentration of fluorophore.
∗

∗

.

.∗

∗ ∗ ∗

.∗

.

This gives the total amount of energy that is absorbed and reemitted by the fluorophores.
This should equal the energy of the photoelectrons emitted multiplied by the number of
photoelectrons emitted. Solving for the required laser power:

=

∗ ∗ ∗ ∗

.

.∗

,

∗

.∗

.

/

The exposure time was chosen to be 100 µsec, the collector efficiency was chosen to be
0.5, also the quantum efficiency was chosen to be 0.5. 5 pL sized droplets were used to calculate
the path length. The BODIPY dye spectra are shown below. The BODIPY dyes used are:
Emission Wavelength (nm) Cat. #

E.C.

511

D2183

91,000

551

D2187

77,000

591

D2228

136,000

618

D6116

68,000

640

D10000 101,000

660

D10001 102,000

Table 6.3 Emision wavelengths of dyes chosen to barcode the library. E.C. is the extinction coefficient otherwise known
as the molar absorbtivity
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The calculated laser powers required for each dye is given in table V.10.2 below
Cat. #

Required Laser Power per
drop at 1 µM hybridized
oligomer to DNA fragment,
Higher Intensity [Watts]

D2183

0.000493

D2187

6.4*10-6

D2228

1.09*10-5

D6116

0.00178

D10000

1.73*10-5

D10001

7.4*10-6

Table 6.4 Required laser power at higher concentration. Using equation 6.10 the required laser power was calculated for the
different BODIPY dyes used.

To calculate the overall laser power required the required laser power per drop is
multiplied by 1000. This is to account for the fact that there are 505 arrayed droplets onto the
microfluidic platform which are separated by their diameter to avoid cross fluorescence. It is
important to note that for a given laser power, the strength of fluorescence emissions will be
different for different dyes. That is to say that certain dyes are not as efficient as others. This
can be easily seen in the table Table 6.4. To get a fluorescence emission spectra like the one
shown in Figure 6.7 below, the concentration of the more active dyes will be decreased. The
reason this is done is to prevent a very bright dye from “shadowing” a relatively dark dye. It
might completely drown out the signal of the adjacent dye and these differing spectra would be
indistinguishable.
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Figure 6.7: Emission spectra of BODIPY dyes. Normalized fluorescence emission spectra of 1)BODIPY FL, 2) BODIPY RG6,
3) BODIPY TMR, 4)BODIPY 581/591, 5)BODIPY TR, 6)BODIPY 630/650 and 7) BODIPY 650/665 fluorophores in methanol.

However, it is still possible to weed out large differences in deviations of intensities by
curve fitting. Further investigations would relate the difference in relative intensities of different
color channels to some critical relative intensity in which some color channels would be lost.
It is important to note that 32 of the oligonucleotides are palindromes. This means that
they read the same forward as backwards. Thus both the forward and reverse sequence are
automatically placed in a drop where they compete for sites and the output signal differs from the
expectations for the scanner. It is possible to deal this by putting in a higher fluorescent
oligonucleotide concentration in order to match the expected fluorescence. Once the fluorophore
concentration is determined, the corresponding laser power required at this concentration for a
given exposure must be determined.

6.9 SCANNING APPROACH: AN OVERVIEW
Once the oligos library is merged with fragments of the patient’s DNA, it is denatured
and rehybridized to canonical Watson-crick base pair the library with the patient DNA. The
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hybridization scheme allows the user to sense hybridization through fluorescence.

The

hybridized plugs of 505 drops are then sent through a microfluidic apparatus to line them up to a
line scanning CCD.

The scanning approach a shines monochromatic laser onto all 505

microdroplets and the emission is collected and relayed to the bioinformatic portion of the
process. The heart of the design is that large numbers of molecules are used and signal to noise
because noncritical. This allows one to use a high speed camera and to have increased design
control and throughput.
The difficulty associated with this design is achieving the target throughput of 106
droplets/sec. The high speed CCD chip chosen has a scanning rate of 1777 frames/second
(Hamamatsu, 2011). By arraying 505 droplets for a line scanner, the throughput can be increases
to about 106 droplets per second. Achieving the droplet configuration requires a fluid mechanics
consideration to line up the droplets.

6.10

THEORETICAL

AND

NUMERICAL

INVESTIGATIONS

OF

DROPLET BREAK UP AND COALESCENSE

Droplet breakup in flow is the result of the competition of viscous stresses associated
with the imposed flow field, and capillary stresses due to surface tension between two phases.
Consider an arbitrary drop of size D, in a matrix fluid of viscosity µ undergoing flow with
characteristic magnitude G of the local velocity gradient, and with surface tension σ. It is
important to note that viscous stresses scale and µG and capillary stresses scale as σ/D.

Micro$eq – Chomvong, King, Mahmoud

136 | P a g e

The relevant dimensionless number characterizing this flow is the capillary number:

=

µ∗

∗

.

which is the ratio of viscous-to-capillary stresses. Viscous stresses deform the droplet and
breakup may occur. Higher flow rates demand smaller droplet sizes or droplet break up will
occur.
The expression above can be further simplified. The velocity gradient in a micro channel
of hydraulic diameter~ Di and flow rate QO can be estimated as G~QO/Di3 . This gives a simple
relationship between generated droplet size and imposed flow rate:

~

∗
µ∗

.

The larger the flow rate, the smaller the droplet size. Droplets are stable once they are formed,
so this also provides the criteria for droplet stability.
As shown in the Figure 6.8, a larger flow rate associated with the oil phase leads to
smaller ratios of droplet diameters to channel diameter.
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Figure 6.8:Two different is scalings are shown for droplet generation. D/Di is the ratio of droplet diameter to the width of the
orifice. Q0 with units of µl/min is the flow rate of the oil phase. The flow rate of the water phase is 0.5 µl/min. Larger oil
flowrates lead to smaller ratios of droplet diameter to width of the orifice. Figure adapted from (Tan, 2004)

For Micro$eq’s applications, droplet volumes are typically are on the order of 5-25 pL,
while the well radius is on the same order as the diameter of the well (Figure 2.3). Based on the
portrayed chip technology, a D/Di of one is assumed. For 5 pL droplets, the number of droplets
per second that can be flowed:
. 5µ

∗

1000000
1µ

∗

1
60

∗

5

= 1666.67

/

For a water liquid phase, σ=10^-3N/m, µ=30*10^-3 kg/ms. Assume the diameter of the
well can be made to be:

5

∗

1
10

R=.00001061 m so D=.00002122 m.
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~

∗
µ∗

Using the critical capillary number this equation gives flow rates at which droplets become
unstable.
Assuming a QO of 12µL/min:

~

10

∗.

(. 00002122 )
12µ
1
1
∗
∗
∗
∗
10 µ 1000 60

30 ∗ 10
∗

= 1.59252 ∗ 10

That volume of microdroplet would be:

=

4
∗
3

∗

=

4
∗
3

∗

2.11472 ∗ 10

1.59252 ∗ 10
2
∗ 1000

∗

= 2.11472 ∗ 10

10
1

= .002105

Calculating number of drops /sec assuming well is a cylinder:
2 ∗ 10
= 0.5655
∗ 3.14 ∗ (. 00001061 m)

=

/

Diameter of droplet~1.59252*10^-6 m

=

0.5655 /
1.59252 ∗ 10

= 3.6 ∗ 10

/

An excel spreadsheet was prepared using these principles and further designs downstreams such
as the tree root design where validated by the underlying fluid mechanics.
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6.11 MICROFLUIDICS
Stage-two microfluidics are tasked with lining up 505 droplets for the S11071 series high
speed CCD line scan camera.

When considering a design, theoretical and numerical

investigations of droplet breakup and coalescence must be considered.

Principally droplet

breakup is determined by the relevant dimensionless number-the capillary number.

As

mentioned earlier, the capillary number is the ratio of viscous stresses associated with the
imposed flow field, and capillary stresses due to surface tension between two phases. At higher
flow rates, only droplets of smaller radius are stable.

6.11.1 Preprocessing
Heading into microfluidic device 2 is a microdroplet array separated from the previous
array by a sheet of air. Because the fluid mechanics in the downstream process dictate bubble
breakup, a preprocessing system was designed. Preprocessing removes the air pockets by
applying a correctly timed vacuum and injects oil to add increased distance between two arrays
and to give the scanner increased time between scans (Figure 6.9). The exposure time for the
arrayed microdroplets was chosen to be 100 µsecs. Based on the velocity of the fluid through
the 1.80 cm tube, the amount of injected oil was calculated to be 0.007 µL.
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Figure 6.9: Preprocessing system. Time lapsed display of preprocessing system. Air pockets are removed from the flowing
fluid and oil is injected to separate out different arrays of 505 droplets.

6.11.2 Droplet Setup before Electrode Gated Scaffold
Heading into microfluidic device 2 is a microdroplet array separated from the previous
array by a sheet of air (Figure 6.10). Preprocessing removes the air pockets by applying a
correctly timed vacuum and injects oil to add increased distance between two arrays.

Figure 6.10: Microdroplet array-heading into the tree root design is a “package” of 505 droplets in a row

In order to array the droplets onto a platform for the high speed CCD line scan camera an
innovative method of lining up the droplets must be employed. One way to do that would be by
employing a tree-root type design to evenly distribute the droplets and then to array the droplets
onto a permeable platform. (Figure 6.11).
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Figure 6.11 Tree Root System: The tree root system is used to evenly distribute the array of 505 droplet across the electrode
gated permeable scaffold used to line up the droplet for the line scan camera.

The stem of the tree root is 1.8 cm in diameter with an oil flow rate of 35 µL/sec. The
droplets are sent down the tree root system and are further subdivided until there exist 16
channels with on average 32 droplets. Bifurcations alter the bell curve type distributions heading
out by eliminating cross over. Another way to say it is that bifurcations partition the probability
distributions. Heading out the tree root system is a droplet’s probability of landing vs. axial
position centering the exit tube (Figure 6.12).
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Figure 6.12 Bell curve depicting probability of a drop landing vs. axial position with respect to the exit tube.

It is important to note that similar microfluidics have been constructed before (Figure
6.13), these validating the feasibility of this design.

Figure 6.13 Microfluidic apparatus which uses a similar tree root type design. This apparatus validates the feasibility of the
design. (Ethan Schonbrun, 2011)

The exit channels are 1.1 mm wide and microfluidic calculations considering the viscous
stresses associated with the imposed flow field and the capillary stresses due to surface tension
between the two phases have determined that 5pL sized droplets are stable in these flows. The
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droplets flow of a rate of 62500 droplets per second and considering that there are 16 channels,
the total droplet flow rate is 1*10^6 droplets per second.

6.11.3 Permeable Electrode Gated Barrier
Two difficulties exist in lining up 505 droplets for the S11071 series high speed CCD line
scan camera using the droplets exiting the tree root system: the droplets exit with a probability
distribution of landing which must be perturbed and the droplets must be arrayed for a certain
period of time and then released.
These challenges can be resolved by employing a permeable electrode gated barrier
(Figure 6.14). On average 32 droplets will exit each root and will be deposited onto a permeable
electrode gated barrier that is inclined. The electrodes are turned on and droplets disperse
themselves across the surface. Cross flow is added to eliminate stacking of the droplets. Once
the droplets are imaged the electrode voltages are removed and the droplets are washed away by
the cross flow.
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Figure 6.14 Permeable, electrode gated barrier. This permeable, electrode gate barrier is used to array microdroplets onto a
straight line. Cross flow is used to skew the exit probability distributions.

It is important to note that there are complicated fluid mechanics problems associated
with this design. Potentially, this design has the right throughput but this is a nonconventional
implementation compared to published fluid mechanics. Therefore, there needs to be an at scale
demonstration verifying the feasibility of this design and more information need to be collected
and tests need to be made-to see state of the art.

6.12 OPTICS
Below is a depiction of the optical setup for sensing fluorescence hybridization for the
Micro$eq platform (Figure 6.15). Microdroplets are lined up in an array for imaging and are
shined with a laser at 405 nm for 100 µsec. Photons emitted from the sample are collected and
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shined onto a prism.

The prism refracts light into a 1.325 mm rainbow.

The image is

deconvoluted by curve fitting and the barcode is identified and hybridization is detected based on
the output.

Figure 6.15 Optical System: The optoelectronics of this system consist of the laser, a prism, and two lenses.

It is important to note that for any optical setup magnification must be larger than 1. In
the design above the magnification is one. Both lenses are the same size. However since the
scanning area is about 1.8 cm wide, relatively large optical devices must be sought which are
typically found in optical microlithography field.
A dimensionless number that characterizes optical lenses is the numerical aperture.
Numerical aperture (NA) is defined as :
=
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Where n is the index of refraction and θ is the half-angle of the maximum cone of light that can
enter or exit the lens. For air, n=1.

6.13 SEQUENCING THROUGHPUT
Based on scanning rate of the CCD line scan camera and the number of droplets arrayed
onto the electrode gated platform, the droplets per second that can be scanned is:
1777

∗

505

= 897385

/

The number of parent drops determined by assembly optimization is 3.63*108 (Section 7.4).
Each of the DNA fragments in the parent drops are amplified and the droplet is split into 505
drops. These 505 droplet are then merged with the 505 droplets that make up the oligos library
giving the total number of daughter droplets. In general, the total number of daughter droplets is:
ℎ

=

∗

.

Thus the total number of drops to scanned per human genome is:
3.63 ∗ 10 ∗ 505 = 1.83 ∗ 10

The total scanning time is thus:
1.83 ∗ 10
897385
sec

= 204277

56.7 ℎ

The number of stations required to sequence one genome per day is:
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56.7 ℎ
24 ℎ

= 2.36

6.14 SEQUENCING CONCLUSIONS
A bifunctional barcoding system was created to keep track of which oligos are in each
drop and whether or not they are hybridized. The key to barcoding is multiplexing fluorescent
oligomers. Adding more than one fluorophore per drop allows one make a larger number of
distinct signal to be detected by a spectrometer.
The target scanning throughput of 106 droplets/sec was achieved by using a high speed
CCD image sensor with a scanning rate of 1777 frames/second (Hamamatsu, 2011). By arraying
505 droplets for a line scanner, the throughput can be increases to about 106 droplets per second.
Achieving the droplet configuration requires a fluid mechanics consideration to line up the
droplets. It is important to note that this is a custom made design and that it is beyond the state
of the art. Further investigations are required into the fluid mechanics of the microfluidic design,
particularly the tree root design and a real time chip with this configuration must be tested.
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CHAPTER 7

Genome Assembly
Previously, genome sequencing strategy is discussed. The process of sequencing begins
by physically breaking DNA into many random fragments. The small fragments are then read
and passed on to the next step—genome assembly. Genome assembly, a fundamental area of
bioinformatics, is essential to personal genome sequencing because it reconstructs the original
sequence from many small fragments. Without this step, the output from DNA sequencing has
little meanings. With microfluidic approach to DNA sequencing, genome assembly scheme for
Micro$eq is customized to accommodate unique raw sequencing data.
In this chapter, two main assembling strategies which are implemented in series are
discussed—de Bruijn graph assembly and shotgun sequencing. Raw sequencing data for
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Micro$eq is a set of 6-mer oligos which bind to the fragments inserted into the droplets. These
bound oligos are assembled to generate secondary reads via de Bruijn graph assembly. The
average length of secondary reads is identical to that of original fragments inserted into
microdroplets. Secondary reads are then used as input in shotgun sequencing to generate contigs
which are contiguous sequence of original genome. The number of contigs depends on
acceptable error rate, which is specified at 10 in a million in Micro$eq proposal.
With an ultimate goal to minimize number of drops required to regenerate original
genome at an acceptable error rate, number of fragments per drop, fragment length, and required
coverage are optimized. In this chapter, each variable is studied separately prior to optimization
step to thoroughly understand relationship among assembling variables. Finally, specified
sequencing requirements are used to estimate assembling time and computational demand.

7.1 SIMULATION OVERVIEW
Due to particularly short reads generated during
sequencing process, Micro$eq developed a strategy to
accommodate unique type of assembling input. The
simulation of genome assembly was conducted in
MATLAB with randomized original genome sequence.
The goal of the simulation is to find the optimal values
of fragments per droplet, estimated fragment length and
required coverage for a given set of oligo library. These
variables are optimized to minimize number of drops
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Figure 7.1 Overall Assembly Scheme The raw
sequencing data is translated to only those which
bind to the fragments within a droplet. De Bruijn
graph approach reconstructs the initial reads (length
= kmers) into elongated secondary reads (length ≈
nBp = fragment length). Shotgun sequencing is
applied as the secondary assembly scheme to
construct contiguous sequences for specified error
rate.
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required in sequencing process.
Micro$eq assembly algorithm integrates Eulerian path approach and shotgun sequencing.
The initial reads from oligo library (k-mers) are aligned using de Brujin graph to generate
secondary reads. The secondary reads must have sufficient length so that the contigs generated
from shotgun sequencing algorithm is feasible at acceptable error rate (Figure 7.1).
For future ease of reference, assembling variables and their definition are clarified:
kmers

–

number of base pairs in each set of oligo library

nFrag

–

2 x number of doubled strand DNA fragments within a droplet.
The doubled strand DNA are comprised of 2 strands which are
both analyzed via assembly algorithm

nBp

–

estimated number of base pairs within one fragment

Initial reads

–

sets of oligo library which bind to portion of any fragments

Secondary reads

–

assembled initial reads, using de Bruijn graph approach

Contigs

–

assembled secondary reads, using shotgun sequencing

Efficiency (Eff)

–

(number of independent outputs) ÷ nFrag

Throughput (Th)

–

number of bases assembled per drop
(nFrag x nBp) x Eff

As discussed in previous chapter, the output from sequencing process is a binary
indicator whether a given oligo library binds with original genome sequence. Due to a limitation
on barcoding scheme, the length of each oligo library is proposed to be 6 base pairs. With four
possible types of bases—A, T, C and G, 46 - 32= 4064 sets of oligo library exist [See 3.3.2.1].
Since the output is binary, if the indicator shows that a particular set of bases binds with the
original sequence, it is undetermined whether the set binds once or more than once. In other
words, the information on repeats is not captured in Micro$eq’s sequencing scheme. Thus, the
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initial reads are derived from the oligos which bind to the inserted fragments. These initial reads
are the building blocks of final assembled genome product.

7.2 DE BRUIJN GRAPH ASSEMBLY
7.2.1 de Bruijn Graph Overview
Eulerian Path approach utilizes the concept of de Bruijn graph. A de Bruijn graph is a
direct graph that represents sequence of symbols and the edge of the graph indicate where the
sequence may overlap. DNA fragment is present in smaller pieces (kmers). De Bruijn graph is
constructed where the nodes for the graph represent the kmers and the paths in the graph
represent connection and relationship between two nodes. The two kmers nodes are connected
when their (kmers-1) bases are identical (Figure 2.6). The structure of de Bruijn graph is suitable
to demonstrate the overlaps between kmers (Abegunde, 2010).
To find a path in a de Bruijn graph, each node must be visited as least once. Therefore,
high redundancy challenge is handled by the graph without an increase in number of nodes. One
of the Eulerian path’s advantages is its ability to accommodate sequences with very different
lengths. Because of one-to-one relationship between each node, overlapping sequences have to
follow the same path. On the other hand, the disadvantages of Eulerian Path approach are
physical memory requirement. De Bruijn has heavy structure which requires considerable
amount of physical memory. However, it was proven that the requirement can be distributed on a
cluster of small commodity computers (Zerbino, 2009). In addition, since the arches of the graph
are determined based on overlapping kmers-1 bases, false sequences can be generated.
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Generally, kmers used are between 21-25 bp in length (Zerbino, 2009). Smaller k-mers
increase connectivity, and thus increasing number of overlaps between each node. As length of
kmers increases, the chance of overlapping between each node decreases because the two nodes
are connected only when (kmers-1) bases are overlapped. As length of kmers decreases, the
probability of accidental overlaps increases. Length of kmers is a critical value which results in a
tradeoff between sensitivity and specificity.
Some of the existing assembler tools have been developed to address assembly problem
based on this approach; for example, Euler and Euler-SR (Abegunde, 2010).

7.2.2 Micro$eq Application of de Bruijn Graph Assembly
Eulerian Path approach is suitable for shorter reads. The length of reads acquired from
sequencing process is equal to the length of oligo library, kmers, which was proposed to be 6
base pairs. The ultimate goal of Eulerian Path approach for Micro$eq is to assemble initial reads
to secondary reads. There are two variables that can be adjusted to maximize assembling
throughput per droplet: number of fragment per drop (nFrag) and fragment length (nBp).
7.2.2.1 de Bruijn Graph Interpretation
Three main steps are to convert raw sequencing data to secondary reads (Figure 7.2):
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Figure 7.2 Micro$eq’s Eulerian Path Approach This part of the strategy is comprised of three steps – (I) Derivation of Initial
Reads, (II) de Bruijn Graph Construction, and (III) de Bruijn Graph Interpretration. The goal of Eulerian Path Approach is to
reassemble Initial Reads to Secondary Reads which will be used as an input for the following shotgun sequencing assembly
algorithm

Step I: Derivation of Initial Reads
Raw sequencing set of information is comprised of a binary indication whether each
oligo binds with genome fragments (Figure 7.2: last column of Oligo Library (k-mers) matrix: 1
indicates that the oligo and 0 indicates that oligo does not bind with genome fragment(s)). If the
oligos are indicated to bind with genome fragments, they can be classified as Initial Reads.
However, since the indication is binary, number of repeats cannot be determined. Initial Reads
are crucial to Micro$eq’s assembly process since they are the basic building blocks of a complete
genome sequence.

Micro$eq – Chomvong, King, Mahmoud

154 | P a g e

Step II: de Bruijn Graph Construction
Initial Reads derived from raw sequencing data are used to construct de Bruijn Graph.
Each initial read is presented as a node with k-mers bp in length. The node can be directionally
connected if (kmers – 1) bases overlap (Figure 7.2: top right region: it can be observed that initial
read #3 is connected to initial read #4 because the last (kmers -1) bases of #3 are identical to the
first (kmers – 1) bases of #4).
Step III: de Bruijn Graph Interpretation
de Bruijn graph interpretation yields set(s) of secondary reads for each droplet. The
interpretation of de Bruijn graph is challenging due to algorithm applied to connect any two
initial reads. Since the (kmers – 1) overlapping bases are used as criteria to connect two nodes, it
is possible that the connection is incorrect, However, the correct connection is always presented
among alternatives. The challenge of repeats further complicates the reassembling process. Since
it is possible that the initial read is presented more than once in the genome sequence, additional
connections cannot be eliminated.
The reassembling process from de Bruijn graph is memory intensive. With more than one
probable path to connect the graph, all possibilities are generated. The set of assembled reads
which do not include all of presented initial reads are incorrect and can be removed. This is
because initial reads are those which bind to the genome fragments. None of them should be left
out when secondary reads are assembled.
To reduce memory required in assembly process, three main strategic algorithms are
introduced so that incorrect connections are eliminated during the time of secondary read
generation.
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Figure 7.3 Three Strategic Algorithms in de Bruijn Graph Reassembly Figure 7.3.a – Eliminate paths which exclude at least
one initial read. Figure 7.3.b – Eliminate paths which create infinite loop. Figure 7.3.c Eliminate self-connecting paths.

1) Eliminate paths which exclude at least one initial read. To illustrate, in Figure 7.3.a, since
node #3 must be included as part of secondary read, the path chosen is node 1 – 3 – 2.
Without this algorithm, two possible paths exist, (1 – 3 – 2) and (1 – 2).
2) Eliminate paths which create infinite loop. Since human genome is not circular, the path
which allows infinite secondary read interpretation is eliminated. For example, in Figure
7.3.b, the path from NODE 1 to NODE 2 is eliminated. The secondary read derived from

this case would be (5 – 3 – 2 – 4 – 1). It is possible that the fragment is comprised of
repeated initial read (5 – 3 – 2 – 4 – 1 – 2 or 5 – 3 – 2 – 4 – 1 – 2 – 4, etc.). However, it
cannot be determined because indication of initial read presence is binary. The shortest
fragment assembled is always guaranteed to be present in the original fragment; thus,
introducing no additional error to the process. The disadvantage of this strategy is that it
potentially decreases the length of interpreted secondary reads, which results in an
increase in required coverage.
3)

Eliminate self-connecting paths. From Figure 7.3.c, it can be observed that

kmer-1 bases of NODE 3 overlap with itself. However, since information on number of
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repeats of initial reads is not available, the self-connecting path is eliminated. This
algorithm can lead to severe errors in assembling interpretation. From this elimination
strategy, the sequence is interpreted as “T A A A A A A G”; however it is possible that
more than 6 bases of ‘A’ exist in this fragment. This example clearly demonstrates the
well known challenge in genome assembly – repeat. However, in the scope of our study,
the possible repeat problems are out of scope and the error rate associated with this case
is assumed to be negligible.

Figure 7.4 Acceptable de Bruijn Graphs Figure 7.4.a) Unambiguous (I and II) and acceptable ambiguous (III and IV) de
Bruijn graphs are selected to generate secondary reads and counted toward throughput per droplet (Th). Figure 7.4.b) ambiguous
but acceptable graph are those with only one crossing point. This type of ambiguous graph generates two possible combinations;
both of which are passed along to shotgun sequencing step.

After the three main algorithms are applied to eliminate certain type of paths from de
Bruijn graph, the final criteria used to assemble secondary reads is executed. Since the
secondary reads are the building blocks of the final contigs in shotgun sequencing, only those
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which are unambiguous or ambiguous at acceptable rate are selected. The unambiguous graphs
are those with no crossing between two fragments (Figure 7.4.a : I and II). The ambiguous but
acceptable graphs are those which consist of one crossing between two fragments (Figure 7.4.a :
III and IV). In the later case, two possible combinations are assembled and passed along to
shotgun sequencing as secondary reads (Figure 7.4.b). The number of acceptable ambiguous
graphs is estimated to be 50% of all secondary reads generated from de Bruijn step. This is a
significant error rate which is passed along to shotgun sequencing step.
After the acceptable graphs are selected, complimentary sequence of genome fragment(s)
are generated by walking through the path of the graphs. The kmerth base from each initial read
is added in order of the graph’s path, generating secondary reads. This set of secondary reads
are used as inputs for next assembling step, shotgun sequencing, to reconstruct contiguous
sequences; thus original genome sequence.
7.2.2.2 Throughput Maximization
It is beneficial to determine optimal number of fragment numbers per droplet (nFrag) and
expected number of bases per fragment (nBp) for a given size of oligo library (kmers). Crucial
parameter used to determine nFrag and nBp is throughput per droplet (Th). As defined earlier:
ℎ=(

=

×

)×

Equation 7.1
Equation 7.2

Where Th is throughput per droplet, nFrag is number of individual input genome fragments per
droplet from nFrag/2 doubled strand DNA fragments, nBp is expected number of bases per input
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genome fragment, Eff is efficiency rate of assembly per droplet, and ind is the number of
acceptable graphs which are selected as secondary reads.
Initial study is conducted with suggested value of k-mers equals to 6 bases. The
relationships betweem nBp, nFrag and throughput per droplet are studied individually while
holding other variables constant.
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Figure 7.5 Throughput Maximization Figure 7.5.a – For a given length of fragments and size of oligo library, optimal number
of fragments to be inserted in a droplet exists. At this value, maximum throughput is achieved. For expected fragment length of
20 bp with 6-mers oligo library, optimal number of fragments per droplet is 10 fragments. The de Bruijn assembly throughput is
maximized to be ~ 105 bases per drop. The simulation was run 30 times for each nFrag value to calculate standard error bars,
thus confidence level of the results. Figure 7.5.b – for varied numbers of expected bases per fragment, maximum throughput
increases as nBp decreases.

1) Throughput per droplet vs. number of fragments per droplet
For k-mers equal to 6 bases, nBp is held constant to study the effect of nFrag variation. In
this case, expected number of bases per fragment (nBp) is randomly assigned the value of 20
bases. The result from simulation is presented in Figure 7.5.a.
It can be observed that initially the throughput increases as number of fragments
increases. However, the assembling throughput reaches its maximum value where 10
fragments, equivalent to 5 doubled strand DNA pieces, of approximately 20 bases are
deposited in one droplet. If more fragments are inserted into a droplet beyond this value,
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assembling throughput decreases drastically. This result is observed because as more
fragments is inserted in a droplet, the probability that initial reads are repeated or overlapped
increases. Thus, assembling efficiency rate (Eff) decreases as number of fragment increases
(Equation 7.2). Nevertheless, the process goal is not to maximize efficiency rate but
throughput. Since higher number of fragments in a droplet provides more initial reads to be
reassembled, maximum throughput can be achieved with optimal values of nFrag for a given
nBp. In other words, for a given length of fragment, optimal number of fragment which
maximize throughput can be derived (Equation 7.3).
= (

,

)

Equation 7.3

2) Maximum throughput per droplet vs. expected length of fragment (nBp)
Since optimal value of nFrag depends on specification of nBp, the relationship between
nBp and maximum throughput is studied. By repeating the pre6ous simulation, each time
with different value of expected bases per fragment, maximum throughput and optimal value
of nFrag can be determined for each nBp. The result from repeated simulation is shown in
Figure 7.5.b. It can be observed that maximum throughput increases rapidly as expected
length of fragment decreases. However, nBp cannot be decreased indefinitely because
secondary reads, which have expected length of nBp, are used as inputs for the next
assembling step (shotgun sequencing). As the length of secondary read decreases, the
assembling throughput in shotgun sequencing step decreases (this relationship is explored in
more detail in section 3.2.4) Since de Bruiji assembly prefers smaller fragment length but
shotgun assembly prefers larger fragment length, sensitivity analysis is required to determine
the optimal fragment length. Nevertheless, according to pre-sequencing process, the
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minimum length of fragments that could be cut with acceptable deviation is 17-18bp. This
limitation must be taken into account since it underlies the feasibility of genome sequence
fragmentation.
3) Consequence of k-mers variation
k-mers has been kept as suggested at 6 bases to study relationship between throughput
vs. number of fragments per droplet and maximum throughput per droplet vs. length of
fragment. Although variation of k-mers has more constrains associated with it due to the
limitation during sequencing process, its consequence on de Bruijn assembling throughput is
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Figure 7.6 Consequences of k-mers Variation Figure 7.6.a – as kmer increases, the de Bruijn assembling throughput increases
dramatically. The optimal number of fragment per droplet also increased from 4 individual fragments for 5kmers, to 10 for 6mers
and to 50 fragments for 7mers. Figure 7.6.b – The maximum throughput when 20bp fragment is used increased by 5.3 fold
when 7mers is used instead of 6mers. The effect of elongated kmers accelerates as number of base pairs per fragment decreases.
The simulation for each data point is repeated 30 times to generate standard error bars, identifing level of confidence associated
with the results.

As k-mers elongates, expected de Bruijn assembling throughput per droplet increases.
This is because with increased number of oligo library (4k-mers), the potential repeat problem
decreases. For example, while 6-mers generates 4096 unique sets of oligos in the library, 7mers generates 16384 sets. The 4-fold increase in burden of barcoding scheme results in
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approximately 5.3-fold increase in maximum throughput in de Bruijn assembling process for
fragments with nBp = 20 bases. De Bruijn assembling throughput with k-mers = 7 and nBp =
20 reaches its maximum, 560 bases reassembled/drop, when 40 individual fragments, which
is equivalent to 20 doubled strand DNA fragments, are inserted within a droplet (Figure
7.6.a). In comparison to the throughput result when kmer = 6 bases is used, the de Bruijn
throughput increases drastically. In Figure 7.6.b, it can be observed that the effect of
elongated kmers on maximum throughput accelerates as number of base pairs per fragment
decreases. Therefore, regarding de Bruijn assembling throughput, the smaller number of
bases per fragment and the longer kmers are preferred. The optimal number of fragment per
droplet is chosen so that the throughput is maximized as shown in Figure 7.5.a and Figure
7.6.a.
Elongated kmer increases throughput during de Bruijn assembly as well as that during
shotgun sequencing assembly. However, the tradeoff is the cost and time required to create
and maintain larger size of oligo library which decreases the throughput in genome
sequencing process. Currently, it is determined that the potential margin gain of using 7mer
instead of 6mer is not sufficient to invest time and effort in higher fixed cost of oligo library
maintenance.
In Figure 7.6.a, the blue data point represented the throughput when oligo library with
5kmer is used. The maximum throughput is reached at 45.33 bases/drop when 2 doubled
strand DNA fragments (nFrag = 4) are inserted in the drop, each with approximately 20 base
long. The throughput which is meaningful to shotgun sequencing assembly is only half of the
raw value because the doubled strand DNA fragment yields repetitive information. Thus,
only 23 bases/drop is relevant to the final assembling process. This value is less than that in
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the original proposed base case where the throughput per droplet was experimentally proven
to equal 35 bases/drop (Table 3.1) As explored earlier in Section 3.3, the adjusted throughput
of less than 35 bases/drop is not feasible. Thus, the 5mer oligo library which yields
throughput in the range lower than the specified threshold is not selected. Even though
maintaining oligo library with the 5mer is simpler than that with 6mer the later is selected
chosen because of the higher assembled throughput it delivers.
To conclude, the two critical variables in de Bruijn assembling process – number of
fragments per droplet and expected length of fragment– are determined using MATLAB
simulation to maximize assembled throughput per droplet. The simulation shows that the optimal
number of fragment per droplet exist for a given value of fragment length (Equation 7.3). The de
Bruijn graph assembling yields highest throughput when expected fragment length is short.
However, the shearing limitation prohibits fragments which are smaller than 17 bp (New
England Biolabs). Shorter fragments also results in higher coverage required during shotgun
sequencing process which possibly decreases overall assembling throughput. The relationship
between length of fragment and shotgun sequencing throughput is explored in the following
section.

7.3 SHOTGUN SEQUENCING ASSEMBLY
7.3.1 Shotgun Sequencing Overview
Shotgun sequencing was introduced in 1982 by Fred Sanger. In shotgun sequencing,
DNA is first shredded into smaller fragments which can be sequenced individually. The
sequences of these fragments are then reassembled into their original order, based on overlaps,
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yielding the complete sequence. The algorithm went through many major developments and has
been used in majority of genomic sequencing projects. The International Human Genome
Sequencing Consortium, 2001, was conducted using shotgun sequencing strategy (Pop, Salzberg,
& Shumway, 2002).
Generally, the sequence is randomly sheared into small pieces with approximately 1000
bp in length (Rogers, 2007). The overlapping reads of these small pieces are presumed to come
from the same area of the genome. By aligning and merging DNA fragments, long contiguous
sequences, contigs, are formed Figure 2.7.
Main challenge associated with shotgun sequencing is that the assembly is only possible
when enough DNA reads are generated to cover the original sequence. Mathematically, this
limitation was studied by Eric Lander and Michael Waterman in 1988 (CBCB). The correlation
between the oversampling of genome, coverage, and the number of contigs which can be
successfully reconstructed was published.
Let G, n, L, c, and t represent genome length, number of sequences (fragment and its
complementary count as one), length of sequences, depth of coverage, and the amount by which
two sequences need to overlap in order to computationally detect this overlap, respectively.

=
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Figure 7.7 Lander-Waterman estimation of number of contigs vs.
Coverage 8-10 coverage of reads is required to generate small number
of contigs.

fragments into a small number of
contigs. The smaller numbers of contigs
result in smaller number of gaps,
enabling final contig assembly (CBCB).

7.3.2 Micro$eq Application of Shotgun Sequencing Assembly
Secondary reads assembled via de Bruijn graph are used as input fragments for shotgun
sequencing. The base at each position is determined using aligning and merging algorithm. Since
shotgun sequencing is the final step before genome sequences are delivered, the specification of
sequencing process is determined based on targeted overall error rate. As previously discussed,
fragment length must be optimized as a function of overall process since de Bruijn assembly
prefers smaller fragments while shotgun prefers elongated fragments.
7.3.2.1 Read Error Calculation
Read error rate, the probability that a given base in a fragment is incorrect, depends upon
fragment length, accumulated error rate from sequencing step and de Bruijn assembly step. As
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the fragment length increases, the probability that the fragment repeats in the entire genome
sequence decreases (Equation 7.6).

(

)=

4

Equation 7.6

Where G is genome length = 2.9 x 109 bases and nBp is fragment length. For a given fragment
length, 4nBp possible combinations of bases exist. Thus, it is less likely that the fragments are
repeated as number of bases per fragment increases. This advantage of longer fragment allows
shotgun sequencing to achieve specified error rate with lower coverage.
In addition to the error rate expected as a result of fragment length, the accumulated rates
from previous steps, sequencing and de Bruiji assembly, must be taken into account. Since the
secondary reads are consisted of 50% acceptable but ambiguous graphs, the total error rate
increased by 50%. Given such a high rate from de Bruijn assembly, the effect of pre-sequencing
and sequencing error rates are considered negligible. Thus the probability that base in each
position of the fragment is incorrect, Read Error, can be calculated (Equation 7.7):

=

=

4

× 1.5

Equation 7.7

This read error is further used to calculate the overall error rate upon completion of
shotgun sequencing.
7.3.2.2 Total Error Rate vs. Coverage
Acceptable error rate for personal genome project is specified at 10-5. A trade-off
between lower error rate and higher coverage exists because more information is required to
determine the base at each position with higher accuracy. Unfortunately, higher coverage
requires more fragments, more sequencing drops, and thus higher cost. In order to minimize cost
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of the personal genome project, the coverage is selected such that the total error rate is slightly
below the threshold, 10-5.
To understand the relationship between process error rate and shotgun sequencing
requirements, coverage, a primary shotgun variable is studied. Coverage is the number of times
fragments are expected to overlap or the amount of genome oversampling. The actual number of
coverage is a Poisson distribution around expected number of coverage.
( ,µ ) =

!

Equation 7.8

Where k = actual coverage, µc = expected number of

0.12

Probability of Occurence

µ

0.1

coverage, P = probability of occurrence. For example, in
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Figure 7.8, Poisson distribution of actual coverage for

0.06
0.04
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Figure 7.8 Poisson Distribution of Actual
Number of Coverage When the Coverage is
stated, it is referred to Expected Coverage. For a
particular Expected Coverage value, it is possible
that more or less coverage exists. The probability
of each coverage incident is presented in this
figure. As the actual number moves away from
expected value, the probability of occurrence
decreases (Equation 7.8)

because it is equal to expected value. Probability of
occurrence decreases as actual number of coverage moves
away from the expected number of coverage.

For each possible value of coverage, error rate from shotgun algorithm exists. This error
rate is the result of Read Error and insufficient genome oversampling. Shotgun algorithm
implements the usage of overlapping fragments to determine the base at each position. In order
for the position to be incorrectly determined, equal or greater than half of the base presented
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must be incorrect. To illustrate the following shotgun error per base is calculated for actual
coverage (Table 7.1).

Actual Coverage

Shotgun Error Rate

1

= Read Error = x

2

= Probability that fragment 1 or fragment 2 or fragment 1&2 are incorrect
= 2x(1-x) + x2

3

= Probability that frag 1&2 or frag 2&3 or frag 1&3 or frag 1&2&3 are incorrect
= 3x2(1-x) + x3

Table 7.1 Error Rate for Actual Coverage Calculation Error Rate can be calculated when read error is given
for actual number of coverage. This calculation can be represented by mathematical formula presented in
Equation 7.9.

Mathematically, the error rate for a given number of actual coverage can be calculated:

( , )=

!
( ) (1 − )
( !)( − )!

Equation 7.9

Where k = actual coverage, x = read error, σ = minimum number of incorrect base required to
affect incorrect final base conclusion; σ ≥ k/2 while σ is an integer. From Equation 7.9, it can be
observed that as number of actual coverage increases, error rate for a given number of actual
coverage decreases. This can be explained by the oversampling of information which decreases
the probability that majority of presenting bases are incorrect ( x << 1-x ).
Finally, total error rate of the project can be calculated from Equation 7.8 and Equation
7.9. The total error rate of the process is the summation of all possible cases of number of actual
coverage:

(µ , ) =
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Figure 7.9 Total Error vs. Expected Number
of Coverage The total error derived from
Equation 7.10 for different expected number of
coverage is presented. In this case, read error is
assumed to be 1%.

The target error rate for personal genome project
is set at 10-5. For a given read error, optimal coverage
can be selected such that the total error rate is slightly
less than 10-5.

7.4 ASSEMBLY OPTIMIZATION
Thus far, specification on fragment length has not been done. The ambiguous optimal
fragment length is due to a trade-off between de Bruijn Assembly throughput and shotgun
sequencing throughput. In addition, the final goal of the optimization is to minimize the required
number of parent drops needed to be generated during sequencing step; thus, minimize the cost
of the entire process. The following equation explores the relationship between fragment length
and required number of parent drops (Equation 7.1Equation 7.3Equation 7.7Equation 7.10):

=

=

( × )⁄
ℎ⁄(2 ×

ℎ
1
)
2 ×
{ }
{
2× ×
=
=2 ×
=2 ×
}
ℎ
ℎ{
ℎ{
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Equation 7.11
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Where n is the number of fragment required for shotgun sequencing, Th is the throughput per
droplet (bp), nBp is the expected fragment length, c is expected coverage, G is total genome
length and x is read error which is the probability that a given base in a shotgun input fragment is
incorrect. The assembled throughput per drop Th is divided by 2 in Equation 7.11 because the
information gain from assembled base is redundant. The fragments inserted into a droplet are
doubled strand DNA; thus for nFrag = 10, only 10/2 = 5 independent fragments exist. When
these assembled secondary reads are used as input in shotgun sequencing, the redundant
information of complementary fragments is not taken into account. Hence, when number of
parent drops is calculated, only half of the assembled throughput is relevant for shotgun
sequencing.
From Equation 7.11, it can be observed that the
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Figure 7.10 Number of Parent Drops Required
vs. Expected Fragment Length The optimal
length of fragment is selected such that the number
of parent drop is minimized. The number of drops
is the result of de Bruijn graph assembly and
shotgun sequencing. From Equation 7.11, as
number of expected fragment length decreases, de
Bruijn throughput increases while more coverage is
required. This results in inconclusive direction of a
preferred fragment length. However, the simulation
is conducted to combine the effect of both steps for
a given fragment length. The optimal fragment
length which minimize number of parent drops is
shown to be equal to 22 bases.
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results in inconclusive direction of fragment length.
Thus, sensitivity analysis is conducted to explore
relationship between number of parent drops required
and variation of fragment length.
For a 6-mer oligo library with targeted error
rate slightly below 10-5, expected number of parent
drops required is calculated for different fragment
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length (Figure 7.10). It is clear that when fragment length is short, the high read error rate (x)
which resulted from possible repeat of in the entire genome (Equation 7.7) dominates the higher
de Bruijn throughput. On the other hand, when the fragment length is long, the low de Bruijn
throughput dominates the ease of shotgun assembly and results in higher number of parent drop
required. Figure 7.10 shows that the optimal fragment length that requires minimal number of
parent drops is 22 bp.
Given that the fragment length is 22 bases, optimal number of fragments inserted into a
droplet is 10 fragments which is equivalent to information obtained from 5 independent doubled
strand DNA (Equation 7.3). With these values, de Bruijn assembly throughput is maximized at
185 bases per droplet (see 7.3.2.2 Throughput Maximization). The read error rate for 22 base
fragment is 2.47 x 10-4 (Equation 7.7). This specification results in minimum 11.55 coverage
requirement for 9.98 x 10-6 total error rate (Equation 7.10). The number of fragment required is
1.52 x 109 (Equation 7.1) and number of parent drops required to achieve the specification is
3.63 x 108 drops (Equation 7.11).

7.5

COMPUTING

TIME,

COMPUTATIONAL

AND

PERSONNEL

DEMAND
The two main steps implemented to assemble initial reads to final sequence are de Bruijn
assembly and shotgun sequencing. The two steps can be 6sualized in series; however,
computationally, they can be parallelized since the assembled secondary reads from de Bruijn
graph can be passed along to align with the reference sequence instantaneously, decreasing
overall computing time for a given genome sequence.
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7.5.1 De Bruijn Computing Time and Computational Demand
The expected number of initial reads per drop came from de Bruijn graph estimation.
Since the fragment length is 22 bases, the maximum number of initial reads that could be
generated for a non-repeating fragment is 22 – 6 +1 = 17 reads, for kmer = 6 bases. However,
from previous simulation, other possibilities of crossing exist for the combination of 22 bases of
10 fragments per drop. Thus, the average number of initial reads per fragment is estimated to be
15. Since there are 10 fragments in one drop, the estimated number of initial reads per drop is
150. This number can be used to calculate de Bruijn computing time of one parent drop:
=

≈ 150 = 22500
Equation 7.12

Because kmer-1 bases must match in order for de Bruijn nodes to be connected, 1352
times of comparison must be looped in order to generate the graph (FLOPS stands for floating
point operations per second). Upon completion of graph generation, de Bruijn assembly
algorithm is estimated to be 2 fold of the graph generating time. From this estimation, de Bruijn
assembly computing time can be estimated:

=

22500
1

×

3.63 × 10
1

×3×

1
2.4 × 10

= 2.83 ℎ /
Equation 7.13

In this case, the specification of a processor is 2.4 GHz which is translated to the ability
to complete 2.4 x 109 FLOPS in one second.
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7.5.2 Shotgun Computing Time and Computational Demand
To minimize shotgun computing time, which traditionally has been a bottleneck of
genome sequencing process, the most efficient algorithm is selected. Bowtie, an open source
memory efficient and short read aligner is suitable for personal genome project. It has been
tested to achieve 25 million 35-bp reads alignment of human genome in one hour. In
additionally, the run was conducted on standard PC with 2 GB RAM. Bowtie algorithm is
capable of handling doubled strand DNA which is applicable to Micro$eq’s requirement
(Langmead, Trapnell, Pop, & Salzberg, 2009). The estimation of Micro$eq runtime is estimated
based on Bowtie algorithm:
1.52 × 10
1

×

= 60.9 ℎ /
Equation 7.14

For the same number of fragments, run time is expected
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Figure 7.11 Bowtie CPU Time vs. Read Length
This relationship is derived from data from Table
5 of (Langmead, Trapnell, Pop, & Salzberg,
2009). In the experiment, server with a four-core
2.4 GHz AMD Opteron processor and 32 BP of
RAM is selected. The system aligned 2M
untrimmed reads from 1,000 Genome project. It
can be observed that as read length shortens, the
CPU time decreases.
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7.11) (Langmead, Trapnell, Pop, & Salzberg, 2009).
Since the decrease in CPU time decelerates as read
length decreases, the computing time is estimated
conservatively to be equal to that of 35 bp read length.
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To achieve higher speed of the process, alignment can be parallelized by distributing
reads among different threads for a multi-core server. The speed increases by 3.12 fold if the
alignment is run on four threads instead of one on the four-core server (Langmead, Trapnell,
Pop, & Salzberg, 2009). Thus, the estimated shotgun runtime improved to:

1

60.9

×

1
= 19.1 ℎ /
3.19

Equation 7.15

Thus, with four core server, 19.1 hour is required to shotgun human genome.

7.5.3 Overall Computing Time and Personnel Demand
The overall computing time of assembly process depends on the bottleneck process, the
aligning and merging shotgun sequencing. Since the output from de Bruijn assembly can be
passed along to shotgun step instantaneously, the total assembly time only depends on shotgun
sequencing step. For one genome, 19.1 hours of computing time is required to reassemble reads
into original genome.
Personnel demand for genome assembly process is minimal. One technician is needed to
maintain the servers and deliver final sequenced genome electronically to clients for a
throughput of less than 72 genomes per day. Occasionally, the technician might have to modify
assembly code to minimize assembling time according to newly launched algorithm.

7.6 GENOME ASSEMBLY SUMMARY
Many genome sequencing variables are interrelated. Small change in one variable might
cause dramatic fluctuation on others. The optimal values of fragment length, number of
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fragments to be inserted in each parent droplet, and number of coverage are determined in this
chapter using sensitivity analysis. It is concluded that the optimal fragment length which
minimize number of parent drops required is 22 bases. With specified fragment length, number
of fragments to be inserted to each droplet is optimized so that de Bruijn throughput reaches its
maximum—in this case, 10 fragments from 5 doubled strand DNA, each with 22 base in length
yields assembled throughput of 185 bases/parent drop. Fragment length also affects the read
error—probability in which a given base on fragments prior to shotgun sequencing is incorrect.
The read error is then to calculate coverage required to shotgun the entire genome at acceptable
error rate. In this case, 11.55 expected number of coverage is required to achieve 9.98x10-6 error
rate. The number of coverage is further applied to calculate number of fragment required to
accomplish shotgun sequencing (1.52x109 fragments), which implies number parent drops
needed to be generated (3.63x108 drops). The computing time expected per genome is 19.1
hours. Specification that minimum of 12 genomes must be sequenced per day can be
accomplished by using 10 servers of four core 2.4 GHz AMD Opteron processor and 32 GB of
RAM.
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CHAPTER 8

Cost Estimation Breakdown
While the technical aspects of Micro$eq’s entire process have now been outlined, the
financial costs of each of the processes has not been discussed. As one of Micro$eq’s primary
objectives is to generate a relatively low-cost, sequenced genome product, it is necessary to
verify that its proposed process is feasible in a low-cost operating environment. While a financial
analysis will be done on the whole-company level in Chapter 9 of this report, this chapter aims to
outline in detail the reagent, microfluidic platform, and equipment costs associated with each
step in the process.
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8.1 REAGENT COSTS
Annual reagent costs will be directly related to annual genome throughput as reagents are
non-recyclable and thus a certain quantity most be allotted to each sequenced genome. This
section outlines the reagents required for the pre-sequencing and sequencing steps of the process.
As no physical sample handling takes place in the reassembly step of the process, it requires no
reagents.

8.1.1 Presequencing Reagents
All reagents required for the presequencing steps outlined in Chapter 5 of this report have
been summarized in Error! Reference source not found.. Most of the presequencing step
reagents are obtained in the form of kits, which include all the necessary reagents (buffers, salts,
enzymes, etc) for that particular reaction. However, while standard kits were available for most
of the presequencing reactions, a few custom oligonucleotides (adaptors, primers, quenched
primers) had to be synthesized which add additional costs.
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Initial DNA Extraction and Purification
Unit price
OrageneSaliva kit (Genotek)
$778
Preliminary DNA Fragmentation
Quick purification kit
(Qiagen)
$471
Adenosine Tail Addition
A-ligaiton kit (Qiagen)
$1,000
Internal Adaptor Insert
Basic Ligation kit (Qiagen)
$1,000
Internal Adaptors (IDT)
$17.50
Exonucleolysis
Exonuclease Kit (NEB)
$244
MmeI Digestion
MmeI Digestion Kit (NEB)
$244
Quick purification kit
(Qiagen)
$471
End-it DNA repair kit
(Epicenter Biotech)
200
Terminal Adaptor Ligation
Basic Ligation kit (Qiagen)
$1,000
Internal Adaptors(IDT)
$1.75
PCR Amplificaiton1
PCR basic kit (Qiagen)
$1,000
Custom primers (IDT)
$0.63
PCR Amplification 2
PCR basic kit (Qiagen)
$1,000
Custom primers (IDT)
$0.63
Primer Quenchers (IDT)
$0.25

Genomes per unit
960

Cost per Genome
$0.81

500

$0.94

1124

$0.89

1124
4000

$0.89
$0.00

1500

$0.16

1000

$0.24

500

$0.94

500

$0.40

1124
4

$0.89
$0.44

1124
100

$0.89
$0.01

1124
10
10
Total per genome

$0.89
$0.06
$0.03
$8.49

Table 8.8.1 Presequencing Reagent Cost estimates(amounts in US$)

As seen in Table 8.8.1, no single reaction is particularly costly on the per genome level.
Because all purchased kits may be stored for at least a year-long time period, and no kit purchase
exceeds Micro$eq’s annual throughput, the prices cited for each unit are for the company’s
largest available bulk price, making it the cheapest cost per individual kit.
Because the genomes are processed on a small scale, the amount of reagents required per
genome is relatively small. The amount of genomes per unit of reagents/kits were calculated by
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adjusting the processing volume or DNA weight per each kit by the volume or weight of DNA
being processed per genome at each particular step.
The custom-made adaptors were priced on a per base pair level, with an economies of
scale pricing scheme as the number of bases increased. This is the reason for the discrepancy
between the two sets of adaptors: the 250bp adaptor costs approximately ten times as much as
the 25bp adaptor.
The custom primers are required in smaller amounts than custom adaptors. However, as
primers are used in every copy of DNA generated, each unit of primers served a much smaller
number of genomes. Similarly, the primers required for the first amplification served more
genomes than the primers required for the second amplification as the second amplification
produced more copies of DNA.
As seen in Table 8.8.1 the total presequencing reagent cost of one genome is $8.49,
which is very reasonable in terms of the current competitive market. The main reason this
reagent cost is low is that the microfluidic platform used both requires the processing of a very
small amounts of DNA and capitalizes on the droplet microreactors yielding high-efficiency
reactions.

8.1.2 Sequencing Reagents
The sequencing reagents are the fluorescent 6-bp oligomers and 6-bp dark quenchers for
fluorophore –dark quencher hybridization system (Section 4.3.2.2.2). The concentration of the
oligomers was chosen based on signal to noise analysis (Section 6.8). This concentration was
chosen to be 1µM for the both the fluorophore and quencher.
The fluorophores and dark quenchers are purchased from Integrated DNA Technologies
(IDT). To calculate the cost associated with sequencing the human genome, one first has to

Micro$eq – Chomvong, King, Mahmoud

179 | P a g e

calculate the total number of moles of 6-mers required to sequence the human genome. The 6mer concentration in each 5 pL drop is 1 µM. The total number of drops required is given by the
size of the oligos library, the number of fragments in each droplet, and the depth. Optimization
of throughput determined that 1.83x1011 droplets are required to sequence a human genome.
Multiplying the number of drops by the number of moles of oligomers in each drop gives the
total number of moles of 6-bp oligomer required to sequence the human genome. A summary of
these calculations can be seen in Table 8.2

Table 8.2 Sequencing Reagents Cost: The oligos library is custom synthesized by Integrated DNA technologies (amounts
in US$)
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For the calculations in Table 8.2, it was assumed that the oligomers are purchases on a 10
µM synthesis scale. Modifications are assumed to be purchased on a 10 micromole scale for the
fluorophores and a 1 micromolar scale for the quencher. Multiplying the total number of moles
by the modification cost and adding both modified strands gives the total cost of the prepared
quencher-fluorophore system to sequence a human genome of $19.22.

8.2 MICROFLUIDIC PLATFORM COSTS
The cost estimates for the microfluidic platforms for this process are important. As
microfludic technology is a relatively new field, equipment costing is still relatively expensive,
thus these microfluidic platforms present the potential for being a financially-limiting factor in
the overall process.
Each microfluidic platform must have a microfluidic syringe pump which provides the
driving force for droplet flow, as well as a custom-made microfluidic chip containing the flow
channels for the droplets. The syringe pump to be used in this process can feed up to 10 different
channels simultaneously (Dolomite). The custom-made chips may be recycled via washing, but
must be disposed of every 10 days (for daily base output of 12 genomes per day). Thus while the
syringe pumps are a fixed cost and will be lumped with equipment costing in the final cost
estimates spreadsheet, the required microfluidic chips will be a scalable cost dependent on the
company’s throughput and will be lumped with inventory.
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8.2.1 Presequencing Microfluidic Platforms
The presequencing process involves two microfluidic apparatuses. The first is initial
parent droplet generation and merging with PCR reagent droplets prior to amplification. As
discussed in chapter 5, this process will be run for 12 samples simultaneously, with each sample
being split into 10 parallel channels. The required flow rate of the microfluidic chip is
100µL/min. The Syringe pump is capable of 1mL/min of flow, thus 10 parallel channels at
100µL/min each can be powered by one syringe pump. This implies that a syringe pump is
required for each genome for this droplet generation step. The syringe pump has a base unit price
of $6,250, with a required supplementary syringe attachment, which costs $165 per unit, yielding
a total unit cost the syringe pump station of $6,415.
Additionally, the size of the microfluidic chip can be estimated based on the size of the
droplets. The channel width are estimated based on microfluidics as discussed in Chapter 6 of
this report, and will for estimated using the merged droplet size, as this will limit the flow
channel size. For the 1nL merged parent droplets, the required diameter size of the channel will
be 0.15mm. The distance between the channels will be assumed to be the same as channel width.
Thus the total width of each channel is calculated as shown below:

(120 × Channels + 120 × Spacers ) ⋅ 0.15mm = 36mm
The length required for the merging process is 25mm, thus the total area of the chip is calculated
as shown below:
36mm × 25mm ×

0.00155in 2
= 1.4in 2
2
mm

It is important to note that a residence volume for all drops on the chip need not be
calculated as the merged droplet will be directed off the chip and into the tubes for PCR
amplification, thus not all droplets need reside on the chip at a single time, which decreases the
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length of chip required as the only plumbing that must exist on the chip is that which is required
for the merge operation.
At an estimated market price of $100 per square inch of custom-made microfluidic chip
(Dolomite), the total microfluidic chip price for this first step is $140. Again, as each chip may
be used for 120 genomes, this is a inventory microfluidic price of $1.17 per genome.
The second step in requiring microfluidic platform in the presequencing process is the
parent droplet split. As the number of droplet has not changed from the previous microfluidic
process, the number of droplet injectors will remain the same (1 per genome). Additionally, the
number of required channels will initially be the same. As the parent droplets are split the
number of required channels increases, but the channel width decreases proportionally, so the
total width of this chip will still be 36mm. The required length for the split process is again
estimated as 25mm, therefore the total chip area will also be 1.4in2, and thus cost out to $140, or
$1.17 per genome.
A summary of the presequencing Microfludic platform costs can be found below in Table
8.8.3:
DNA-PCR Reagent Droplet merge
Unit Cost
Mitos-XS Pump Basic (Dolomite) $6,250
Custom Microfluidic Chip
$140
(Dolomite)
Parent Droplet Split
Mitos-XS Pump Basic &
$6,415
Accompanying Syringe
(Dolomite)
Custom Microfluidic Chip
$140
(Dolomite)

Genomes per Unit
1
120

Cost per Genome
$6250
$1.17

1

$6415

120

$1.17

Total per
Genome

$12,502.34

Table 8.8.3 Presequencing MicroFluidic Platform Cost Estimates (amounts in US$)

As can be seen from Table 8.8.3, the estimated cost per genome for the presequencing
microfluidics platforms are ~$12.5 thousand. While this may seem unrealistically high for a per
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genome market price point aimed at $1000, it is important to keep in mind that only $2.34 of the
microfluidics costs are disposable inventory, and the remaining $12,500 are fixed equipment
costs.

8.2.2 Sequencing Microfluidic Platforms
The sequencing process involves only one microfluidic setup. However, this process is
slightly more complex as it involves the merging of the 6mer oligonucleotides library droplets
with the sets of daughter droplets generated by the presequencing steps. This microfluidic setup
will require the same type of pump and syringe setup as the presequencing step. The required
generated flow rate for the downstream sequencing process is 35 µL/min. Thus one syringe
pump at 1mL/min will suffice for the generation of the oligos library required for one station,
again costing $6,415 per syringe pump unit. As ~2.63 stations are required for each genome, this
means a total of 2.63 syringe pump setups are required per genome.
The dimensions associated with the sequencing microfluidic platform are mainly
determined by the dimensions of the semi-permeable electrode gated barrier used to align the
drops for scanning by the CCD camera. The diameter of 5 pL droplet is 22 micrometers. In
order to array 505 droplets in a line, while leaving a gap whose dimension is equal to the
dimension of a droplet for the electrode (Figure 6.11.14) the microfluidic chip’s dimension must
be at least:
0.000022

∗ 505

∗ 2 = 0.022

2.2

In addition to possessing a dimension larger than the dimension of the electrode gated
barrier needed to array the droplet, room must be given for the tree root design (Figure 6.11). 25
mm are allocated to the tree root system.
Thus the area of the chip is calculated as shown below:
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(25

) ×

0.03937

= 0.9687

So, for a 0.9867in2 chip at $100 per square inch, each chip will cost $96.87. As with the
sequencing chips, the chips will be replaced every 10 days for a base of 12 genomes per day,
thus this cost will be divided by 120 to get a per genome microfluidic chip cost of ~$0.81.
A summary of the costs associated with the microfluidics platforms in the sequencing step is
shown below in Table 8.8.4
Parent Droplet Split
Mitos-XS Pump Basic &
Accompanying Syringe
(Dolomite)
Custom Microfluidic Chip
(Dolomite)

$6,415

2.63

$16,871.45

$96.97

120

$0.81

Total per
Genome

$16,872.26

Table 8.8.4 Sequencing MicroFluidic Platform Cost Estimates (amounts in US$)

As can be seen from Table 8.8.4, the estimated cost per genome for the presequencing
microfluidics platforms are ~$16.9 thousand. While, similarly to the presequencing microfluidic
platform costs, this may seem unrealistically high for a per genome market price point aimed at
$1000, it is important to keep in mind that only $0.81 of the microfluidics costs are disposable
inventory, and the remaining $16.9 thousand are fixed equipment costs.

8.3 EQUIPMENT COSTS
This section will provide a detailed breakdown of the equipment costs on the per genome
or per 12 genome unit basis. In this analysis, it is important to remember that while the reagents
are inventory costs, equipment is fixed costs and while dependent on Micro$eq’s targeted
throughput, will be a one-time purchase at the beginning of the sales phase. As will be discussed
in this section, some of the required equipment or equipment station setups will be multiplied in
order to increase process throughput to achieve a one-day genome sequencing process.
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8.3.1 Presequencing Equipment
All required equipment for the presequencing process were explicitly stated in the
presequencing process chapter (Chapter 5) of this report, with the exception of the conventional
laboratory centrifuging and vortexing machines, were are necessary in many of the DNA
preparation protocols.
A summary of all the required presequencing equipment is shown below in
Equipment
Vortex mixer (VELP)
Lab Centrifuge (UNICO)
Magtration 12GC (Pss
Bioinstruments)
s2 Shearer (Covaris)
ThermalCycler (Biometra)

Cost per unit
179.99
679.68

units per base process
1
0.5

total cost
179.99
339.84

$1,000
$500
$4,000

1
1
4
Total

$1,000
$500
$4,000
$18,019.83

Table 8.8.5 Presequencing Equipment Costing Estimates for base process of 12 genome simultaneous processing (amounts
in US$)

It should be noted that the “base process” referred to in Table 8.8.5 refers to the
simultaneous processing of 12 genomes. For this reason, the centrifuge, which can handle 24
samples at once, it marked as only having 0.5 units required. For the overall process cost
estimates found in chapter 9 of this report, the number of centrigues required will be rounded up
if the total process integer multiples of the 12 genomes base process is not even (thus divisible
by 24).
Similarly, the Thermal Cycler can handle 3 genomes at once, thus a total of 4, for the base
process of 12 genomes, is required.
The sum total of presequencing equipment, as seen in Table 8.8.5, is ~$18,000, a very
reasonable price when compared to the equipment required of the sequencing and genome
reassembly equipment costs, and thus will not be the cost-determining portion of the process.

Micro$eq – Chomvong, King, Mahmoud

186 | P a g e

8.3.2 Sequencing Equipment
Sequencing equipment is required for the optical system and for the microfluidic system.
For the optical system, a prism is required to refract fluorescence emitted from the droplets onto
the line scanning CCD camera (Figure 5.12.15). Furthermore, two lenses of 1X magnification
are required to transmit fluorescence. A Nikon 60 mm Micfo-Nikkor Lens was selected which
possesses a lens diameter of 2.9 inches. Also a Hamamatsu back thinned CCD image sensor is
required to scan the microdroplets. A CCD chip was found the specifications required.
Hamamatsu was contacted, and a representative can be quotes a price of a fully equipped CCD
camera with power sources to be on the order of $25,000. A laser is also required to excite the
fluorphores. The required laser power is roughly10 mW (Section 6.8). A summary of the costs
associated with one optical setup station can be seen below in Table 8.8.6. As shown, the total
optical setup cost per station is ~$27 thousand.
Item
Price ($)
Tedco Prism
$6
Nikon Micro-Nikkor Lensx2
$945.98
Hamamatsu back thinned CCD image sensor
$25,000
Laser
$6.74
Hp Compaq 8200 Small Form Factor Desktop PC with Screen
$989
Total Cost per optical setup station
$26,947.72
Table 8.8.6 Sequencing Equipment Associated with the Optical System: The optical system consists of a prism, two lens, a
fully equipped CCD image sensor, a laser, and a computer. (amounts in us$)

As 2.63 stations per genome are required to achieve a throughput time of 24hrs per unit
of genomes, the total optical equipment cost per genome will 2.63 times the optical setup station,
thus $70.9 thousand per genome. While this number may seem alarming, it is important to note
that it is a fixed equipment cost based on the annual throughput. At a throughput of ~25,000
genomes per year, this is less than $3 per genome per optical setup for only a year of operations,
much less for the three years of full operations and one year of 50% operations.
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In addition to the optical setup, a computer is translate the signal information to the
bioinformatic computation system. The Hamamatsu CCD chip has a pixel dimension of 1024 by
16 pixels and scans at a frame rate of 1777 frames per second. Thus, the total amount of pixels
transferred per second is:
= 1024

= 29

∗ 16

/

∗

1777

= 29 ∗ 10

If one images in a 24 bit format, a typical screen resolution of 1024 x 768 pixels take up
2,359,296 bytes.
The number of bytes in a pixel is:
2,359,296
1024 ∗ 768

=3

/

Translating the Megapixels/sec transferred into bytes per seconds.
29 ∗ 10

Using the fact that 1 byte=8bits
. ∗

∗
∗

3

= 8.7 ∗ 10
∗

/

= 696

/
/ ec

A typical 2010 computer with an RPM of 7,200 has a data streaming rate of 1030
MB/sec. Thus one computer can be used to stream data from 1.48 stations. For this process, the
Core IF-2400 processor from Intel will be used, with a price of $889 per computer, which
translates into a price of $1,315.72 per station and thus $3460.31 per genome. A summary of all
sequencing equipment costs is shown below in .
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Equipment

Cost per unit

Tedco Prism
Nikon Micro-Nikkor Lensx2
Hamamatsu back thinned CCD
image sensor
Laser
Hp Compaq 8200 Small Form
Factor Desktop PC with Screen
Intel Core IF-2400 processor

units per genome

total cost

$6
$945.98
$25,000

2.63
2.63
2.63

$15.78
$2,487.93
$65,750.00

$6.74
$989

2.63
2.63

$17.73
$2,601.07

$889

3.89

$3,460.30
Total

$74,332.80

Table 8.8.7 Sequencing Equipment Costing Estimates per genome (amounts in US$)

Again, as the sum of ~$74 thousand per genome seems extraordinarily high, it is
important to remember that these are all fixed equipment costs and will therefore be virtually
negligible on the per genome basis.

8.3.3 Genome Reassembly Equipment
In addition to the existing computer system discussed in 8.3.2, supplementary servers are
required to complete genome assembly step. As previously discussed in Section 7.5
computational equipment required for genome assembly process is based off of assembly
algorithm. To assemble one genome, raw sequencing data has to be processed through de Bruijn
assembly and shot gun sequencing. The bottleneck of assembling process is the later one where
19.1 hours is required to assemble one genome on a four core 2.4 GHz AMD Opteron Processor
with 32 GB of RAM (Equation 7.16). Computational demand specification is based off of an
open source assembly algorithm, Bowtie, where Red Hat Enterprise Linux AS release 4 was
selected as operating system (Langmead, Trapnell, Pop, & Salzberg, 2009).
For Micro$eq’s assembly process, Quad-Core AMD Opteron Processor 8356 is selected
because it is applicable to Linux operating system and satisfies 2.4GHz and 32 GB RAM
requirement (Geekbench Result Browser, 2008).
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The specification of personal genome project is to assemble 12 genomes per day. In order
to do so, more than one server is required since 1 server takes 19.1 hours to assemble 1 genome.
Number of servers required can be calculated:
12

×

1

19.1 ℎℎ
1

×

1
= 9.55 = 10
24 ℎℎℎ

If 10 servers of defined specification are run in parallel, 12 individual genomes can be
assembled per day. Then the relationship between number of genome assembled and
computational demand is further explored,
9.55
12

⁄

×

Equation 8.1

=
= 0.796 ×
= 2.41 × 10

Equation 8.2

×

The relationship between number of specified server and target number of genome to be
assembled per day is illustrated in Equation 8.2. The estimation was also illustrated for number of
targeted assembled genome annually, assuming 330 operating days. The calculated number of servers
must be rounded up to satisfy the capacity required. From Equation 8.2, as number of target genome to be
assembled increases, number of server requires to accomplish genome assembly increases linearly. The
cost of each server is approximately $1650 including associated hardware and Red Hat Linux software
(AMD). Based on relationship in Equation 8.2, the cost of computational equipments required for genome
assembly process can be estimated as a function of targeted number of genome product:
= 0.796 ×
= 1313 ×
= 3.979 ×

As illustrated in

× $1650

Equation 8.3

Equation 8.3, the cost of servers and their associated software and hardware

can be estimated as a function of targeted number of genomes Micro$eq wishes to accomplishes. With the
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initial target of 12 genome per day for Series A investor, the server cost associated with genome assembly
is $15,756. After Series B funding, the targeted genome increases to 10,000 genomes per year with
associated assembly server cost equals to $39,792.

8.4 COST ESTIMATE BREAKDOWN SUMMARY
This chapter provided a detailed breakdown of the required reagents, microfluidics platforms, and
equipment for all three stages of Micro$eq’s genome sequencing process. This breakdown will be applied
in the next chapter, and thus a full process summary will not be provided here, as it can be found in
section 9.2 of Chapter 9 in this report. A full analysis of the cost estimates, within the context of the entire
company’s financial analysis will be provided there. However, it is interesting to note that from the above
summarized, the most expensive equipment and microfluidics sector is the DNA scanning, whereas the
most expensive reagents sector is the presequencing preparation steps. The genome reassembly is not
financially limiting in any sector of the discussed cost breakdown.
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CHAPTER 9

Financial Analysis
While the previous sections have discussed the technical aspects of Micro$eq, it is
necessary to analyze the financial feasibility of such a company. As a major objective of this
project was to minimize the cost of sequencing a whole human genome, the actual market price
of Micro$eq’s production that would allow it to remain profitable must be explored. The goal is
to achieve a market price at least an order of magnitude less than the current market price, and
have the capability of a throughput that will match the currently growing market demand. In
order to achieve the necessary low price per genome, but still maximize the investors’ margins, a
balance between a low market price and a financially profitable company must be found.
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While the project specification was originally set at 12 genomes per day and priced at
$100 per genome, the financial analysis shows that this is unfeasible. However, the financial
analysis will show that at an increased throughput, a market price of $999 per genome– a full
order of magnitude

below the current market standard of $10,000 per genome – may be

achieved while still operating well above Micro$eq’s breakeven point. It is important to note that
this financial analysis includes several assumptions and a few simplifications. Thus, these
numbers may not be exact, but are sufficient estimates to show the potential feasibility of the
project.
The analysis begins with revenue projections that are based on the annual genome
throughput and market price. As the project’s financial feasibility is highly dependent on the
product price, a separate sensitivity analysis will be done on the market price after a throughput
number has been determined. Next, the total costs and depreciation values are explored. Costs
are pseudo-dependent on genomic throughput, as rental space, personnel, and equipment often
need to be adjusted when throughput is increased. The cost and depreciation values are then
combined with the projected revenues to create an income statement. However, as the income
statement is concerned only with earnings, free cash is the real figure that needs to be examined.
The income statement is then combined with financial investments, working capital, and other
cash affecting items to get the free cash flows.
Once free cash flow projections have been decided, the company can then be valued by a
combination of the terminal value analysis and the discounted cash flow analysis. This company
value is then translated into a rate of return analysis for investors. This analysis is key in
convincing investors to fund the project, as they need to know their potential gain by becoming
financially involved.
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The scheme of investors for this project is slightly more complicated than a simple startup venture capital model. For this project, two distinct series of investors (series A and series B)
will be involved, the series A investors investing from day one and the series B investors getting
involved later on in the company life. To simplify the calculations involved in investor return, an
equity stake analysis is performed. The results of all the calculations are summarized in a
complete financial statement for the company, at the determined optimal annual throughput and
market price.
Once this preliminary analysis has been performed, a what-if analysis which tests some
of the assumptions made will be performed to explore how these assumptions affect Micro$eq’s
bottom line and to confirm the final throughput and market price that were chosen. Additionally,
while the base financial calculations model a small-scale company with ~25,000 genomes
produced annually, a company expansion is modeled to evaluate the feasibility of achieving a
monopoly on the Pharmaceuticals and Healthcare markets, as previously discussed in the Market
Analysis, section 1.1, of this report.

9.1 MARKET AND REVENUE PROJECTIONS
The genome sequencing market is a relatively new and volatile market. For this reason,
the standard market price of whole genome sequencing is somewhat unknown. Until five years
ago, whole genome sequencing was limited to basic science research, as its price was enormous
(>$10,000,000 per genome). In 2006, the X Prize Foundation, along with the J. Craig Vetner
Science Foundation launched the Archone X Prize for Genomics, which was to be awarded to
the first team that can build a device that has the capability of sequencing 100 human genomes in
10 days or less, with an error rate of 1 in 100,000 bases at the cost of $10,000 per genome
(Archon Genomics X Prize Overview). Since the launch of this challenge, a race to the
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commercialization of whole genome sequencing has shown the potential of the market shift for
this industry. As the price has decreased by orders of magnitude from the original cost of whole
genome sequencing, the proposed market is now high wealth individuals who wish to have as
much information about their personal biology as possible. At a price of $10,000 or more per
genome, having this diagnostic test is still not feasible as a routine medical requirement or as a
means of research for drug companies. Since 2006, several companies such as IBM, Pacific
Biosciences, Complete Genomics, Knome, and Illumina have claimed that they will soon be
able to achieve costs of $1000 or less per genome (Carlson). However, as of April 2011 the
Archone X prize is still unclaimed and the lowest found market price (for non-medically required
whole genome sequencing) is $10,000 per human genome from Complete Genomics, as of June
2010 (Complete Human Genome Sequencing Technology Overview, 2009).
For the purpose of this discussion, the market price of our genome was chosen to be $999
per genome. The determination of this price will be discussed later in the section. Additionally,
at 100% design capacity, Micro$eq sells 72 genomes per day, or 23,760 genomes per year (at
330 operating days per annum). Thus at full operating capacity, Micro$eq should gross ~$24
Million per year.
The growth and development of the company can be divided into four stages: the
research stage, the scale up stage, the sales stage, and the terminal stage. During the research
stage, scientists are developing a working prototype and there is no revenue. All needed capital
for the research stage is provided by the series A investor. Immediately after the working
prototype is fully developed, series B investors are brought into the picture. This second set of
investors provides the necessary capital to being the scale up stage of company development.
Scale up involves the addition of new equipment, new staff, physical company expansion, and
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the first intake of revenue. Ideally, the scale up stage will operate at an average of 50% of
nominal design capacity. After full scale up, the sales stage begins during which the company
operates ideally at 100% design capacity. During the sales stage, the company takes in its
maximum revenue and must turn a profit in order for the entire company to be financially
feasible. Finally, the terminal stage is the means by which the company will liquidate. This step
is very important for biotech companies such as Micro$eq, as the market is so dynamic and one
technology will become obsolete very quickly. A terminal value for the company will be
calculated based on the free cash flow projections. The idea of the terminal value will be
discussed in more detail in a later section.
Ideally, the research stage takes on year, the scale up stage takes another year, and by the
beginning of the third year, the company is fully developed and has entered the sales stage. For
this company, the total company life is modeled as five years. Thus, the sales stage will be
projected as lasting three years, at the conclusion of which, the terminal value will be determined
and the company will liquidate.
Using this timeline and the above discussed genomic throughput and market price, the
results of the revenue projections are summarized below in Table 9.8.

Revenue Projections
Year

2012

Stage

Research

Design Capacity
Revenue

2013
Scale-up

2014
Sales

2015
Sales

2016
Sales

0%

50%

100%

100%

$0.00

$11,879,881.20

$23,759,762.40

$23,759,762.40

2017
Terminal

100%

$23,759,762.40 Terminal Value

Table 9.8 Micro$eq’s Revenue Projections for a 5-year company lifetime (amounts in US$)

It should be noted that for the purpose of all financial analysis, inflation is ignored. The
inflation calculated over such a short lifetime is unnecessary and are only relevant in the event of
Micro$eq – Chomvong, King, Mahmoud
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hyperinflation. In 1986, the Financial Accounting Standards Board determined that inflations
account is unnecessary for financial statements, and thus will be ignored here in the discussion of
Micro$eq’s financial feasibility.
As seen in Table 9.8, for the proposed annual throughput and market price, Micro$eq’s
gross revenue at full operating capacity is ~$24 million. How this translates into Micro$eq’s
overall profitability will be discussed in the remained of this chapter.

9.2 COSTS, PPE AND DEPRECIATION
There costs associated with a start-up such as Micro$eq can be divided into equipment
purchase and annual cost. Each of these categories contains a research and a sales sector. The
research equipment consists of what’s required to develop a working prototype. The sales
equipment will be an expansion of the equipment required for the research phase and will be
purchased after a working prototype has been secured, to the amount required for Micro$eq to
operate at fully scaled-up conditions. Annual costs during the research stage will be primarily lab
space rent and personnel salary. Once a working prototype has been developed, annual costs
during full operation will also include inventory, research and development, and sales.

9.2.1 Preliminary Investment
Two series of investors will be brought into the picture. The series A investors will be
involved from day one – supplying money for research equipment purchase, and one year’s
value of research annual cost. Because preliminary funding occurs before a working prototype
has been confirmed, these investors are generally wealthy “angel” investors that are willing to
invest in a risky new technology. Consequentially, series A investors will receive the highest
return on investment as they are undertaking the greatest risk. The details of this financial
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arrangement will be discussed later on in the Equity Shares section of this chapter. Additionally,
at scale up time, the series A investors will have the first right of refusal. This allows them to
invest further (thus making them a series B investor as well) before any other investors are
petitioned. For the purpose of this discussion the series A and series B investors will be treated as
separate entities. However it is important to keep in mind that there will most likely be an
overlap between the two groups of investors. The funding required of series A investors is
determined in the Cost Estimates spreadsheet (which can be found at the end of this section –
Table 9.2) and is $600,000.
The second series of investors – series B investors – provide funding after a working
prototype has been developed, thus seriously reducing their risk of investing from that of the
series A group. Series B funding occurs, ideally, one year after series A investment. It is assumed
that a working prototype may be developed within this time frame. The Series B investors
provide funding for production scale-up. Their investment is used for the required additional
equipment purchase, and three months of space rent, personnel salary, and inventory purchases,
with the assumption that the company will achieve 50% of design capacity by the end of this
time period. After this period, it is assumed that all remaining costs can be funding by company
revenue. The required series B investment for this project is $7,000,000.
The manner in which these monetary investments will be converted to company
ownership will also be discussed in detail later on in the Equity Shares section of this chapter.

9.2.2 Personnel Costs
During the research stage, personnel will be minimized in order to have the lost possible
operating costs. Staff will include a single secretary and four senior scientists. Of these scientists,
one will serve as chief technical officer (CTO). Additionally, until a working prototype is
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confirmed, all scientists will earn two-thirds of their scale up salary. As compensation for this
sacrifice, the four scientists will own 10% of the original company (2.5% each). It is typical for
series A investor of this type – particularly when the company employs personnel with very little
or no entrepreneurial experience (i.e. senior scientists) - to own 85% of the start-up company.
However, because this is a biotechnology company, and the market is so volatile, this company
carries more inherent risk than most ventures. Hence, the series A investors in this case will own
an additional 5% of the company – 90% - to help compensate for the additional risk they are
undertaking. It assumed that one of the primary investors will also serve as the company’s CEO
from day one, and will be involved in financial planning for the second series of investors and
company scale up, even during the research stage. However, he will not receive a salary until the
scale up stage.
Once a prototype has been confirmed and the company scales up, the initial four senior
scientists will receive their full salaries. Additional personnel at this point will be added, such as
junior scientists, sales personnel, and an IT specialist.
As was discussed in each of the process stage chapters (Chapters 5,6, and 7 of this
report), the number of technicians required depends somewhat on process throughput. A Gant
chart of the total processing of a base unit output of 12 genome per day, as shown below in
Figure 9.75 is used to determine the number of technicians required.
Ti me (hr): 6:00 10:00 14:00 18:00 22:00 2:00
DNA Pre se q Pre p(12.5 h rs)

6:00 10:00 14:00 18:00 22:00 2:00 6:00 10:00
DNA Pre se q Pre p(12.5 h rs)

DNA Se que n cing (24)

14:00

18:00

DNA Pre se q Pre p(12.5 hrs)

DNA Se que ncing (24)
Ge nome Re asse m bly (19.1 hrs)

22:00

2:00

6:00 10:00 14:00 18:00 22:00

2:00

6:00

DNA Pre seq Pre p(12.5 hrs)
DNA Seque nci ng (24)
Genome Re asse mbl y (19.1 hrs)

Ge nome Re assem bl y (19.1 hrs)

Figure 9.75 Gant Chart of Micro$eq's overall process
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As seen in Figure 9.75, the very first process will begin with a 31.6 hr delay (it will take
the standard 24 hrs plus an additional 31.6 hours to produce the first batch of genomes).
However, once the process has begun, it can be seen that a whole unit output is produced every
24 hours, which the DNA sequencing step being the process bottleneck, in taking 24 hours.
The most important steps in this process are the initial genomic DNA preparation and
amplification, as well as the 6mer library generation and preparation. It was found that the DNA
preparation requires two lab technicians for every unit output of 24 genomes per day. Similarly,
the DNA sequencing process was found to require one lab technician for every unit output of 12
genomes per day. The DNA reassembly process was found to require only one IT personnel for
up to a unit output of 72 genomes per day. However, as the computational part of this process
requires a very different set of skills than the more molecular biology based-sequencing and
presequencing steps, and a backup IT is required as the other more molecular-biology oriented
technicians may not necessarily have the skills to fill in for the IT position.
As the throughput is 72 genomes per day, a total of 12 lab technicians and 2 IT personnel
are required. It is feasible that with so many lab technicians on hand, with two shifts of
technicians, one might be able to substitute for another in the event of an emergency or
complication.

Additionally, four senior scientists are on staff that my substitute for a lab

technician in an absolute emergency. This allows the required throughput to be attainable even in
the occurrence of some inefficiencies regarding personnel.

9.2.3 Inventory Costs
The inventory costs for this process included the required bioprocess kits and
accompanying reagents, additional reagents for processes such as the 6mer library, and genomic
DNA amplification process, and the microfluidic chips. A detailed breakdown of the inventory
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costs for each stage in the process was previously given in section 8.1 of Chapter 8 of this report.
These costs were estimated on a per genome basis and are multiplied by the total annual genome
throughput to adjust the inventory costs to an annual sum. Additionally, the total inventory costs
depend on the design capacity. During the research stage, it is assumed that inventory costs are
negligible, as the only production is prototype development. At the initial 50% scale up
operation, inventory costs total ~$360,000 At the second scale up, to 100% design capacity,
inventory costs are double this and total ~$720,000.

9.2.4 Operating Costs
Operating costs include further research and development costs. This component of the
company is necessary in order for the company to remain competitive. The biotechnology
market, as previously discussed, is extremely dynamic. It is assumed that the original working
prototype will become obsolete very quickly. In order for the company to have enough value to
sell at the end of the prescribed five-year period, its intellectual property and patent ownership
must remain competitive.
Operating costs also include sales cost and have been estimated as a percentage of
revenue.

9.2.5 Rental Costs
The location of the company is assumed to be Arizona, USA. This location was chosen as
it is not too rural to exclude the recruitment of well-qualified personnel and investors.
Additionally, shipping costs of both inventory and patient samples is minimized by being inside
the continental united sates. The annual rental price is estimated from the current market price of
laboratory and office space in this location, as of April 2011 (Arizona Real Estate). Rental costs
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are minimized during the research stage, but scale-up operation requires a large increase in
required space. The plant is assumed to be expanded after the first year to full capacity, and thus
rental costs will be at 100% even when design capacity is only at 50%. Required rental space
included laboratory space, sequencing space, and office space.
These cost estimates are summarized on the next two pages in Figure 9.76. As seen from
this summary, the total annual cost estimates for the Research stage are ~$566 thousand, thus the
initial investment required of Series A investors will be set at $600 thousand. The total scale-up
annual costs are ~$9 million. However, this entire sum is not required from the Series B
investors, as this phase will also generate income. Instead, the required Series B investment is set
as slightly greater than the Series B equipment purchase (~$6.7 million) at $7 million.
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1

Total Cost
$6.00

Total

$340,000.00

$20,000.00

$60,000.00

$25,000.00

as he is also paid 10% of the total equity stake

*T his salary is less than typical market price

IT person (PT )

$40,000.00

$50,000.00

$120,000.00
Junior Scientist

$120,000.00

$200,000.00

Salary

$6,415.00

$4,000.00

$500.00

$1,000.00

$679.68

$179.99

$889.00

Senior Scientist

CT O

Secretary

1

$240,000.00

CEO*

Personnel

Droplet Syringe

T hermalCycler (Biometra)

s2 Shearer (Covaris)

Lab Centrifuge (UNICO)
Magtration 12GC (Pss
Bio)

Vortex mixer (VELP)

Core IF-2400 Processor(Intel)

Quad-Core Opteron Processor 8356$1,650.00
(AMD)

as they are also paid 10% of the research stage equity stake.

$40,000.00

Secretary (PT )

3

$80,000.00

$54,093.67

$19,245.00

$4,000.00

$500.00

$1,000.00

$679.68

$179.99

$6.00
$472.00

Unict Cost

FFT -CCD Camera (Hamamatsu) $25,000.00

Optical Lenses (Nikkon)

Salesperson

$80,000.00

Senior Scientist*

1

3

1

1

1

1

$889.00

$1,650.00

$25,000.00

$944.00

*T he research phase salaries are 70% of the final salary,

$80,000.00

Salary

CT O*

Personnel

Labor Costs

$4,000.00
$6,415.00

Droplet Syringe (Dolomite)

$500.00

T hermalCycler (Biometra)

s2 Shearer (Covaris)

Quantity

$679.68

Lab Centrifuge (UNICO)

Total

$179.99

Vortex mixer (VELP)

$1,000.00

1

$889.00

Core IF-2400 Processor(Intel)

Magtration 12GC (Pss Bio)

1
1

1

2

$25,000.00

$472.00

Quad-Core Opteron Processor 8356 (AMD) $1,650.00

FFT -CCD Camera (Hamamatsu)

Optical Lenses (Nikkon)

$6.00

Acrylic Prism (T edco)

Total

3

1

1

2

1

1

12

Quantity

Total

261.36

24

6

6

3

6

57.2976

189.36

378.72

189.36

Quanity

$1,136.16

$1,540,000.00

$50,000.00

$40,000.00

$50,000.00

$720,000.00

$360,000.00

$120,000.00

$200,000.00

$6,793,176.42

$1,676,624.40

$96,000.00

$3,000.00

$6,000.00

$2,039.04

$1,079.94

$94,541.04

$4,734,000.00

$178,755.84

T otal Cost

Item

Quanity

Item

Unit Cost

Remaining Equipment Required for Full Scale-up

Equipment Cost for Protoype Development

Acrylic Prism (T edco)

Sales Phase (Series B)

Research Phase (seires A)

Figure 9.76 Summary of Cost Estimates for Micro$eq's Operations (Amounts in US$)
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Total Annual Costs

none

Item

Sales
$0.00

$1,000.00

Maintenance

Operating Costs

$5,000.00

Cost/month

Utilites

Item

$30.00

$100.00

Sequencing Space

Office Space

$100.00

Cost/ft 2

Lab space

Item

Rental Costs

$0.00

Unit cost

*No inventory is used during research stage

none*

Item

Inventory Costs

Total

Total

0

1000

200

500

0

12

12

Month/yr

Total

Quantity

$0.00

$0.00

$0.00

$0.00

$566,093.67

T otal Cost

$172,000.00

$12,000.00

$60,000.00

T otal Cost

$30,000.00

$20,000.00

$50,000.00

T otal Cost

T otal Cost

$23,759,762.40

Sales

Total Annual Costs

$23,759,762.40

Sales

$2,000.00

$10,000.00

Cost/month

$30.00

$100.00

Research

Item

Maintenance

Utilites

Item

Office Space

Sequencing Space

Lab space

Item

$100.00

$2.34

Presequencing
Sequencing

$0.81

MicroChips

$8.49
$19.22

Cost/ft 2

Unit cost

Sequencing

Presequencing

Reagents

Item

2000

1000

750

$60,000.00

$100,000.00

$75,000.00

T otal Cost

$717,195.60

$55,598.40

$379,000.00

$24,000.00

$120,000.00

Total

3.00%

6.00%

$9,450,755.81

$21,383.79

$7,127.93

$14,255.86

% of Sales T otal Cost

Total

12

12

$3,207.60

$456,667.20

$201,722.40

T otal Cost

Month/yr T otal Cost

ft 2

Total

23760

3960

23760

23760

Quantity

9.2.6 Depreciation
Depreciation of equipment will be estimated using a 5-year MACRs depreciation
schedule. An alternative model to the MACRS is the Accelerated Tax Schedule, but this does not
provide the company with tax savings. While depreciation is a non-cash expense, it still affects
pre-tax income, from which taxes are deducted. If the pre-tax income decrease, the money lost to
taxes will also decreases.

Tax, unlike depreciation, is a cash expense. An accelerated

depreciation schedule for short lived projects such as this one will have a significant import on
the NPV and MIRR analysis. The depreciation percentages for a 5-year MARCS schedule are, in
chronological order, 20%, 32%, 19.2%, 11.52%, 5.76%. The effects of this estimated
depreciation are displayed in Table 9.9 Depreciation Schedule using the 5 year MACRs schedule
(amounts in US$).
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Depreciation Schedule
MACR Tax Schdule:

Year

Series A equipment

20.00%

32.00%

19.20%

11.52%

11.52%

2012

2013

2014

2015

2016

($108.19)

($173.45)

($104.40)

($62.76)

($21,738.16)

($13,084.64)

($7,865.86)

($108.19)

($21,911.61)

($13,189.04)

($7,928.62)

$6,847,161.90

$6,825,250.29

$6,812,061.26

$6,804,132.64

$54,093.67

Depreciation

Series B Equipment

$6,793,176.42

Depreciation

Begininning Net PPE
PPE Purchase/(Sold)

$54,093.67

Less: Total Depreciation

Ending Net PPE

$54,093.67

$6,793,176.42

Table 9.9 Depreciation Schedule using the 5 year MACRs schedule (amounts in US$)

Equipment denoted as series A is that purchased in the research phase. Equipment
denoted as series B is that purchased for the operation scale-up. The ending net PPE figures are
balance sheet items and represent how much property and equipment the company owns postdepreciation. The total depreciation is what appears on the income statement and will decrease
pre-tax income. Note: these calculations assume that the research stage takes exactly one year.
As science is very volatile, it is possible that it will be a full two years before a working
prototype as been confirmed. If this is the case, the depreciation schedule percentages would
remain unchanged, simply the series B equipment would be shifted to year three instead of year
2. This would additionally affect total depreciation and Ending Net PPE. This scenario will be
further discussed in a later section.
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9.3 INCOME STATEMENT
Total costs are divided into costs of sales and operating and selling, general, and
administrative services (SG&A) expenses. The cost of sales (alternatively referred to as the costs
of goods sold, COGS) is the sum of fixed costs and variable costs and includes costs that are
directly involved in the making of the goods. Fixed costs include rent and overhead, because
these are assumed to be constant during each of the two stages (research and full operation).
Variable costs include inventory costs, which is virtually a direct function of the sample
throughput. The gross profit is calculated by subtracting the cost of sales from the revenue. The
gross margin is a percentage showing how much money is left from the revenue after the cost of
sales is subtracted. Operating and SG&A expenses are costs associated with business
management. These include salary, as well as research and development, and sales cost.
Subtracting these new expenses and the depreciation, as previously discussed, yields the pre-tax
income. The summary of these results are displayed in Table 9.10.
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Income Statement
Year

2012

2013

2014

2015

2016

Revenue

$0.00

$11,879,881.20

$23,759,762.40

$23,759,762.40

$23,759,762.40

Cost of Sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

($172,000.00)

$11,499,277.40

$23,377,554.80

$23,377,554.80

$23,377,554.80

$340,000.00

$1,550,691.89

$1,561,383.79

$1,561,383.79

$1,561,383.79

($512,000.00)

$9,948,585.51

$21,816,171.01

$21,816,171.01

$21,816,171.01

40% tax rate

($204,800.00)

$3,979,434.20

$8,726,468.41

$8,726,468.41

$8,726,468.41

Net Income

($307,200.00)

$5,969,151.30

$13,089,702.61

$13,089,702.61

$13,089,702.61

0

50

100

100

100

Gross Margin %

0.00%

96.80%

98.39%

98.39%

98.39%

Profit Margin %

0.00%

50.25%

55.09%

55.09%

55.09%

Gross Profit
Operating, SG&A expenses

Pre-tax Income

Design Capacity %

Margins

Table 9.10 Income statement showing gross and profit margins (amounts in US$)

The tax rate is calculated via the addition of both Federal and State tax. Federal tax is
assumed to be ~35%, with State tax assume to be 5%. As seen from the income seen in the
income sheet in Table 9.10 Income statement showing gross and profit margins (amounts in US$), the
company loses money in the first year. Tax shields (alternatively called negative taxes) apply to
many start-up companies, and it will be assumed that this is the case for Micro$eq. When a tax
shield is in place, a company that loses money in its first year actually receives funds from the
government. This is reflected by the positive tax figure for year one.
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9.4 WORKING CAPITAL
While the income statement allows calculation of net income, net income is the the
equivalent of cash flows. In order to obtain true cash estimates, and thus subsequent NPV and
IRR analyses, the net income must be adjusted for cash items, such as change in working capital.
Working capital is the amount of capital required for normal company operation. A
portion of net income must be allocated daily operations before a profit is calculated. Working
capital can be thought of as the difference between current assets and current liabilities. Current
assets may be easily and almost immediately converted to cash, whereas current liabilities are
bills and debts the company has to pay almost immediately. Working capital is therefore the cash
leftover after the company has paid its imminent bills.
Working capital can be broken into four main items: accounts receivables, accounts
payable, inventory, and cash reserve. Accounts receivables are earnings that have been recorded
but have yet to receive cash payment. The time gap between recording and receiving of these
earnings is generally between 30-60 days. For the purpose of this discussion, it will be assumed
that the client pays within 30 days. Because all accounts receivables convert into revenue
eventually, accounts receivable (AR) can be expressed as:
=

($)

×

×

Accounts payable is the inverse of accounts receivable. Accounts payable are bills the
company has recorded as paid, and subtracted from the revenue, but has not actually paid in cash
yet. It will be assumed that bills are paid on a monthly basis (assume to be a 30 day period). It is
traditional that accounts payable(AP) is expressed as :
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($)

=

×

×

Where cost of sales contains rent, operating costs, and inventory costs. For the purpose of
this project, we have separated out inventory sales, and cost of sales consists almost exclusively
of rent and operating costs. Thus AP may be more specifically expressed as:

=

(

+

)($)

×

×

Similarly, to accounts payable and receivable inventory – what the company requires in
order to produce its goods – will be bought on a monthly basis (assume to be a 30 day period), so
that inventory (Inv) may be defined as:

($)

=

×

×

Cash reserve is defined as the cash available on hand to pay future salaries. For the
purpose of this discussion, it will be assumed that 3 months worth of salaries will be reserved, so
that cash reserve(CR) may be defined as:

=

($)

×

×

The results of these calculations are displayed in Table 9.11.
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Working Capital
Year

2012

2013

2014

2015

2016

$0.00

$976,428.59

$1,952,857.18

$1,952,857.18

$1,952,857.18

$14,136.99

$32,029.47

$32,908.26

$32,908.26

$32,908.26

$0.00

$131.82

$263.64

$263.64

$263.64

$85,000.00

$385,000.00

$385,000.00

$385,000.00

$385,000.00

Changes in AR

$0.00

($976,428.59)

($976,428.59)

$0.00

$0.00

Changes inAP

$14,136.99

$17,892.48

$878.79

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

Changes in CR

($85,000.00)

($300,000.00)

$0.00

$0.00

$0.00

Total Change in Working Capital

($70,863.01)

($1,258,404.29)

($975,417.99)

$0.00

$0.00

Working Capital Item Estimates
Acounts Receivable ((AR)
Accounts Payable (AP)
Inventory (Inv)
Cash Reserve (CR)

Changes in Working capital

Table 9.11 Working Capital and Changes in Working Capital (amounts in US$)

As seen in Table 9.11, it is important to consider to effects of changes in each of the four
sectors of working capital. Any increase in assets decreases total cash. Conversely, a decrease in
assets increases total cash. Increased liability increases cash temporarily, as the company has that
liability on hand to spend before it must be repaid. A decrease in liability implies that the
company has spent money to repay that liability and thus implies a decrease in cash.
Increase in accounts receivable since the previous fiscal year decrease cash because net
income has taken this amount into account, but the company has yet to actually receive the
money. The following fiscal year, however, the account will have been paid, which is reflected
by a decrease in account receivable (assuming no additional chances in accounts receivable).
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Increase in accounts payable increase cash because net income is revenue less accounts
payable, and the company has yet to actual let go of the cash.
Increases in inventory decrease cash, as cash spending is required for the purchase of
additional inventory.
Increases in cash reserve decrease cash, as cash has to be set aside to pay for future
salaries, and thus cannot be used to pay company owners.
It is also important to note that two other cash items have yet to be discussed: PPE and common
stock. Purchasing PPE (plan, property, and equipment) decrease cash almost immediately.
However, a PPE purchased does not show up on the income statement and instead is slowly
amortized. This is because the income statement reflects the company’s operational efficiency,
which doesn’t necessarily include one-time cash expenses. Selling of equipment is the same
principle, simply inverted. Selling of equipment generated immediate cash, but is not included as
part of the revenue as revenue only reflects the company’s normal operations and selling
unused/unwanted equipment is a one-time event.
Similarly, the issuance of common stock is not included in part of the revenue. The
selling of stock to investors – either series A or B – does generate immediate cash, but is a onetime event. Repurchasing of existing shares from investors similarly decrease cash, but will not
be reflected on the income statement. Instead, all the cash items will be found in the cash flow
statement.

9.5 FREE CASH FLOW AND TERMINAL VALUE
As mentioned in the previous section, net income does not directly imply net cash. Net
income must be adjusted by cash from operation activity (which includes depreciation, changes
in working capital, accounts receivable, accounts payable, inventory, and cash reserve), cash
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from investing activities such as purchasing/selling equipment, and cash from financing
activities. The summation of these four sectors yields free cash flow, the complete projections of
which are displayed in

Free Cash Flow
Year

Net Income

2012

2013

2014

2015

2016

(307,200.00)

5,969,151.30

13,089,702.61

13,089,702.61

13,089,702.61

0.00

(108.19)

(21,911.61)

(13,189.04)

(7,928.62)

0.00

0.00

Cash Flow Operating Activites
Plus:Depreciation
Changes in Working Capital
Changes in AR

0.00

(976,428.59)

(976,428.59)

0.00

0.00

Changes in AP

14,136.99

17,892.48

878.79

0.00

0.00

Changes in Inv

0.00

131.82

131.82

0.00

0.00

Changes in CR

(85,000.00)

(300,000.00)

0.00

0.00

0.00

Total Change in Working Capital

(70,863.01)

(1,258,404.29)

(975,417.99)

0.00

0.00

(54,093.67)

(6,793,176.42)

600,000.00

7,000,000.00

96,980.30

3,659,058.12

11,116,955.02

13,076,513.57

13,081,773.99

2012

2013

2014

2015

2016

Cash From Investing Activities
Purchasing/Selling of Equipment

Cash from Financing Activites
Issuance of Common Stock

Total Free Cash Flow

Table 9.12:

Free Cash Flow
Year
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Net Income

(307,200.00)

5,969,151.30

13,089,702.61

13,089,702.61

13,089,702.61

0.00

(108.19)

(21,911.61)

(13,189.04)

(7,928.62)

0.00

0.00

Cash Flow Operating Activites
Plus:Depreciation
Changes in Working Capital
Changes in AR

0.00

(976,428.59)

(976,428.59)

0.00

0.00

Changes in AP

14,136.99

17,892.48

878.79

0.00

0.00

Changes in Inv

0.00

131.82

131.82

0.00

0.00

Changes in CR

(85,000.00)

(300,000.00)

0.00

0.00

0.00

Total Change in Working Capital

(70,863.01)

(1,258,404.29)

(975,417.99)

0.00

0.00

(54,093.67)

(6,793,176.42)

600,000.00

7,000,000.00

96,980.30

3,659,058.12

11,116,955.02

13,076,513.57

13,081,773.99

Cash From Investing Activities
Purchasing/Selling of Equipment

Cash from Financing Activites
Issuance of Common Stock

Total Free Cash Flow

Table 9.12 Free Cash Flow from Net Income (amounts in US$)
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These free cash flow will be used to calculate net present value (NPV) and internal rate
of return (IRR), which represent real cash received by the company shareholders. However,
before these analyses, the terminal value of the company needs to be determined. This value is
the present value off the continuing future cash flows, which assumes that all future cash flows
are entirely predictable. Terminal values may be estimated using the perpetuity growth model as
seen below:

Terminal Value
=

×

(

(

)

)

Where the cash flow is the last free cash flow, g
is the growth rate of cash flow and the company, and r is
the discount rate. Using this value, the terminal value is
predicted for for growth rates varying between 25 and 25%, as seen in Table 9.13.
Note: when the growth rate is zero, the terminal value
simplifies to being = cash flow/r, which is defined as the
basic perpetuity model.
For this majority of this discussion the growth
will be assumed to be zero, with alternative possibilities

Last Free Cash Flow

$13,081,773.99

Discount Rate

25.00%

Growth Rate

Terminal Value
-20.00%

$23,256,487.10

-15.00%

$27,798,769.73

-10.00%

$33,638,847.41

-5.00%

$41,425,617.64

0.00%

$52,327,095.97

5.00%

$68,679,313.46

10.00%

$95,933,009.28

15.00%

$150,440,400.91

20.00%

$313,962,575.82

Table 9.13 Terminal Values for Varying Growth Rates
(amounts in US$)

discussed as possible cases toward the end of this
chapter.
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9.6 NPV VALUATION
The net present value (NPV) is a mathematical model that describes the financial gain
possible for an investor. At the point where the NPV is zero, the company has broken even.
Above a NPV of zero, the company is operating above their bottom line. The NPV is the sum of
all present values of every cash flow, and is highly dependent on the discount rate. In this case,
every cash flow includes only free cash flow and terminal value. The discount rate is dependent
on the risk-level involved in the model industry. A high-risk industry such as the Biotech
industry used for this model company will have a relatively high discount rate. For the purpose
of this discussion, the discount rate will be approximated as 25%. However, the discount rate
during the research stage is significantly higher, as the company’s risk is much greater when a
working prototype has yet to be confirmed. It will be assumed that during the research phase, the
discount rate is 50%.
In order to calculate the NPV’s, all projected free cash flows and terminal values are
discounted back into present values. The present values are then summed, and the present values
of the cost of the project (initial investments) must be subtracted. This calculation is complicated
by the fact that two different investment times from two different investors. The initial
investment – series A – has a present value equal to the actual investment amount ($600,000)
and will not be discounted. This is because the initial investment is not a future cash flow, but
rather occurs at time equals zero. However, the second investment – series B – is a future cash
flow which occurs after a working prototype has been confirmed. Thus, the series B investment
must be discounted at the 25% discount rate as previously discussed.
It is also important to note that the terminal value of the company is terminal value of the
company, because it is a future projected values, is discounted to the present. For the purpose of
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this discussion it is assumed that the growth rate is 0%. The possibility that growth is in fact
greater than 0% will be discussed in a later section. The net present value, therefore, is the sum
of all present values, which includes all positive future cash flows with present negative
investments subtracted. The summary of these analyses is displayed in Table 9.14.

NPV Calculations @ 25% Discount Rate
Year

2012

2013

2014

2015

2016

0

1

2

3

4

5

6

Free Cash Flow

$0.00

$96,980.30

$3,659,058.12

$11,116,955.02

$13,076,513.57

$13,081,773.99

$41,031,281.01

Discount Rate

0.00%

50.00%

25.00%

25.00%

25.00%

25.00%

25.00%

Present Value

$0.00

$64,653.54

$2,341,797.20

$5,691,880.97

$5,356,139.96

$4,286,635.70

$10,756,104.13

(600,000)

(7,000,000)

Discount Rate

0.00%

25.00%

Present Value

(600,000.00)

(5,600,000.00)

Year of Operation

Investments

2017 Terminal Value

Sum of All Present Vales (NPV)

$4,556,104

Table 9.14 Net Present Value Calcuations using a 25% Discount Rate (all amount in US$)

As seen in Table 9.14, the NPV under the above assumed conditions, is estimated to be
~$4.5 million, which indicates that Micro$eq is operating well above its bottom line and predicts
that all combined investors will earn approximately an additional $4.5 million for their initial
investment .

9.7 EQUITY SHARES
Of course, this total cash gain by the investors is not divided equally between all
investors. As previously discussed, the series A investors own 90% of the original company,
during the research phase. However, once the series B investors become involved, the percentage
Micro$eq – Chomvong, King, Mahmoud

217 | P a g e

of the total company that series A investors own will significantly decrease. The amounts that
each investors’ series contributed are considered and their relative company percent ownership is
calculated. It is important to note that in order to directly compare the two monetary investments,
the series A investment must be discounted for the first year by 50% (as previously discussed,
this was the discount rate during the research phase). The results of these calculations are shown
in Table 9.15.

Percentage of Investments
Investment

FV Investment

Share Fraction

Series A Investors

$600,000.00

$750,000.00

9.68%

Serirs B Investors

$7,000,000.00

$7,000,000.00

90.32%

Total

$7,600,000.00

$7,750,000.00

100.00%

Table 9.15 Percentage of Investments for the two Series (amounts in US$)

It should be noted that, as previously discussed, the series A investors took on a higher
level of risk by investing before a working prototype was confirmed. As incentive to undertake
this increased risk level, the series A investors were promised a larger company ownership
percentage than later investors. While it is illegal to arbitrarily give the series A investors an
additional monetary (chare) compensation for their increased risk, it can be seen from Table 9.15
that the series A investors “purchased” their shares at a lower “price” that the series B, due to the
time difference between the two investments. Additionally, it was discussed that the original
four senior scientists would collectively own 10% of the original company, which translates into
10% of the 9.68% of the fully scaled-up company owned by the original investors.
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Using the previously-calculated NPV values, these adjusted shares and each owner’s
share values for each year of the projected company existence can be calculated. The results of
these calculations are shown in Table 9.16.
Equity Percentage
Year

2012

2013

2014

2015

2016

2017

Scientists

10.00%

0.97%

0.97%

0.97%

0.97%

0.97%

Series A Investors

90.00%

8.71%

8.71%

8.71%

8.71%

8.71%

Series B Investors

0.00%

90.32%

90.32%

90.32%

90.32%

90.32%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

($27,799,310.17)

($27,134,656.63)

($15,842,775.66)

($10,486,635.70)

($6,200,000.00)

$4,556,104.13

Total

NPV @ 25%

Shares Values v. Time
Scientists

$0.00

$0.00

($153,317.18)

($101,483.57)

($60,000.00)

$44,091.33

Series A Investors

$0.00

$0.00

($1,379,854.65)

($913,352.14)

($540,000.00)

$396,821.97

Series B Investors

$0.00

$0.00

($14,309,603.82)

($9,471,799.99)

($5,600,000.00)

$4,115,190.83

Total

$0.00

$0.00

($15,842,775.66)

($10,486,635.70)

($6,200,000.00)

$4,556,104.13

Table 9.16 Equity Percentage and Share Values of Owners (amounts in US$)

It is important to note that the total share value at the completion of the 5-year company
projection is the same total NPV calculated in the previous section. This agreement confirms the
idea that the NPV is the total amount of investment return to be received collectively by all
investors.

9.8 RATE OF RETURN ANALYSIS
Rate of return analysis is traditionally done using the internal rate of return model (IRR).
However, the IRR model assumes that free cash flows are reinvested at the rate they are
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calculated at. This assumption does not hold for this company model, as there are only two
rounds of investments and none of the free cash flows are ever reinvested, much less continually
reinvested. Thus, for the purpose of this discussion, the IRR model will not be used.
Instead, the modified internal rate of return (MIRR) model will be used. This model requires
specification of the finance and reinvestment rates. The finance rate is the annual percentage rate
(APR) the company must pay to debt lenders if any negative cash flows exist. The APR will be
chosen to be 3.95, as is estimated as the Term Loan Rate by the US treasury as of April 2011
(Bankrate). The reinvestment rate is the rate at which the owners receive payment on positive
cash flows. For the purpose of this discussion, a 4.84% reinvestment rate will be assumed. This
number is derived from the current (as of April 2011) yield on a 1 year US Treasury bills
(Bankrate), which can be used to define a risk free rate in the current economy. It is possible that
a higher reinvestment rate could be chosen, as the investors are assumed to be experienced
enough in the financial world to be able to earn more than the risk free rate. However, in order to
maintain a conservative profitability analysis, the risk free rate will be used in these calculations.
This adjusted model involved two relatively simple steps. First, the investment is defined.
Then, all free cash flows the investor would receive are divided into the equity percentages as
defined in the previous section. The results of these calculations are shown in Table 9.17.
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MIRR Analysis
Year

Free Cash Flows

2012

2013

2014

2015

2016

2017

$96,980.30

$3,659,058.12

$11,116,955.02

$13,076,513.57

$13,081,773.99

$41,031,281.01

Equity Percentages
Series A

90.00%

8.71%

8.71%

8.71%

8.71%

8.71%

Series B

0.00%

90.32%

90.32%

90.32%

90.32%

90.32%

Cash Flows

Investment

Series A

600,000

Series B

7,000,000
Divided Free Cash Flows
$87,282.27

$318,692.16

$968,250.92

$1,138,922.15

$1,139,380.32

$3,652,527.82

$0.00

$3,304,955.72

$10,041,120.67

$11,811,044.52

$11,815,795.86

$36,972,916.77

Future Value of Positive Cash Flows @4.84 Reinvestment Rate
Series A

$410,198.89

Series B

Series A MIRR %

89.11%

Series B MIRR %

77.34%

$1,398,303.44

$2,604,903.48

$3,870,361.12

$4,057,686.60

$3,304,955.72

$13,506,036.25

$25,970,772.92

$39,043,554.19

Table 9.17 MIRR Calculations at APR rate of 3.95% and Reinvest rate of 4.84% (amounts in US$)

From Table 9.17, it can be seen the series A investors can expect ~89% returns and the
series B investors can expect ~77% returns, both of these values being very competitive in the
current Biotech start-up industry (BCC Research). It is important to note that without the
adjusted finance and reinvestment rates, the original IRR model would yield about 130% returns,
which can be seen to be a gross overestimation of the actually found numbers using the MIRR
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model. It is also important to note the series B investors are not included in the first year’s
earnings, as they were not involved in the company at this stage. Additionally, as previously
discussed, the series A investors receive a higher return on investment than the series B
investors, as they undertook the higher risk upon their initial investment and thus were promised
higher return as an incentive to undertake that risk.

9.9 PRELIMINARY FINANCIAL SUMMARY
To this point, a preliminary financial analysis has been performed. This includes the
creation of a pro forma income statement, which was subsequently adjusted to get free cash
flows. From the calculated cash flows, the NPV and MIRR analyses were performed, using a
modeled equity share scheme. The results of this preliminary financial analysis are summarized
in Table 9.18. It can be seen that the projected NPV is ~$6.5 million with MIRR for series A and
series B investors at 89.1% and 77.3% respectively, indication that both the company is
operating well above the bottom line and that both series of investors will receive a significant
returns on investment.
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Growth Case Financial Summary - 72 genomes/day @$999/genome & 25% annual growth
Year

2012

Stage

Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

100.00%

2017
T erminal

100.00%

100.00%

Income Statement
$0.00

$11,879,881.20

$23,759,762.40

$23,759,762.40

Cost of sales

Revenue

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operat eing, SG&A expenses

$340,000.00

$1,550,691.89

$1,561,383.79

$1,561,383.79

$1,561,383.79

Depreciation
Pre-t ax income

$0.00
($512,000.00)

($108.19)
$9,948,585.51

($21,911.61)
$21,816,171.01

($13,189.04)
$21,816,171.01

$23,759,762.40

($7,928.62)
$21,816,171.01

T ax @ 40%

($204,800.00)

$3,979,434.20

$8,726,468.41

$8,726,468.41

$8,726,468.41

Net income

($307,200.00)

$5,969,151.30

$13,089,702.61

$13,089,702.61

$13,089,702.61

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation
Changes in Working Capital
Changes in AR
Changes in AP
Changes in Inv

$0.00

($108.19)

($21,911.61)

$0.00

($976,428.59)

($976,428.59)

$14,136.99

($13,189.04)

($7,928.62)

$0.00

$0.00

$17,892.48

$878.79

$0.00

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$11,116,955.02

$13,076,513.57

$13,081,773.99

$41,031,281.01

$0.00

Changes in CR

($85,000.00)

($300,000.00)

T otal Change in Working capital

($70,863.01)

($1,258,404.29)

($54,093.67)

($6,793,176.42)

$600,000.00

$7,000,000.00

$96,980.30

$3,659,058.12

($975,417.99)

Cash from Investing Activities
Purchase/Sale of Equipment
Cash from Financing Activities
Issuance of Common St ock
Free Cash Flow
NPV@25% Di scount Rate

Equity Shares

$4,556,104.13

Investment

Series A Equity

600,000

Series B Equit y

7,000,000
Divided Free Cash Flows
$87,282.27

$318,692.16

$968,250.92

$1,138,922.15

$1,139,380.32

$3,652,527.82

$0.00

$3,304,955.72

$10,041,120.67

$11,811,044.52

$11,815,795.86

$36,972,916.77

Se ri es A MIRR

89.11%

Se ri es B MIRR

77.34%

Table 9.18 Preliminary Financial Summary for 72 genomes per day output @ $999/genome (amounts in US$)
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9.10 PRICE AND THROUGHPUT DETERMINATION
Thus far, the preliminary financial analysis has been with the determined optimal market
price and annual throughput. However, before these numbers were determined, alternative
scenarios were explored.

9.10.1 Original Project Specifications
As previously discussed, the original project statement was to achieve a throughput of 12
genomes per day (3460 per year @ 330 operation days per year) at a market price of $100 per
genome. By adjusting the required inventory, personnel, and equipment to this throughput, the
financial analysis was first run at this market price. The summary of the results of this analysis
are displayed in Table Table 9.19 on the next page. As seen in this table, the found NPV is ~ $3.2 Million, with MIRR’s for the series A and series B investors being -148% and -163%,
respectively. It is evident that this throughput and market price, for the process as designed,
Micro$eq would be financially infeasible.
Next, with the project specified throughput of 12 genomes per day, the minimum price
for Micro$eq to break even (NPV value =~0) was found. The summary of the results from this
calculation are found in Table 9.20, adjacent to Table 9.19. As seen in this table, the NPV is
found to be $0 indicating the company is exactly the breakeven level of operation, for market
price of $1,710 per genome. For this MIRR’s for the series A and series B investors being 58.6%
and 47.8%, respectively. While these are low, but plausible values, investors, particularly in such
a high-risk industry, generally expect projected margins to be at minimum, 50%. This breakeven
market price is almost a full order of magnitude lower than the lowest current market price
($10,500, Complete genome) but still more than an order of magnitude greater than the project’s
original target price of $100 per genome.
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Preliminary Financial Summary - 12 genomes/day @ $100/genome
Year
St age

2012
Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

100.00%

2017
Terminal

100.00%

100.00%

Income Statement
$0.00

$198,000.00

$396,000.00

$396,000.00

Cost of sales

Revenue

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,000,178.20

$1,000,356.40

$1,000,356.40

$1,000,356.40

Depreciation

$0.00

$396,000.00

($108.19)

($3,796.47)

($2,285.17)

($1,373.74)

Pre-t ax income

($512,000.00)

($1,182,782.00)

($986,564.00)

($986,564.00)

($986,564.00)

T ax @ 40%

($204,800.00)

($473,112.80)

($394,625.60)

($394,625.60)

($394,625.60)

Net income

($307,200.00)

($709,669.20)

($591,938.40)

($591,938.40)

($591,938.40)

$0.00

($108.19)

($3,796.47)

($2,285.17)

($1,373.74)

$0.00

($16,273.97)

($16,273.97)

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation
Changes in Working Capital
Changes in AR

$0.00

$0.00

Changes in AP

$14,136.99

$17,028.35

$14.65

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

Changes in CR

($85,000.00)

($165,000.00)

T otal Change in Working capital

($70,863.01)

($164,113.81)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($1,132,196.07)

Cash from Financing Activities
Issuance of Common Stock

$600,000.00

$3,000,000.00

$96,980.30

$829,798.93

($627,989.89)

($594,223.57)

($593,312.14)

Divided Free Cash Flows
$87,282.27
$149,363.81

($113,038.18)

($106,960.24)

($106,796.18)

($90,148.53)

($502,391.91)

($475,378.86)

($474,649.71)

($788,581.34)

Free Cash Flow
NPV@25% Discoun t Rate

Equity Shares

($16,127.51)

($888,746.37)

($3,232,979.53)

Investment

Series A Equity

600,000

Series B Equity

3,000,000

$0.00
S e rie s A MIRR

-148.58%

S e rie s B MIRR

-163.28%

$663,839.14

Table 9.19 Financial Summary for 12 genomes per day @ $100 per genome (all amounts in US$)
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Preliminary Financial Summary - 12 genomes/day @$1,710/genome
Year

2012

Stage

Research

% of Design Capacit y

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

100.00%

2017
Terminal

100.00%

100.00%

Income Statement
Revenue

$0.00

$3,386,634.76

$6,773,269.52

$6,773,269.52

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,003,047.97

$1,006,095.94

$1,006,095.94

$1,006,095.94

Depreciation

$0.00

($108.19)

($3,796.47)

($2,285.17)

$6,773,269.52

($1,373.74)

Pre-tax income

($512,000.00)

$2,002,982.99

$5,384,965.98

$5,384,965.98

$5,384,965.98

T ax @ 40%

($204,800.00)

$801,193.20

$2,153,986.39

$2,153,986.39

$2,153,986.39

Net income

($307,200.00)

$1,201,789.79

$3,230,979.59

$3,230,979.59

$3,230,979.59

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion

$0.00

($108.19)

($3,796.47)

($2,285.17)

($1,373.74)

Changes in AR

$0.00

($278,353.54)

($278,353.54)

$0.00

$0.00

Changes in AP

$14,136.99

$17,264.22

$250.52

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$3,228,694.41

$3,229,605.85

$11,444,091.80

Changes in Working Capital

Changes in CR

($85,000.00)

($165,000.00)

T ot al Change in Working capital

($70,863.01)

($425,957.51)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($1,132,196.07)

$600,000.00

$3,000,000.00

$96,980.30

$2,217,570.52

($277,971.20)

Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discount Rate

Equity Shares

$2,671,240.70

$0.00

Investment

Series A Equity

600,000

Series B Equity

3,000,000
Divided Free Cash Flows
$87,282.27
$399,162.69
$0.00

Serie s A MIRR

58.63%

Serie s B MIRR

47.79%

$1,774,056.42

$480,823.33

$581,164.99

$581,329.05

$2,129,762.34

$2,136,992.56

$2,582,955.53

$2,583,684.68

$9,077,689.20

Table 9.20 Preliminary Financial Summary for 12 genomes per day @ $1,710 per genome (all amounts in US$)
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9.10.2 Modified Throughput and Price Sensitivity
In order to achieve a market price lower than one order of magnitude greater than the
original project goal, increasing the throughput of the process was explored. It was determined
that a throughput of 72 genomes per day (23,760 genomes per year at 330 operating days per
year) was the optimal throughput with respect to economies of scale for personnel, lab space, and
equipment requirements (financial summaries for alternative throughput scenarios with
corresponding breakeven operations can be found in Appendix D). At this throughput, the
breakeven market price was found to be $466 per genome – almost a quarter of the required
price at a throughput of 12 genomes per day. The results of this calculation are displayed in
Table Table 9.21 on the next page.
The set market price was then increased above this breakeven price to generate larger
company profit and larger MIRR’s for the investors. As previously discussed the final price was
set at $999 per genome. This price was chosen partially for its marketing benefit of still being
under the $1000 per genome benchmark. This benchmark is a significant milestone in the
genome market as it is a ten-fold decrease from the current minimum market price. As
previously stated, for this final determined throughput, the projected NPV is ~$4.5 million with
MIRR for series A and series B investors at 89.1% and 77.3% respectively, which is a significant
increase in return for investors from the $466 per genome breakeven market price. For the
purpose of comparison, the full financial analysis of Micro$eq’s final market price and output
can be found in figure Table 9.18 in section 9.9 of this chapter.
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Preliminary Financial Summary - 72 genomes/day @$466/genome
Year

2012

Stage

Research

% of Design Capacit y

2013
Scale Up

0.00%

2014
Sales

5000.00%

2015
Sales

10000.00%

2016
Sales

10000.00%

2017
T erminal

10000.00%

10000.00%

Income Statement
Revenue

$0.00

$5,534,280.52

$11,068,561.04

$11,068,561.04

$11,068,561.04

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operat eing, SG&A expenses

$340,000.00

$1,904,980.85

$1,909,961.70

$1,909,961.70

$1,909,961.70

Depreciation

$0.00

($108.19)

($21,911.61)

($13,189.04)

($7,928.62)

Pre-tax income

($512,000.00)

$3,248,695.87

$8,776,391.73

$8,776,391.73

$8,776,391.73

T ax @ 40%

($204,800.00)

$1,299,478.35

$3,510,556.69

$3,510,556.69

$3,510,556.69

Net income

($307,200.00)

$1,949,217.52

$5,265,835.04

$5,265,835.04

$5,265,835.04

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion

$0.00

($108.19)

($21,911.61)

Changes in AR

$0.00

($454,872.37)

($454,872.37)

Changes in AP

$14,136.99

($13,189.04)

($7,928.62)

Changes in Working Capital

Changes in Inv

$0.00

$0.00

$17,423.08

$409.39

$0.00

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$5,252,646.00

$5,257,906.42

$11,444,091.80

$0.00

Changes in CR

($85,000.00)

($390,000.00)

T otal Change in Working capital

($70,863.01)

($827,317.47)

($54,093.67)

($6,793,176.42)

($454,331.17)

Cash from Investing Activities
Purchase/Sale of Equipment
Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discount Rate

Equity Shares
Series A Equity
Series B Equity

$600,000.00

$3,000,000.00

$96,980.30

($3,498,702.02)

$4,335,261.09

($0.00)

Investment
600,000
3,000,000
Divided Free Cash Flows
$87,282.27

($629,766.36)

$780,347.00

$945,476.28

$946,423.16

$2,129,762.34

$0.00

($2,798,961.62)

$3,468,208.88

$4,202,116.80

$4,206,325.14

$9,077,689.20

Se ri es A MIRR

56.06%

Se ri es B MIRR

45.28%

Table 9.21 Financial Summary for 72 genomes per day @ $466 per genome (all amounts in US$)
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In order to ensure that, at this increased throughput from the originally proposed project,
sales would still be at 100%, the customer demand at this annual output was analyzed. The
market price and market sales for whole genome sequencing from the past 5 years were
analyzed, along with a 2-year forward projection of the increased market demand as the market
price of whole genome sequencing continues to drop (GenomeWeb, 2010) (Kleiner, 2008) (Next
Big Future, 2008) (Complete Human Genome Sequencing Technology Overview, 2009). The
results of this analysis are displayed in Table 9.21.

Figure 9.14 Global Genome Sequencing Industry Demand from years 2007-2011, projected to 2013

From Table 9.21, it can be seen that the demand-set market price does not go as low as
Micro$eq’s proposed market price of ~$1000 per genome. The lowest projected market price is
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for year 2013, which will be the first year of sales for Micro$eq, is projected to be $5,000 per
genome at a market demand of ~85,000 genomes per year – nearly quadruple Micro$eq’s
proposed throughput of ~25,000 genomes per year. This implies that Micro$eq should easily be
able to operate at full capacity with full sales of ~25,000 genomes per year. Additionally,
Micro$eq should be able to gain an effective monopoly on the industry if it can offer a market
price one quarter below what the customer would be willing to pay.

9.11 WHAT-IF SCENARIOS
Thus far, all previous financial analyses hold under certain stated assumptions.
However, the cases where these assumptions are no longer true and need to be examined for their
effects on the financial analysis.
Several different cases where previously stated assumptions were no longer upheld were
examined and the financial analyses were redone, with the adjusted effects of the changes in
these assumptions. The different possible scenarios were broken up into assumptions involved in
the three main stages of company development. The different cases examined are summarized in
Table 9.22 and the results of financial analyses for each of these scenarios are summarized in
Table 9.23. The complete financial analysis summaries for each of the What-If Scenarios may be

found in Appendix D.
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What-if Scenarios

Research Stage
R1

The start up takes one year, as planned

R2

The start up stage takes two years

Scaleup stage
SU1

The forst years of sales ruls at 50% design capacity

SU2

The first year of sales runs at 30% design capacity

Sales Stage
S1

The company remains at 100% sales

S2

The company sales decline ~15% each year

S3

The company is forced to liquidate after the first year of sales

Table 9.22 What-if Scenarios, where Combination of R1, SU1, and S1 is the base case scenario discussed in the
preliminary financial analysis earlier in this chapter

Scenario Summary
Base Case (R1, SU1, S1) NPV

Series A MIRR Series B MIRR

$4,556,104.14

89.11%

77.34%

$1,559,155.11

115.93%

55.01%

$3,808,686.63

84.39%

72.79%

S2

$2,239,434.81

75.08%

63.79%

S3

($5,756,801.69)

-22.6%

-38.2%

Research Stage
R2

Scaleup stage
SU2

Sales Stage

Table 9.23 What-If Scenario Summary, MIRR and NPV Values (all amounts in $US)
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For the Research stage, if the start up stage takes two years instead of one years, the
initial required investment by series A investors would increase. The amount of fixed costs
(equipment, etc.) may be assumed relatively unchanged, but an additional year of all annual costs
(Personnel Salary Costs, Rental and Utilities Costs, etc.) will need to be supplied by the series A
investors. However, as the series A investors will then be invested for two years prior to the
series B investors, their increased MIRR over the series B investors will be even larger than in
the one-year research case phase. Post the Research stage, if all other stages go as previously
assumed, the remainder of the financial analysis should be relatively similar to the base case. It
can be seen that, in such a short lifetime as Micro$eq has, an additional year (another 20% of the
lifetime) without profit, and will decreased the company’s overall profit. However, even with
this decrease it can be seen that the company still operates at a final NPV of ~$1.5 million, and
the while the series A investors actually have an increased MIIR (~116%) the series B investors,
while having a decreased MIRR (~55%) still have greater than 50% margins. Thus, even in the
event that the research stage takes twice as long as projected, Micro$eq will still be financially
feasible and a wise investment, particularly for series A investors.
For the Scale Up stage, if the company only reaches 30% capacity instead of 50%
capacity, revenues for that year will be decreased by 40%. In the long term, this will simply
decreased the Terminal Value of Micro$eq, and it will take the company longer to turn a profit
during the sales stage. However, it can be seen that the company is still able to turn a profit in
this case, with a final NPV of ~$3.8 million. Additionally, while both series of investors have
decreased margins from the financial base case, it can be seen that they both still have
significantly greater than 50% returns (84% and 72% for series A and series B investors,
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respectfully). Hence, even in the event of a decreased scale up stage, Micro$eq is still not only
financially feasible, but a wise investment for both series of investors.
For the Sales stage, if the company sales decrease by a fixed percentage each year, the
annual revenues will decline, as will the NPV and investors MIRR’s. However, within in a
certain limit of sales percentage decrease, the company should still be able to break even.
Additionally, if sales decrease due to competition, it is possible that by this time, the R&D of the
company will have been able to develop improvements on the prototype such that production
costs are decreased. If this is the case, the market price may be able to be decreased such that
sales percentages may be rescued. Even if an improved prototype is not available, as shown
earlier in this chapter, Micro$eq is capable of operating above the breakeven point for any
market price greater than $466 per genome. Thus, it is possible for Micro$eq to ward off
decreased sales due to competition by further decreasing its market price so that its new
competitor no longer remains competitive.
The case shown above for S2, a sales decrease of 10% each was assumed. It can be seen
at this sales decrease, the company is still able to function well above the breakeven line with a
final NPV of ~$2.2 million and investor MIRR’s of ~75% and ~64% for series A and series b
respectively.
The only what-if scenario that leave Micro$eq financially unfeasible is case S3, where
the company never reached full capacity and instead is forced to liquidate after its first year of
sales. For this case the company ends a final NPV of ~($2.2 million) and investor MIRR’s of ~22% and -38% for series A and series B investors, respectively.
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This What-if Analysis shows promise for Micro$eq, that, with the exception of the highly
unlikely S3 case, if is still financially feasible and significantly profitable even when the base
case assumptions are tested. Micro$eq’s financial robustness even in variable scenarios should
be further evidence of its value as an investment.

9.12 GROWTH CASE SCENARIO
Thus far, it has been assumed that the company has no growth. However, with the base
case financial analysis indicating that the companies margins are well above the breakeven point,
it is feasible that the company could – and would – expand. This expansion would happen once
the company has entered the sales phase. For the purpose of this discussion, a growth rate of
25% for each of the sales stage years will be assumed. In this case, the projected NPV is
~$8.1Million, and the series A and series B investors MIRR’s are 107% and 94.7% respectively.
As, in reality, it will most likely be feasible for the company to expand, these projections are
very positive with respect to Micro$eq’s projected growth. The full financial analysis of the
growth case may be found in Appendix D.

9.13 LARGE-SCALE OPERATION SCENARIO
As previously discussed in both intital Market Analysis (section 1.1 of this report) and
earlier in this Financial Analysis chapter, a potential modified business model for Micro$eq is a
large-scale operation that targets the Pharmaceutical industry. Over the past five years, an
average number of 25,153 different FDA-approved clinical trials per year take place globally,
with an average of 2,186 participants per trial for an average total of 54.98 million trial
participants per year. (CISCIP). Pharmaceutical companies pay an average of $12 thousand per
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participant (CISCIP). As previously discussed, it would be a long-term benefit for
Pharmaceutical companies to being to accumulate a database of trial participants’ whole genome
sequences that can then be cross-analyzed with their drug-responses in order to further develop
the field of personalized drug response based on genetic predisposition. By using the database
they had built by sequencing all of their trial participants, companies could tailor their
recommended drug treatments for patients with specific genotype mutations and thus increase
both their sales and theoretical efficacy of their products. Thus, Micro$eq could hope to
capitalize on this available market by offering a bulk-discount rate to client such as large
pharmaceutical companies for use in their clinical trials.
If companies are spending an average of $12 thousand per patient, an additional 1.0%5.0% cost per participant would not be unreasonable for a company to be willing due to the
enormous benefits with minimal additional cost. Therefore, in order to participate in the market,
Micro$eq must be able have a profitable large scale market price of $120-$600 per genome. It
will be assumed that Micro$eq can serve 90% of this market, assuming no other competition.
This assumption seems valid, as no company is even within an order of magnitude of Micro$eq’s
small-scale market price, much less its further reduced large-scale market price. This requires
Micro$eq’s target large-scale annual throughput to be ~52 million genomes.
The large-scale model involves adjustments of required personnel, inventory, and
equipment costing scalable to the increase in throughput. Additionally, increases in rental and
utility costs must be accounted for. Additionally, the CEO and CTO will have higher salaries, as
fitting for a larger-scale biotech company. The adjusted cost estimates spreadsheat for the largescale case may be found in Appendix D of this report.
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The breakeven point for a target annual throughput of 52.2 million genomes is found to
be $197 per genome (full financial analysis summary found in Appendix D). As this is on the
low end of the acceptable price range, the large-scale market price will be set at $299 per
genome, which is just under a 2.5% cost increase for the Pharmaceutical companies, and is in the
middle of the allowable price range. Setting the market price below the maximum allowable
helps ensure that a true 90% of the market share may be achieved. The financial summary
analysis for the Large-scale case is displayed in Table 9.34 on the next page. It can be seen that
for the target throughput rate of 52.2 million genomes per year, at a market price of $299 per
genome, the projected NPV is ~2.7 trillion, with MIRR margins for series A and series B
investors being 325% and 302%, respectively. These margins may seem artificially high, but the
initial required investments follow economies of scale as the company size is expanded, and thus
the relative margins increase with the company scale up.
This financial analysis shows that not only would a target market of the Pharmaceutical
companies, specifically as they concern clinical trial participants, would be feasible, but it would
be highly profitable. As previously discussed, this market has yet to be tapped into by the whole
genome sequencing industry, as market price points are still too high. Micro$eq’s ability to
achieve a low price point not only eliminates competition on the small-scale level, but also opens
up a whole new, and extraordinarily large, market sector.
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Table 9.34 Large Scale Financial Analysis Summary (amounts in US$)
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($85,000.00)
($70,863.01)

Changes in Inv

Changes in CR

Total Change in Working capital

325.50%
302.40%

Se rie s A MIRR

Se rie s B MIRR

$0.00

$87,282.27

Divided Free Cash Flows

600,000
150,000,000

Series B Equity

Investment

$2,688,351,213.98

$96,980.30

$600,000.00

Series A Equity

Equity Shares

NPV@25% Di scount Rate

Free Cash Flow

Issuance of Common Stock

Cash from Financing Activities

Purchase/Sale of Equipment

($54,093.67)

$0.00

Changes in AP

Cash from Investing Activities

$0.00
$14,136.99

Changes in AR

Changes in Working Capital

Plus:Depreciation

Cash from Operating Activities
$0.00

($307,200.00)

Net income

Cash Flow Statement

($204,800.00)

Tax @ 40%

$0.00
($512,000.00)

Pre-tax income

Depreciation

$340,000.00

Operateing, SG&A expenses

$0.00

0.00%

2012

$172,000.00

Research

Cost of sales

Revenue

Income Statement

% of Design Capacity

Stage

Year
Scale Up

($13,055,901,732.47)

($58,751,557.80)

($13,121,181,241.14)

$150,000,000.00

($14,924,402,740.91)

($1,036,301,207.33)

($395,759,545.45)

$131.82

$874,644.66

($641,416,438.36)

($108.19)

$3,725,824,022.63

$2,483,882,681.75

$6,209,706,704.38

($108.19)

$1,590,401,691.82

$3,791,603.80

$7,803,900,000.00

50.00%

2013
Sales

$7,039,316,048.41

$31,676,922.22

$7,074,512,628.65

($640,839,031.74)

$0.00

$131.82

$577,274.79

($641,416,438.36)

($47,758,262.22)

$8,403,948,954.35

$5,602,632,636.23

$14,006,581,590.58

($47,758,262.22)

$1,597,425,201.82

$3,793,207.60

$15,607,800,000.00

100.00%

2014
Sales

Large-Scale Financial Summary - 52.2 million genomes/year @$299/genome

$8,333,534,628.02

$37,500,905.83

$8,375,202,301.16

$0.00

$0.00

$0.00

$0.00

$0.00

($28,746,653.19)

$8,403,948,954.35

$5,602,632,636.23

$14,006,581,590.58

($28,746,653.19)

$1,597,425,201.82

$3,793,207.60

$15,607,800,000.00

100.00%

2015
Sales

$8,344,943,130.64

$37,552,244.09

$8,386,667,846.29

$0.00

$0.00

$0.00

$0.00

$0.00

($17,281,108.06)

$8,403,948,954.35

$5,602,632,636.23

$14,006,581,590.58

($17,281,108.06)

$1,597,425,201.82

$3,793,207.60

$15,607,800,000.00

100.00%

2016
Terminal

$10,661,892,074.58

$48,065,796.61

$10,715,298,515.26

10000.00%

2017

9.14 FINANCIAL CONCLUSIONS
The preliminary financial analysis has provided sufficient evidence that Micro$eq would
be a profitable investment. The what-if scenarios have shown that under most circumstances the
company may cease to be profitable. Only in the worst possible case scenario, which is highly
unlikely to actually occur, did Micro$eq prove to be an unwise inestment. The growth case
scenario of the company shows promising opportunity for Micro$eq’s growth and subsequent
increase in profitability. Finally, the large-scale alternative business model illustrates the
potential of immense financial benefit from a large-scale whole genome sequencing company
that targets the Pharmaceutical company market.
It is important to note, however, that this entire discussion must be taken within the
context that all of the projected figures are just that – projections. While financial models are
useful guides for how the company’s financial status may proceed, they are far from set in stone.
These models provide the investors with the tools to make their investment decision, by making
them aware of potential risks and gains in they do become financially involved with Micro$eq.
However, as they are only estimations, any investment involves at least a nominal degree of risk.
It is also important to emphasize the novelty of this company and this impact on its
potential profitability. As previously discussed, Micro$eq shows the capacity of bringing whole
human genome sequencing to the market at 10% of the current market price. This would make
Micro$eq the only vendor of this product, at least for its first year on the market. While other
companies have claimed to be able to provide genome sequencing at prices within Micro$eq’s
order of magnitude, no company has yet to actually come close. In such a short lifetime as
Micro$eq’s it is most likely that the company will be able to remain the exclusive – or at least
one of the few - providers of this product, even within such a dynamic industry. Additionally,
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this large price discrepancy between Micro$eq’s product and other competitors’ products allows
Micro$eq the flexibility of exploring the new market of Pharmaceutical companies for BulkSequencing. The company’s positive financial projections allow for the possibility that a smallscale Micro$eq would be able to expand, at least to some percentage, during its limited lifetime.
It is also possible that, if a sufficient third round of investors were available, Micro$eq could
make the transition to a large-scale company after a year of operating as a small-scale company.
During this first year of operation, Micro$eq would establish its reputation for a high-end
product and thus have a better chance of achieving 100% sales on the large-scale right away.
Micro$eq’s potential ability to open this new market will not only be enormously financially
beneficial to the company, but will also be a huge step in the field of Personalized Medicine.
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CHAPTER 10

Conclusions
The ultimate goal of this project was to design a whole human genome sequencing
strategy for a start-up Biotech company, Micro$eq’s, that would allow high-throughput, low-cost
sequencing. Micro$eq’s original objective was to produce a minimum of 12 genomes per day at
a market price of less than $1000 per genome. The proposed sequencing approach was to utilize
Raindance Technology’s microdroplet based technology as a platform for a continuous
sequencing process.
Micro$eq’s proposal of a continuous rather than batch sequencing process has the
potential to revolutionize the Biotech industry’s approach to genome sequencing. Current batch
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processes methods such as those used by companies such as Illumina, Helicos Bioscience’s, and
Roche/454 Sequence require large numbers of flushing, scanning, and washing cycles. Similarly,
current single molecule approaches require costly optical setups and long scanning times.
Micro$eq’s continuous, multi-molecule method avoids both of these bottlenecks which currently
limit the growth of the Human Genome Sequencing Industry.
Fundamental to Microseq’s innovative whole genome sequencing approach are several
novel technologies or novel applications of existing technologies. The preseqeuncing DNA
preparation process involves a unique approach to small fragment cutting and amplification that
allows the generation of exactly-sized DNA fragments at a set concentration – a nearly
impossible task due to molecular biology limitations. The small scale of the reaction due the
microfluidic platform requires only small volumes of reagents, thus reducing presequencing
costs. Additionally, the microfluidic platform used for the presequencing DNA preparation
requires a very minimal amount of input DNA, allowing for the quality of product for a variable
quality of input samples. The high level of control inherent in the DNA preparation process not
only reduces the amount of required preparation time, but allows the optimal inputs for the
sequencing and genome assembly steps of the process.
The sequencing stage of the process uses fluorescence hybridization to detect DNA
sequence, but unlike most of the current processes does do by hybridizing 6bp oligonucleotides
rather than single nucleotide hybridization. This approach reduces the required sequencing time
by reducing the number of hybridization events required for whole genome sequencing. Like the
presequencing preparation, the sequencing process also capitalizes on the unique advantages
associated the microfluidics platform. Large numbers of molecules are placed in each droplet
allowing Micro$eq to have increased design control over the process as well as increased
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throughput. The Large numbers of molecules in each droplet is advantageous over current
microfluidic sequencing platforms which use a single molecule per droplet approach. The
increased concentration decreases the signal to noise ratio during scanning and allows a higher
scanning speed without compromising accuracy. By the use of multiple parallel scanning
processes, the sequencing step in Micro$eq’s process is reduced to 24 hours per unit of
throughput genomes and thus sets the total process turnover time as 24 hours.
The genome assembly stage of this process developed an original algorithm using the
MATLAB computational platform which allowed the assembly of the 6mer readouts from the
sequencing step into large enough fragments so that the conventional method of shotgun
sequencing might be performed to fully compiled the genome. The optimal values of fragment
length, number of fragments to be inserted in each parent droplet, and number of coverage for
maximum computational efficiency were determined, and the presequencing preparations were
designed accordingly. The final process error rate was estimated to 9.98x10-6 (or ~1bp in every
100,000bp). This error rate is competitive with any available genome sequencing surface on the
market as of December 2011 (yang, Dorman, & Aluru, 2010). The sequence processing time was
also optimized such that total processing for a genome was 19.1 hrs, and thus still allowed the
total process turnover time to be 24 hours.
The financial analysis of Micro$eq using this innovative process showed that both a
small-scale company producing 72 genomes per day at a market price of $999 would yield
between 77%-89% margins for investors, and a large-scale company producing 52.2 million
genomes per year at a market price of $299 per genome would yield between 300-325% margins
for investors. The achievement of a profitable market price under $1000 per genome makes
Micro$eq the lowest price on the current market by a factor of 10.
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advantage in costing-efficiency will most likely allow the company to be the exclusive provider
of whole genome sequencing –either to the private wealth sector in the form a small-scale
company, or to the Pharmaceutical Industry in the form of a large scale company.
Additionally, Micro$eq’s ability to profitably bulk produce genomes at a $299 per
genome market price allows it to open the new market sector of Pharmaceutical companies for
Whole Genome Sequencing Industry. While Micro$eq’s venture into this unexplored sector will
be financially profitable, and thus renders Micro$eq a wise investment, its ability to open this
new market is also a major necessary step for the development of the field of Personalized
Medicine.
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Appendix A:
Protocol and Reagent Specifications
A.1

Presequencing Protocols and Reagents
A.1.1 Oragene Saliva Kit (Genotek)
A.1.2 s2 Shearer Protocol (Covaris)
A.1.3 Adenosine Ligation Quick Start Protocol (Qiagen)
A.1.4 Adenosine Ligation Quick Start Protocol (Qiagen)
A.1.5 Exonucleolysis Protocol (NEB)
A.1.6 MmeI Digestion Protocol (NEB)
A.1.7 End-it DNA Repair Kit Protocol (Epicenter Biotechnologies)
A.1.8 PCR Basic Kit Protocol (Qiagen)

A.2

Sequencing Protocols and Reagents
A.2.1 BODIPY Dyes-Used for Fluorescent Barcoding of Oligonucleotides
A.2.2 BODIPY Dyes Absorbance Spectra
A.2.3 Barcading the Oligos Lirary using Fluorescent Polymers
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A.1 Presequencing Protocols and Reagents
A.1. 1 Oragene Saliva kit (Genotek)
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A.1. 2 s2 Shearer Protocol (Covaris)
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A.1. 3 Adenosine Ligation Quick Start Protocol (Qiagen)
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A.1. 4 Adenosine Ligation Quick Start Protocol (Qiagen)
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A.1. 5 Exonucleolysis Protocol (NEB)

Exonuclease degradation of linear DNA
Exonuclease cocktail:
Step 1:
Mix: 5 μl of NEB Buffer 1
6μl of exonuclease I (E. coli, 20 units/μl, NEB)
3μl of exonuclease III (100 units/μl, NEB)
3μl of lambda exonuclease (100 units/μl, NEB).
Step 2:
Add: 36 μl of water
Exonucleolysis Reaction
Step 3:
Add: 0.5μl aliquot from the circular assembly ligation reaction to 20μl of exonuclease cocktail
from steps 1-2
Step 4:
Incubate: total reaction mixture at 37ºC for 45 min.
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A.1. 6 MmeI Digestion Protocol (NEB)
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A.1. 7 End-it DNA Repair Kit Protocol (Epicenter Biotechnologies)
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A.1. 8 PCR Basic Kit Protocol (Qiagen)

Micro$eq – Chomvong, King, Mahmoud

260 | P a g e

Micro$eq – Chomvong, King, Mahmoud

261 | P a g e

A.2 Sequencing Protocols and Reagents
A.2.1 BODIPY Dyes-Used for Fluorescent Barcoding of Oligonucleotides
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A.2.2 BODIPY Dyes Absorbance Spectra
Dye Catalog Number:D2183

D217
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D6116

D2228
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D100001

D10000
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558/568
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A.2.3 Barcading the Oligos Lirary using Fluorescent Polymers
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Finding an optical strategy of ‘barcoding’ the oligos library using fluorescent polyers. Bangs
Laboratories Inc. manufactures fluorescent polymers with varying intensities. The fluorescent dye spectra
of the polymeric microsphere manufactured are given below (absorbance spectra are dotted, while
emission spectra are given by a solid li
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Appendix B:
Equipment Specifications
B.1

Presequencing Equipment
B.1.1 2s Shearer (Covaris)
B.1.2 ND-1000 (NanoDrop)
B.1.3 Magtration System 12GC Plus (PSS Bioinstruments)
B.1.4 BioMetra ThermoCycler - Small
B.1.5 Velp Scientifica RX3 Vortex Mixer
B.1.6 UNICO Micro-Hematocrit Lab Centrifuge with 24 Place Rotor C-MH30

B.2

Sequencing Equipment
B.2.1 CCD Image Sensors
B.2.2 Laser
B.2.3 Lens
B.2.4 Prism
B.2.5 Mitos Duo-XS Pump Basic (3200066)
B.2.6 Syringe for Mitos Duo XS-Pump, 100 µl
B.2.7 HP S2031

B.3

Genome Assembly Equipment
B.3.1 Quad-Core AMD Opteron Processor 8356
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B.1 Presequencing Equipment
B.1.1 s2 Shearer (Covaris)

Specifications for s2 shearer
Parameter
Base Pair Size
Duty Cycle
Intensity
Cycles per burst
Power Mode
Z Height
Temperature
Time
Degassing mode
Volume
DNA mass
Starting material
Water level(FILL/RUN)
AFA Intensifier

Setting
1000(bp)
5%
3
200
Frequency Sweeping
6mm
6-8 ( °C)
40 (s)
Continuous
200µl
<5µg
>50kb
S2 – level 12
E210 – level 6
Yes
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B.1.2 ND-1000 (NanoDrop)
Micro-Volume UV-Vis Spectrophotometer for Nucleic Acid and Protein Quantitation
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B.1.3 Magtration System 12GC Plus (PSS Bioinstruments)

Specifications for Magtration 12GC Plus
Dimension
W500xD535xH574mm
Weight
Approximately 55kg
Power
AC100-120V 50/60Hz 240VA
AC220-240V 50/60Hz 240VA
Throughpu
Sample number 1-12 samples/batch
Process time 30 min~/1-12 samples
*depends on application
Temperature Control
Heating block:room temp ±5°C-80°C
Handling Volume
25-1000μL
Pipetting accuracy
25 μL±10%
50 μL±5%
25 μL±3%
*Using DN1—N tip with DW at room temp(20-25°C)
Protocol
IC Card
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B.1.4 BioMetra ThermoCycler - Small

Specifications for T3000 Thermocylcer 20
T3000 Thermocylcer
T3000 Thermocylcer Combi
48
Block Formats
3 blocks for
20 x 0.5 ml tubes each
3 blocks for
3 combi blocks for
48 x 0.2 ml tubes
18 x 0.5 ml tubes* or
or 48 well
48 x 0.2 ml tubes or
microplates or
48 well microplates
6 x 8 well strips each or 6 x 8 well strips
Block
Aluminium
Aluminium
Aluminium
Max Heating
2.1 °C/sec
2.2 °C/sec
1.4 °C/sec
Max Cooling
1.7 °C/sec
2.0 °C/sec
1.2 °C/sec
Temp Uniformity
+/- 0.5 °C
Temp Range
3 °C to 99 °C
Control Accuracy
+/- 0.1 °C
Software
Program steps are easily entered in a spread sheet
Options: Time increment, temperature increment, set ramping rate, direct
mode (for use as thermoblock), program storage in 10 individual subdirectories
Memory
10 individual subdirectories, total capacity of 1.500 program steps (equivalent
to 250 average programs)
Display
High brightness CFL backlight graphical LC Display, viewing area 124 mm x 34
mm, resolution 256 x 64 dots
Auto restart after
Yes
power failure
Heated Lid
High Performance Smart Lid (HPSL)
Lid Temperature
30 to 99 °C
Range
Power consumption
max. 420 Watt
Power Supply
110, 230 Volt / 50-60 Hz
Noise emission
Very low
Unit Price
$4000
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B.1.5 Velp Scientifica RX3 Vortex mixer

Specifications for RX3 Vortex mixer
Construction material:
Support system:
Orbital diameter:
Power:
Power supply:
Weight:
Dimension (WxHxD):
Unit Price:
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epoxy painted aluminum structure
4 holdfast feet for strong fixing and high stability
5 mm
45 W
115 V or 230 V / 50 or 60 Hz
2 Kg (4.4 lb)
150x134x150 mm (5.9x5.3x5.9 in)
$179.99
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B.1.6 UNICO Micro-hematocrit Lab Centrifuge with 24 Place Rotor C-MH30

Specifications for UNICO Micro-hematocrit Laboratory Centrifuge:
Nominal speed:
Size:
Weight:
Unit Price:

12000 RPM
11.6 in x 10.3 in x 9.3 in (295 mm x 261 mm x 235 mm)
17.4 lbs (7.9 kg)
$679.68
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B.2 Sequencing Equipment
B.2.1 CCD Image Sensors

Cost of custom equipped camera+chip that is compatible with chip above~$25,000
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B.2.2 Laser
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B.2.3 Lens
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B.2.4 Prism
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B.2.5 Mitos Duo-XS Pump Basic (3200066)
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B.2.6 Syringe for Mitos Duo XS-Pump, 100 µl

B.2.7 HP S2031 – 20” – widescreen TFT Active Matrix LCD Display
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B.3 Genome Assembly Equipment

B.3.1 Quad-Core AMD Opteron Processor 8356
Model
Operating System
Processor
Processor ID
Processor Frequency
Cores
Processors
Threads
Memory
Unit Price

Linux PC (Quad-Core AMD Opteron(tm) Processor 8356)
Linux 2.6.18-92.1.13.el5 x86_64
Quad-Core AMD Opteron 8356
AuthenticAMD Family 16 Model 2 Stepping 3
2.40 GHz
16
4
16
128 GB
$1588.99
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Appendix C:
MATLAB Simulation Code
C.1

Raw Sequencing Data Simulation (Individual Fragments)

C.2

Raw Sequencing Data Simulation(Doubled Strand DNA)

C.3

6mer Hybridization Simulation

C.4

de Bruijn Graph Generation

C.5

de Bruijn Graph Interpretation

C.6

Conversion of Simplified Graphs to Simplified Base Sequences

C.7

Shotgun Sequencing Coverage Requirement
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C.1 Raw Sequencing Data Simulation (Individual Fragments)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

function [MatchedOligos] = RawSeqData(nFrag,nBp,kmer)
%--** Simulate raw sequencing data expected from genome **--%
%
Only oligos which bind to complementary sequence are returned
%
nFrag
:expected number of fragments per drop
%
nBp
:expected fragment length
%
kmer
:oligos library size
%
Oligos :all 4^kmer possible combination of oligos library
%
Seq
:complementary sequence
clear Seq row temp three i j row Oligos;
%--Generate random sequences for nFrag fragments, each with nBp bases--%
for i = 1:nFrag
Seq(i,:) = randseq(nBp);
end
Seq = nt2int(Seq);
%--Generate oligos library, size = kmer, 4^kmer possible combination--%
row = 4^kmer;
Oligos = zeros(row, kmer+1);
temp = fi(zeros(row,1));
three = fi(3,1,length(dec2bin(4^kmer)),0);
temp2 = zeros(1,kmer);
for i = 0:(row-1)
for j = 1:kmer
temp1 = bitshift(fi(i,1,length(dec2bin(4^kmer)),0),-2*(kmer-j));
Oligos(i+1,j) = (bitand(temp1,three))+1;
temp2(1,j) = Oligos(i+1,j);
end
end
%--Search for oligo which is identical to complementary sequence--%
% These oligos are the ones which bind to the fragment in droplets%
for i = 1:(4^kmer)
Oligos(i,(kmer+1)) = FindFrag(Oligos(i,(1:kmer)),CompSeq,nBp,kmer);
end
%--Select only those oligos that match and assign to 'MatchedOligos'--%
clear MatchedOligos i n;
n = 0;
for i = 1:(4^kmer)
if Oligos(i, kmer+1) == 1
MatchedOligos(n+1,1:kmer) = Oligos(i,1:kmer);
n = n+1;
end
end
end
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C.2 Raw Sequencing Data Simulation (Doubled Strand DNA)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

function [MatchedOligos] = SequencingDoubleStrand(nDFrag,nBp,kmer)
%--** Simulate raw sequencing data expected from genome for doubled strand DNA fragment**--%
%
Only oligos which bind to complementary sequence are returned
%
nDFrag :expected number of doubled strand DNA per drop
%
nBp
:expected fragment length
%
kmer
:oligos library size
%
Oligos :all 4^kmer possible combination of oligos library
%
Seq
:complementary sequence
clear Fragment row temp three i j MatchedOligos Obind mo Oligos;
%--Generate random sequences for nFrag fragments, each with nBp bases--%
for i = 1:nDFrag
Fragment(2*i-1,:) = randseq(nBp);
Fragment(2*i,:) = seqcomplement(Fragment(2*i-1,:));
end
Fragment = nt2int(Fragment);
%--Generate oligos library, size = kmer, 4^kmer possible combination--%
row = 4^kmer;
Oligos = zeros(row, kmer+1);
temp = fi(zeros(row,1));
three = fi(3,1,length(dec2bin(4^kmer)),0);
temp2 = zeros(1,kmer);
for i = 0:(row-1)
for j = 1:kmer
temp1 = bitshift(fi(i,1,length(dec2bin(4^kmer)),0),-2*(kmer-j));
Oligos(i+1,j) = (bitand(temp1,three))+1;
temp2(1,j) = Oligos(i+1,j);
end
end
%--Search for oligo which is identical to complementary sequence--%
% These oligos are the ones which bind to the fragment in droplets%
for i = 1:(4^kmer)
Oligos(i,(kmer+1)) = FindFrag(Oligos(i,(1:kmer)),Fragment,nBp,kmer);
end
%--Select only those oligos that match and assign to 'MatchedOligos'--%
clear MatchedOligos i n;
n = 0;
for i = 1:(4^kmer)
if Oligos(i, kmer+1) == 1
MatchedOligos(n+1,1:kmer) = Oligos(i,1:kmer);
n = n+1;
end
end
end
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C.3 6mer Hybridization Simulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

function [IsMatch] = FindFrag( Oligo, Fragment, nBp, kmer)
%--** Determine whether a given Oligo of kmer would bind with inserted fragment(s)**--%
%
function returns 1 if a given Oligo binds with complementary sequence
%
and o otherwise
%
Oligo
:one combination of kmer oligo library
%
Fragment:sequences of inserted doubled strand fragments
%
nBp
:expected fragment length
%
kmer
:oligos library size
clear IsMatch k m i row;
IsMatch = 0;
k = nBp - (kmer-1);
row = 1;
while (IsMatch == 0) && (row <= length(Fragment(:,1)))
i = 1;
while(IsMatch ==0) && (i <= k)
if(isequal(Fragment(row,i:(i+(kmer-1))),Oligo))
IsMatch = 1;
end
i = i+1;
end
row = row+1;
end
end
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C.4 de Bruijn Graph Generation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

function [Link OutIn] = deBrujinGeneration( MatchedOligos, kmer )
%--** Generate de Bruijn Graph **--%
%
MatchedOligos
:initial reads with kmer size
%
kmer
:oligo library size (bp)
%
n
:number of initial reads
%
Link
:relationship matrix the first column is the
%
starting point while the second colum (in the
%
same row) is the ending point. The number of
%
node represented in Link matrix comes from the
%
number of row the oligo belongs to in
%
MatchedOligos
%
OutIn
:relationship matrix, the number of row
%
represents number of row the oligo belongs to
%
in MatchedOligos. The number in the first column
%
represents number of times the node has a link
%
pointing out. The number in the second column
%
represents number of times the node has a link
%
pointing in.
clear i k Link ismatch SparseM n temp1 temp2;
%--Link initial reads using de Bruijn algorithm--%
%--the last kmer-1 bases of node x must be idential to the first kmer-1 bases of node y in
order for the link from x to y to be generated--%
n = length(MatchedOligos(:,1));
k = 1;
for i = 1:n
for j = 1:n
if(isequal(find(MatchedOligos(i,2:kmer) == MatchedOligos(j,1:(kmer-1))), [1:(kmer1)])) && (i ~= j)
Link(k,1) = i;
Link(k,2) = j;
k = k+1;
end
end
end
%--de Brujin graph is graphically displayed--%
temp1 = max(Link(:,1));
temp2 = max(Link(:,2));
temp1 = max(temp1,temp2);
SparseM = sparse(Link(1:k-1,1),Link(1:k-1,2),true,temp1,temp1);
view(biograph(SparseM))

%--the OutIn matrix is generated--%
clear OutIn;
OutIn = zeros(n,2);
for i = 1:n
for j = 1:k-1
if (i == Link(j,1))
OutIn(i,1) = OutIn(i,1)+1;
end
if( i == Link(j,2))
OutIn(i,2) = OutIn(i,2)+1;
end
end
end
end
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C.5 de Bruijn Graph Interpretation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67

function [ SimpFrag ind Link] = deBruijnInterp( Link, OutIn )
%--** Interprete de Bruijn Graph; assemble secondary reads from initial reads **--%
%
SimpFrag
:secondary read assembled
%
ind
:number of generated secondary reads
clear SecReads first last i l f FragTemp SimpFrag k sf ind;
sf = 1; ind = 0;
Link(:,3) = 0;
l = 0; f = 0;
for i = 1:length(OutIn(:,1))
if(OutIn(i,1) == 0)
l = l+1;
Last(l) = i;
elseif(OutIn(i,2) == 0)
f = f+1;
First(f) = i;
end
end
clear i;
for i = 1:f
% Reassemble from left to right (first to last)
clear FragTemp ft row x loop;
ft = 1; k = 1;
FragTemp(ft) = First(i);
[Link FragTemp] = ConnectNext(Link,OutIn,1,FragTemp);
ft = sum(FragTemp ~= 0);
if(OutIn(FragTemp(ft),1) == 2)
if(OutIn(FragTemp(ft),2) == 2)
k = 2;
FragTemp(2,:) = FragTemp(1,:);
row = find(Link(:,1) == FragTemp(1,ft));
for j = 1:length(row)
FragTemp(j,ft+1) = Link(row(j),2);
[Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(j,:));
FragTemp(j,1:length(x)) = x;
if(j==1) && (loop == 1)
FragTemp(2,1:end) = 0;
break;
elseif(j==2) && (loop ==1)
FragTemp(1,:) = FragTemp(2,:)
FragTemp(2,:) = 0;
end
end
elseif(OutIn(FragTemp(ft),2) ==1)
%go left first, right becomes the beginning
k = 4;
FragTemp(3,:) = FragTemp(1,:);
row = find(Link(:,1) == FragTemp(1,ft));
%go left first
FragTemp(1,ft+1) = Link(row(1),2);
FragTemp(2,1) = Link(row(2),2);
[Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(1,:));
FragTemp(1,1:length(x)) = x;
[Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(2,:));
FragTemp(2,1:length(x)) = x;
%then go right
FragTemp(3,ft+1) = Link(row(2),2);
FragTemp(4,1) = Link(row(1),2);
[Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(3,:));
FragTemp(3,1:length(x)) = x;
[Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(4,:));
FragTemp(4,1:length(x)) = x;
end
end
SimpFrag(sf:(sf+k-1),1:length(FragTemp(1,1:end))) = FragTemp;
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68
69
70
71
72
73
74
75

sf = sf + k;
if(k == 1) || (k == 2)
ind = ind+1;
elseif (k == 4)
ind = ind+2;
end
end
end
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C.6 Conversion of Simplified Graphs to Simplified Bases
Sequences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

function [ SimpFragSeq ] = Node2Seq( SimpFrag, MatchedOligos,kmer )
%--** Convert coded graph sequence to base sequence for shotgun sequencing assembly**--%
%
SimpFrag
:simplified de Bruijn graph
%
MatchedOligos
:set of kmer oligo library which binds with inserted fragment
%
kmer
:oligos library size
%
SimpFragSeq
:base sequence of simplified assembled output
clear row i j col;
row = length(SimpFrag(:,1));
for i=1:row
col = sum(SimpFrag(i,:) ~= 0);
for j = 1:col
if(j == 1)
SimpFragSeq(i,1:kmer) = MatchedOligos(SimpFrag(i,j),1:end);
else
SimpFragSeq(i,kmer+j-1) = MatchedOligos(SimpFrag(i,j),end);
end
end
end
end
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C.7 Shotgun Sequencing Coverage Requirement
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

function [ Prob, TotErr ] = PoissonError( ExpectedCov, BpErr)
%--** Calculate error rate of shotgun sequencing associated with each actual coverage for a
given expected coverage and read error **--%
%
ExpectedCov
:expected number of coverage
%
BpErr
:read error = probability that a given base in
%
secondary reads is incorrect
%
= (genome length)/4^(fragment length)×1.5 (
%
see Eqn VI-7)
%
TotErr
:summation of error for all actual coverage
%
Prob
%
column 1
:the number of actual coverage
%
column 2
:probability of actual coverage existence for a
%
given ExpectedCov
%
column 3
:the error per base for a given BpErr, which is the
%
error rate of read for each basepair
%
column 4
:total error = column 2*column3 for each possible
%
actual coverage

1
2
3
4
5
6
7
8
9
10
11
12
13
14

function [ OptCov ] = OptimalCov(BpErr)
%--** Calculate minimum expected coverage required to acheive total error rate of 1e-5 for a
given BpErr **--%
%
OptCov
:minimum number of expected coverage required

clear i MinErr j TotErr;
TotErr = 0;
for i = 0:ExpectedCov*2
Prob(i+1,1) = i;
Prob(i+1,2) = (ExpectedCov^i)*exp(-ExpectedCov)/factorial(i);
if(i == 0)
Prob(i+1,3) = 1;
% for odd actual coverage (e.g. 1, 3, 5,...), the incorrect base has be
% equal or greater than i/2+0.5 times for the error to exist
else
if(mod(i,2) == 1)
MinError = i/2+0.5;
elseif(mod(i,2) == 0)
MinError = i/2;
end
Prob(i+1,3) = 0;
for j = MinError:i
Prob(i+1,3) = Prob(i+1,3) + factorial(i)/(factorial(j)*factorial(ij))*(BpErr^j)*(1-BpErr)^(i-j);
end
end
Prob(i+1,4) = Prob(i+1,2)*Prob(i+1,3);
TotErr = TotErr + Prob(i+1,4);
end
end

clear i Prob;
for i = 30:-0.01:0
[ Prob, TotErr ] = Poisson( i, BpErr);
if (TotErr > 1e-5)
OptCov = i+0.01;
break;
end
end
end
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Appendix D:
Financial Pro Forma
D.1

Supplementary Financial Analysis Summaries and Cost Estimates
D.1.1 24 Genomes per Day Throughput Analysis
D.1.1 35 Genomes per Day Throughput Analysis
D.1.3 48 Genomes per Day Throughput Analysis
D.1.4 60 Genomes per Day Throughput Analysis
D.1.5 What-if Scenario SU2
D.1.6 What-If Case R2
D.1.7 Growth Case Financial Summary
D.1.8 What-if Scenario S2 Financial Analysis Summary
D.1.9 What-if Scenario S3 Financial Analysis Summary
D.1.10 Large-Scale Cost Estimates (part 1)
D.1.11 Large-Scale Cost Estimates (part1)
D.1.12 Large Scale Breakeven Financial Analysis Summa
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D.1 Financial Analysis Summaries
D.1.1 24 Genomes per Day Throughput Analysis

Preliminary Financial Summary - 24 genomes/day @$964/genome
Year

2012

Stage

Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

100.00%

2017
T erminal

100.00%

100.00%

Income Statement
Revenue

$0.00

$3,816,163.91

$7,632,327.82

$7,632,327.82

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,183,434.55

$1,186,869.10

$1,186,869.10

$1,186,869.10

Depreciation

$0.00

Pre-tax income

($512,000.00)

T ax @ 40%
Net income

($108.19)

($7,419.50)

($4,465.95)

$7,632,327.82

($2,684.71)

$2,252,125.56

$6,063,251.13

$6,063,251.13

$6,063,251.13

($204,800.00)

$900,850.23

$2,425,300.45

$2,425,300.45

$2,425,300.45

($307,200.00)

$1,351,275.34

$3,637,950.68

$3,637,950.68

$3,637,950.68

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion

$0.00

($108.19)

($7,419.50)

Changes in AR

$0.00

($313,657.31)

($313,657.31)

Changes in AP

$14,136.99

$17,295.99

Changes in Inv

$0.00

$131.82

($4,465.95)

($2,684.71)

Changes in Working Capital

Changes in CR

($85,000.00)

($210,000.00)

T otal Change in Working capital

($70,863.01)

($506,229.50)

($54,093.67)

($2,264,392.14)

$600,000.00

$3,000,000.00

$96,980.30

$1,074,316.01

$0.00

$0.00

$282.29

$0.00

$0.00

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$3,633,484.73

$3,635,265.97

$11,444,091.80

($313,243.20)

Cash from Investing Activities
Purchase/Sale of Equipment
Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Di scoun t Rate

Equity Shares

$3,004,044.78

$0.00

Investment

Series A Equity

600,000

Series B Equity

3,000,000
Divided Free Cash Flows
$87,282.27

$193,376.88

$540,728.06

$654,027.25

$654,347.87

$2,129,762.34

$0.00

$859,452.81

$2,403,235.83

$2,906,787.79

$2,908,212.77

$9,077,689.20

Se rie s A MIRR

58.12%

Se rie s B MIRR

47.30%
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D.1.2 36 Genomes per Day Throughput Analysis

Preliminary Financial Summary - 36 genomes/day @$715/genome
Year
Stage

2012
Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

5000.00%

2015
Sales

10000.00%

10000.00%

2017

2016
Sales

T erminal
10000.00%

10000.00%

Income Statement
Revenue

$0.00

$4,245,693.06

$8,491,386.13

$8,491,386.13

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,363,821.12

$1,367,642.25

$1,367,642.25

$1,367,642.25

Depreciation

$0.00

($108.19)

($11,042.53)

($6,646.72)

$8,491,386.13

($3,995.69)

Pre-tax income

($512,000.00)

$2,501,268.14

$6,741,536.28

$6,741,536.28

$6,741,536.28

T ax @ 40%

($204,800.00)

$1,000,507.26

$2,696,614.51

$2,696,614.51

$2,696,614.51

Net income

($307,200.00)

$1,500,760.88

$4,044,921.77

$4,044,921.77

$4,044,921.77

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

($11,042.53)

Changes in Working Capital
Changes in AR

$0.00

($348,961.07)

($348,961.07)

($6,646.72)

($3,995.69)

$0.00

$0.00

Changes in AP

$14,136.99

$17,327.76

$314.06

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

Changes in CR

($85,000.00)

($255,000.00)

T ot al Change in Working capit al

($70,863.01)

($586,501.49)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($3,396,588.21)

Cash from Financing Activities
Issuance of Common St ock

$600,000.00

$3,000,000.00

Free Cash Flow
NPV@25% Discount Rate

Equity Shares

$96,980.30

($348,515.19)

($68,938.50)

$3,336,848.86

$4,038,275.05

$4,040,926.08

$11,444,091.80

Divided Free Cash Flows
$87,282.27
($12,408.93)

$600,632.79

$726,889.51

$727,366.69

$2,129,762.34

$2,669,479.09

$3,230,620.04

$3,232,740.86

$9,077,689.20

$0.00

Investment

Series A Equit y

600,000

Series B Equit y

3,000,000

$0.00
Serie s A MIRR

57.61%

Serie s B MIRR

46.80%
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D.1.3 48 Genomes per Day Throughput Analysis

Preliminary Financial Summary - 48 genomes/day @$590/genome
Year

2012

Stage

Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

100.00%

2017

2016
Sales

T erminal
100.00%

100.00%

Income Statement
$0.00

$4,675,222.22

$9,350,444.43

$9,350,444.43

Cost of sales

Revenue

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,544,207.70

$1,548,415.40

$1,548,415.40

$1,548,415.40

Depreciation

$0.00

($108.19)

($14,665.56)

($8,827.49)

$9,350,444.43

($5,306.66)

Pre-tax income

($512,000.00)

$2,750,410.72

$7,419,821.43

$7,419,821.43

$7,419,821.43

T ax @ 40%

($204,800.00)

$1,100,164.29

$2,967,928.57

$2,967,928.57

$2,967,928.57

Net income

($307,200.00)

$1,650,246.43

$4,451,892.86

$4,451,892.86

$4,451,892.86

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

($14,665.56)

Changes in Working Capital
Changes in AR

$0.00

($384,264.84)

($384,264.84)

($8,827.49)
$0.00

($5,306.66)
$0.00

Changes in AP

$14,136.99

$17,359.54

$345.84

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$4,443,065.37

$4,446,586.19

$11,444,091.80

Changes in CR

($85,000.00)

($300,000.00)

T otal Change in Working capit al

($70,863.01)

($666,773.48)

($54,093.67)

($4,528,784.28)

($383,787.18)

Cash from Investing Activities
Purchase/Sale of Equipment
Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Di scount Rate

Equity Shares

$600,000.00

$3,000,000.00

$96,980.30

($1,212,193.01)

$3,669,652.94

$0.00

Investment

Series A Equity

600,000

Series B Equity

3,000,000
Divided Free Cash Flows
$87,282.27
($218,194.74)
$0.00

Serie s A MIRR

57.10%

Serie s B MIRR

46.29%
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D.1.4 60 Genomes per Day Throughput Analysis

Preliminary Financial Summary - 60 genomes/day @$516/genome
Year

2012

Stage

Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

100.00%

2017

2016
Sales

T erminal
100.00%

100.00%

Income Statement
Revenue

$0.00

$5,104,751.37

$10,209,502.73

$10,209,502.73

$10,209,502.73

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,724,594.28

$1,729,188.55

$1,729,188.55

$1,729,188.55

Depreciation

$0.00

($108.19)

($18,288.58)

($11,008.26)

($6,617.64)

Pre-tax income

($512,000.00)

$2,999,553.29

$8,098,106.58

$8,098,106.58

$8,098,106.58

T ax @ 40%

($204,800.00)

$1,199,821.32

$3,239,242.63

$3,239,242.63

$3,239,242.63

Net income

($307,200.00)

$1,799,731.97

$4,858,863.95

$4,858,863.95

$4,858,863.95

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

($18,288.58)

($11,008.26)

($6,617.64)

Changes in AR

$0.00

($419,568.61)

($419,568.61)

$0.00

$0.00

Changes in AP

$14,136.99

$17,391.31

$377.61

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$4,847,855.68

$4,852,246.31

$11,444,091.80

Changes in Working Capital

Changes in CR

($85,000.00)

($345,000.00)

T otal Change in Working capital

($70,863.01)

($747,045.48)

($54,093.67)

($5,660,980.35)

($419,059.17)

Cash from Investing Activities
Purchase/Sale of Equipment
Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discoun t Rate

Equity Shares

$600,000.00

$3,000,000.00

$96,980.30

($2,355,447.51)

$4,002,457.02

$0.00

Investment

Series A Equity

600,000

Series B Equity

3,000,000
Divided Free Cash Flows
$87,282.27

($423,980.55)

$720,442.26

$872,614.02

$873,404.34

$2,129,762.34

$0.00

($1,884,358.01)

$3,201,965.61

$3,878,284.55

$3,881,797.05

$9,077,689.20

Series A MIRR

56.58%

Series B MIRR

45.79%
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D.1.5 What-if Scenario SU2

What-if SU2 Scenario Financial Analysis - 72 genomes/day @ $999/geome
Year
Stage

2012
Research

% of Design Capacity

2013
Research

0.00%

2014
Scale Up

30.00%

2015
Sales

50.00%

2016
Sales

100.00%

2017
T erminal
156.00%

100.00%

Income Statement
Revenue

$0.00

$7,127,928.72

$23,759,762.40

$23,759,762.40

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,550,691.89

$1,561,383.79

$1,561,383.79

$1,561,383.79

Depreciation

$0.00

($108.19)

($21,911.61)
$21,816,171.01

($13,189.04)
$21,816,171.01

$23,759,762.40

($7,928.62)

Pre-tax income

($512,000.00)

$5,196,633.03

$21,816,171.01

T ax @ 40%

($204,800.00)

$2,078,653.21

$8,726,468.41

$8,726,468.41

$8,726,468.41

Net income

($307,200.00)

$3,117,979.82

$13,089,702.61

$13,089,702.61

$13,089,702.61

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

($21,911.61)

Changes in AR

$0.00

($585,857.16)

($1,367,000.03)

Changes in AP

$14,136.99

$17,892.48

Changes in Inv

$0.00

$131.82

($13,189.04)

($7,928.62)

Changes in Working Capital

Changes in CR

($85,000.00)

($300,000.00)

T otal Change in Working capital

($70,863.01)

($867,832.85)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($6,793,176.42)

$600,000.00

$7,000,000.00

$96,980.30

$1,589,029.51

$0.00

$0.00

$878.79

$0.00

$0.00

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$13,076,513.57

$13,081,773.99

($1,365,989.42)

Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discoun t Rate

Equity Shares

$10,335,812.15

$38,180,109.52

$3,808,686.63

Investment

Series A Equity

600,000

Series B Equity

7,000,000
Divided Free Cash Flows
$87,282.27

$138,399.34

$900,215.90

$1,138,922.15

$1,139,380.32

$3,404,199.98

$0.00

$1,435,252.46

$9,335,572.27

$11,811,044.52

$11,815,795.86

$34,397,665.10

Series A MIRR

84.39%

Series B MIRR

72.79%

Micro$eq – Chomvong, King, Mahmoud

300 | P a g e

D.1.6 What-If Case R2

What-if Case R2 Financial Summary -72 Genomes Per Year @ $999/genome
Year

2012

Stage

Research

% of Design Capacity

2013
Research

2014
Scale Up

0.00%

0.00%

$0.00

$0.00

2015
Sales

50.00%

2016
Sales

100.00%

2017
T erminal

100.00%

156.00%

Income Statement
Revenue

$11,879,881.20

$23,759,762.40

$23,759,762.40

Cost of sales

$172,000.00

$172,000.00

$380,603.80

$380,603.80

$380,603.80

Operateing, SG&A expenses

$340,000.00

$1,545,345.95

$1,550,691.89

$1,550,691.89

$1,550,691.89

Depreciation

$0.00

($108.19)

($21,911.61)

($13,189.04)

($7,928.62)

Pre-tax income

($512,000.00)

($1,717,345.95)

$9,948,585.51

$21,828,466.71

T ax @ 40%

($204,800.00)

($686,938.38)

$3,979,434.20

$8,731,386.68

$21,828,466.71
$8,731,386.68

Net income

($307,200.00)

($1,030,407.57)

$5,969,151.30

$13,097,080.02

$13,097,080.02

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation
Changes in Working Capital
Changes in AR
Changes in AP
Changes in Inv

$0.00

($108.19)

$0.00

$0.00

$14,136.99

$17,453.09

$0.00

$131.82

($21,911.61)
($976,428.59)

($13,189.04)

($7,928.62)

$0.00

$0.00

$439.39

$0.00

$0.00

$131.82

$0.00

$0.00

Changes in CR

($85,000.00)

$0.00

($300,000.00)

$0.00

$0.00

T otal Change in Working capital

($70,863.01)

$17,584.91

($1,275,857.38)

$976,428.59

$0.00

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($6,793,176.42)

Cash from Financing Activities
Issuance of Common Stock

$600,000.00

$7,000,000.00
$15,036,748.17

$13,089,151.41

Free Cash Flow
NPV@25% Discount Rate

Equity Shares

$96,980.30

($395,345.93)

$3,602,348.51

$31,429,882.46

$1,559,155.11

Investment

Series A Equity

600,000

Series B Equity

7,000,000
Divided Free Cash Flows
$87,282.27

($69,114.43)

$629,763.09

$2,628,726.48

$2,288,247.33

$5,564,904.74

$0.00

($318,552.12)

$2,902,611.75

$12,115,940.97

$10,546,654.37

$25,246,654.98

Serie s A MIRR

115.93%

Serie s B MIRR

55.01%

Micro$eq – Chomvong, King, Mahmoud
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D.1.5 Growth Case Financial Summary

Growth Case Financial Summary - 72 genomes/day @$999/genome & 25% annual growth
Year

2012

Stage

Research

% of Design Capacit y

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

125.00%

2017
T erminal

156.00%

156.00%

Income Statement
Revenue

$0.00

$11,879,881.20

$23,759,762.40

$29,699,703.00

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,550,691.89

$1,561,383.79

$1,561,383.79

$1,561,383.79

Depreciation

$0.00

($108.19)

Pre-tax income

($512,000.00)

$9,948,585.51

T ax @ 40%

($204,800.00)

Net income

($307,200.00)

($21,993.29)

($13,238.20)

$37,065,229.34

($7,958.17)

$21,816,171.01

$27,756,111.61

$35,121,637.96

$3,979,434.20

$8,726,468.41

$11,102,444.65

$14,048,655.18

$5,969,151.30

$13,089,702.61

$16,653,666.97

$21,072,982.77

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion
Changes in Working Capital
Changes in AR

$0.00

($108.19)

($21,993.29)

$0.00

($976,428.59)

($976,428.59)

($13,238.20)

($7,958.17)

$0.00

$0.00

Changes in AP

$14,136.99

$17,892.48

$878.79

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

$0.00

$0.00

$0.00

$488,214.30

$605,385.73

$17,616,857.36

$22,275,796.06

Changes in CR

($85,000.00)

($300,000.00)

T ot al Change in Working capital

($70,863.01)

($1,258,404.29)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($6,818,702.50)

$600,000.00

$7,000,000.00

$96,980.30

$3,633,532.04

($975,417.99)

Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discount Rate

Equity Shares
Series A Equity
Series B Equity

$11,116,873.34

$54,740,039.10

$8,149,772.81

Investment
600,000
7,000,000
Divided Free Cash Flows
$87,282.27
$316,468.92
$0.00

Serie s A MIRR

107.09%

Serie s B MIRR

94.64%

Micro$eq – Chomvong, King, Mahmoud

$3,281,899.91

$968,243.81

$1,534,371.45

$1,940,149.98

$4,846,516.43

$10,041,046.89

$15,912,000.19

$20,120,073.86

$49,355,020.85
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D.1.8 What-if Scenario S2 Financial Analysis Summary

What-If Scenario S2 Financial Summary - 72 genomes/day @$999/genome
Year
Stage

2012
Research

% of Design Capacity

2013
Scale Up

0.00%

2014
Sales

50.00%

2015
Sales

100.00%

2016
Sales

90.00%

2017
T erminal

81.00%

10000.00%

Income Statement
Revenue

$0.00

$10,731,492.68

$21,462,985.37

$19,316,686.83

Cost of sales

$172,000.00

$380,603.80

$382,207.60

$382,207.60

$382,207.60

Operateing, SG&A expenses

$340,000.00

$1,549,658.34

$1,559,316.69

$1,559,316.69

$1,559,316.69

Depreciation

$0.00

($108.19)

($21,882.37)

($13,171.43)

$17,385,018.15

($7,918.03)

Pre-tax income

($512,000.00)

$8,801,230.54

$19,521,461.08

$17,375,162.54

$15,443,493.86

T ax @ 40%

($204,800.00)

$3,520,492.22

$7,808,584.43

$6,950,065.02

$6,177,397.54

Net income

($307,200.00)

$5,280,738.32

$11,712,876.65

$10,425,097.53

$9,266,096.32

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

($21,882.37)

($13,171.43)

($7,918.03)

Changes in AR

$0.00

($882,040.49)

($882,040.49)

$0.00

$0.00

Changes in AP

$14,136.99

$17,807.54

$793.84

$0.00

$0.00

Changes in Inv

$0.00

$131.82

$131.82

$0.00

$0.00

Changes in Working Capital

Changes in CR

($85,000.00)

($300,000.00)

T otal Change in Working capital

($70,863.01)

($1,164,101.14)

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($6,784,037.45)

$600,000.00

$7,000,000.00

$96,980.30

$3,168,390.40

$0.00
($881,114.84)

$0.00
($176,408.10)

$0.00
($158,767.29)

Cash from Financing Activities
Issuance of Common Stock
Free Cash Flow
NPV@25% Discoun t Rate

Equity Shares

$9,928,764.61

$10,059,109.90

$8,940,643.71

$32,193,888.91

$2,239,434.81

Investment

Series A Equity

600,000

Series B Equity

7,000,000
Divided Free Cash Flows
$87,282.27

$275,956.58

$864,763.37

$876,116.02

$778,701.23

$2,882,819.47

$0.00

$2,861,771.98

$8,967,916.42

$9,085,647.65

$8,075,420.12

$28,990,756.16

Series A MIRR

75.08%

Series B MIRR

63.79%

Micro$eq – Chomvong, King, Mahmoud
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D.1.9 What-if Scenario S3 Financial Analysis Summary

What-if S3 Scenario Financial Analysis - 72 genomes/day @ $999/genome
Year
Stage
% of Design Capacity

2012
Research

2013
Scale Up

0.00%

2014
T erminal

50.00%

50.00%

Income Statement
Revenue

$0.00

$7,127,928.72

$0.00

Cost of sales

$172,000.00

$380,603.80

$0.00

Operateing, SG&A expenses

$340,000.00

$1,540,000.00

$1,540,000.00

Depreciation

$0.00

($108.19)

$0.00

Pre-tax income

($512,000.00)

$5,207,324.92

($1,540,000.00)

T ax @ 40%

($204,800.00)

$2,082,929.97

$0.00

Net income

($307,200.00)

$3,124,394.95

$0.00

Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation

$0.00

($108.19)

$0.00

Changes in Working Capital
Changes in AR

$0.00

($585,857.16)

$0.00

Changes in AP

$14,136.99

$17,013.70

$0.00

Changes in Inv

$0.00

$131.82

$0.00

Changes in CR

($85,000.00)

($300,000.00)

$0.00

T otal Change in Working capital

($70,863.01)

($868,711.64)

$0.00

Cash from Investing Activities
Purchase/Sale of Equipment

($54,093.67)

($6,793,176.42)

Cash from Financing Activities
Issuance of Common Stock

$600,000.00

$7,000,000.00

$96,980.30

$1,593,687.07

$0.00

Divided Free Cash Flows
$87,282.27
$138,805.00

$0.00

Free Cash Flow
NPV@25% Discount Rate

Equity Shares
Series A Equity
Series B Equity

($5,756,801.69)

Investment
600,000
7,000,000

$0.00
Se rie s A MIRR

-22.60%

Se rie s B MIRR

-38.12%

Micro$eq – Chomvong, King, Mahmoud

$1,439,459.29

$0.00
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1

T otal Cost
$6.00

Total

$340,000.00

as he is also paid 10% of the tot al equity st ake

*T his salary is less than typical market price

$25,000.00

IT person (PT )

$60,000.00

Junior Scientist

$50,000.00

$120,000.00

Senior Scient ist

$200,000.00

$500,000.00

$40,000.00

$20,000.00

CT O

Salary

$6,415.00

$4,000.00

$500.00

$1,000.00

$679.68

$179.99

Secretary

1

$240,000.00

CEO*

Personnel

Droplet Syringe

T hermalCycler (Biometra)

s2 Shearer (Covaris)

Lab Cent rifuge (UNICO)
Magt ration 12GC (Pss
Bio)

Vortex mixer (VELP)

$889.00

$1,650.00

$25,000.00

$472.00

Salesperson

$40,000.00

Secretary (PT )

3

$80,000.00

$54,093.67

$19,245.00

$4,000.00

$500.00

$1,000.00

$679.68

$179.99

Core IF-2400 Processor(Intel)

Quad-Core Opteron Processor 8356 (AMD)

FFT -CCD Camera (Hamamatsu)

Optical Lenses (Nikkon)

$6.00

as t hey are also paid 10% of the research stage equit y stake.

$80,000.00

Senior Scientist*

1

3

1

1

1

1

$889.00

$1,650.00

$25,000.00

$944.00

Unict Cost

*T he research phase salaries are 70% of the final salary,

$80,000.00

Salary

CT O*

Personnel

Labor Costs

$4,000.00
$6,415.00

Droplet Syringe (Dolomite)

$500.00

T hermalCycler (Biomet ra)

s2 Shearer (Covaris)

Quantity

$679.68

Lab Centrifuge (UNICO)

Total

$179.99

Vortex mixer (VELP)

$1,000.00

1

$889.00

Core IF-2400 Processor(Int el)

Magtration 12GC (Pss Bio)

1
1

1

2

$25,000.00

$472.00

Quad-Core Opteron Processor 8356 (AMD) $1,650.00

FFT -CCD Camera (Hamamat su)

Optical Lenses (Nikkon)

$6.00

Acrylic Prism (T edco)

Total

Quantity

Total

2

1

1

26,364

6

1

1

574200

52727.27273

13181.81818

13181.81818

6590.909091

13181.81818

125881.0909

416018.1818

832036.3636

416018.1818

Quanit y

It em

Quanity

Item

Unit Cost

Remaining Equipment Required for Full Scale-up

Equipment Cost for Protoype Development

Acrylic Prism (T edco)

Sales Phase (Series B)

Micro$eq – Chomvong, King, Mahmoud

Research Phase (seires A)

$2,496,109.09

$3,683,493,000.00

$210,909,090.91

$6,590,909.09

$13,181,818.18

$4,479,709.09

$2,372,595.45

$207,703,800.00

$10,400,454,545.45

$392,721,163.64

$1,583,378,181.82

$50,000.00

$40,000.00

$50,000.00

$1,581,818,181.82

$720,000.00

$200,000.00

$500,000.00

$14,924,402,740.91

T ot al Cost

D.1.10 Large-Scale Cost Estimates (part 1)
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none

Item
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Total Annual Costs

Sales
$0.00

$1,000.00

Maint enance

Operating Costs

$5,000.00

Cost /month

Utilites

Item

$30.00

$100.00

Sequencing Space

Office Space

$100.00

Cost /ft 2

Lab space

Item

Rental Costs

$0.00

Unit cost

*No inventory is used during research st age

none*

Item

Inventory Costs

Total

Total

0

1000

200

500

0

12

12

Month/yr

Total

Quantity

$0.00

$0.00

$0.00

$0.00

$566,093.67

T ot al Cost

$172,000.00

$12,000.00

$60,000.00

T ot al Cost

$30,000.00

$20,000.00

$50,000.00

T ot al Cost

T ot al Cost

Total Annual Costs

$10,304,846,451.31

Sales

$20,000.00

$100,000.00

$10,304,846,451.31

Sales

Cost /month

$30.00

$100.00

Research

Item

Maint enance

Utilites

Item

Office Space

Sequencing Space

Lab space

Item

$100.00

$2.34

Presequencing
Sequencing

$0.81

MicroChips

$8.49
$19.22

Cost /ft 2

Unit cost

Sequencing

Presequencing

Reagents

Item

Total

% of Sales

Total

Month/yr

ft 2

Total

3.00%

6.00%

12

12

20000

10000

7500

52200000

3960

52200000

52200000

Quantit y

$443,178,000.00

$9,274,361.81

$3,091,453.94

$6,182,907.87

$3,790,000.00

$240,000.00

$1,200,000.00

$600,000.00

$1,000,000.00

$750,000.00

$1,568,613,207.60

$122,148,000.00

$3,207.60

$1,003,284,000.00

$18,089,458,492.13

T otal Cost

T otal Cost

T otal Cost

T otal Cost

D.1.11 Large-Scale Cost Estimates (part 2)
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($85,000.00)
($70,863.01)

Changes in Inv

Changes in CR

T ot al Change in Working capital

-299.20%
-289.99%

Se rie s A MIRR

Se rie s B MIRR

($63,918,665.31)
($14,204,147,846.54)

($14,275,168,585.78)

$150,000,000.00

($14,924,402,740.91)

($818,567,746.08)

($395,759,545.45)

$131.82

$678,508.02

($423,486,840.46)

($108.19)

$2,136,369,755.48

$1,424,246,503.65

$3,560,616,259.13

($108.19)

$1,588,015,362.72

$3,791,603.80

$5,152,423,225.66

50.00%

2013

$0.00

Scale Up

$87,282.27

Divided Free Cash Flows

600,000
150,000,000

Series B Equit y

($0.00)

$96,980.30

$600,000.00

Series A Equity

Equity Shares

NPV@25% Discount Rate

Free Cash Flow

Issuance of Common Stock

Cash from Financing Activities

Purchase/Sale of Equipment

($54,093.67)

$0.00

Changes in AP

Cash from Investing Activities

$0.00
$14,136.99

Changes in AR

Changes in Working Capital

Plus:Depreciation

Cash from Operating Activities
$0.00

($307,200.00)

Net income

Cash Flow Statement

($204,800.00)

T ax @ 40%

$0.00
($512,000.00)

Pre-tax income

Depreciation

$340,000.00

Operateing, SG&A expenses

$0.00

0.00%

2012

$172,000.00

Investment

Research

Cost of sales

Revenue

Income Statement

% of Design Capacit y

Stage

Year
Sales

$4,309,523,399.86

$19,392,855.30

$4,331,071,016.86

($423,105,570.49)

$0.00

$131.82

$381,138.16

($423,486,840.46)

($47,758,262.22)

$5,225,040,420.05

$3,483,360,280.04

$8,708,400,700.09

($47,758,262.22)

$1,592,652,543.62

$3,793,207.60

$10,304,846,451.31

100.00%

2014
Sales

Large-Scale Financial Summary - 52.2 million genomes/year @$197/genome

$5,170,441,559.06

$23,266,987.02

$5,196,293,766.86

$0.00

$0.00

$0.00

$0.00

$0.00

($28,746,653.19)

$5,225,040,420.05

$3,483,360,280.04

$8,708,400,700.09

($28,746,653.19)

$1,592,652,543.62

$3,793,207.60

$10,304,846,451.31

100.00%

2015
Sales

$5,181,850,061.68

$23,318,325.28

$5,207,759,311.99

$0.00

$0.00

$0.00

$0.00

$0.00

($17,281,108.06)

$5,225,040,420.05

$3,483,360,280.04

$8,708,400,700.09

($17,281,108.06)

$1,592,652,543.62

$3,793,207.60

$10,304,846,451.31

100.00%

2016
T erminal

$457,667,174.06

$2,146,784.56

$460,052,490.23

10000.00%

2017

D.1.12 Large Scale Breakeven Financial Analysis Summa
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